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Distal-less 3 (Dlx3) is a homeodomain containing transcription factor that is 
required for the normal development of the mouse placenta. Moreover in human 
trophoblasts, DLX3 appears to be a necessary transcriptional regulator of the 
glycoprotein hormone α subunit gene, a protein subunit of placental-derived chorionic 
gonadotropin. The aim of my studies described here was to determine the role of Dlx3 
in gene regulation within the placenta. 
My studies initially sought to determine if Dlx3 could interact physically with 
other transcriptional regulators in placental trophoblast cells and how these protein-
protein interactions might influence Dlx3-dependent gene expression. Yeast two-
hybrid screens provide evidence that mothers against decapentaplegic homolog 6 
(SMAD6) was a binding partner for DLX3. SMAD6 was found to be expressed and 
nuclear localized in placental trophoblasts and interacted directly with DLX3. 
Structure-function analysis revealed that this interaction occurred within a DLX3 
domain that overlapped the homeobox, a key domain necessary for DLX3 DNA 
binding. SMAD6 was found to repress DLX3 transcriptional activity through 
inhibition of DLX3-DNA interactions at target genes. 
To develop a more comprehensive understanding of the gene profile regulated by 
Dlx3, microarray studies were used to determine differences in gene expression within 
the placenta of wild type and Dlx3 null mice at embryonic day 9.5. Loss of Dlx3 
resulted in a marked reduction in gene expression of placental growth factor (Pgf). To 
investigate the mechanism(s) of regulation of Pgf gene expression, 5.2 kb of the 
 mouse Pgf gene promoter was cloned and used in reporter gene assays. Over-
expression of Dlx3 increased the Pgf promoter activity in choriocarcinoma cells, 
suggesting that Dlx3 may have a direct effect on transcriptional activation of the Pgf 
gene promoter. 
To determine the functional importance of Dlx3 in the regulation of Pgf gene 
transcription, two Dlx3 binding sites in the mouse Pgf 5.2 kb promoter were identified 
and mutated by site-directed mutagenesis. The mutations effectively abolished the 
ability of Dlx3 to bind these sites. Pgf promoter activity was found to be reduced by 
the combined mutation of both Dlx3 binding sites. Thus, Dlx3 appears to be an 
important determinant for Pgf gene promoter activity and ultimately Pgf secretion in 
placental trophoblast cells. Since PGF is an important marker for risk of preeclampsia 
in women, studies in a mouse model of preeclampsia were undertaken to determine if 
Dlx3 and Pgf were mis-regulated during gestation in this model. Indeed, both Dlx3 
and Pgf transcript levels were greatly reduced in early gestation in BPH/5 mice 
suggesting that Dlx3 and Dlx3 target genes may underlie genetic mechanisms 
associated with preeclampsia prior to the onset of maternal disease. To determine if 
similar mis-regulation of the DLX3 gene network might occur in placentas from 
women with preeclampsia, we next examined DLX3 and PGF transcript abundance in 
a preliminary cohort of patients. This preliminary study supported our findings in the 
BPH/5 mouse model.  
Together, these data suggest that Dlx3 may be an important factor during the 
development of mouse placenta by regulating genes such as Pgf. Further, mis-
regulation of this gene network may direct early changes in placental function leading 
to symptoms characteristic of preeclampsia. 
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CHAPTER ONE 
 
REVIEW OF THE LITERATURE 
 2 
1. Introduction 
As the first organ forming in the mammalian embryo, the placenta is essential for 
survival and growth of the fetus. It mediates implantation and forms the interface 
between the maternal and fetal circulation, facilitating metabolic and gas exchange as 
well as fetal waste disposal. In addition to the transfer of gases and nutrients, it also 
produces hormones and growth factors that affect both the mother and the fetus. Any 
genetic or environmental factor that negatively influences the development of the 
placenta can lead to placental insufficiency and fetal growth retardation, and in more 
severe situations, preeclampsia, eclampsia and potentially fetal and/or maternal death. 
The goal of this review is to summarize details and background of the development 
and function of the mouse placenta and genetic determinants required for placental 
morphogenesis.  
 
2. Mouse placenta morphogenesis 
In mice, placental development starts at embryonic day (E) 3.5 when the 
trophectoderm of the blastocyst is separated from the inner cell mass 1. As the 
blastocyst enters the uterus at E4.5, the trophectoderm cells distal to the inner cell 
mass stop dividing but continue to replicate their DNA to form trophoblast giant cells 
(extravillous trophoblasts in human). These giant cells secrete proteolytic enzymes 
such as matrix metalloproteinases (Mmp) to erode the uterine epithelia and create 
implantation sites for the blastocyst 2. The trophectoderm cells immediately adjacent 
to the inner cell mass proliferate to generate extraembryonic ectoderm and 
ectoplacental cone as shown in Figure 1.1 3. The extraembryonic ectoderm develops 
into the trophoblast cells of the chorion layer and later the labyrinth (chorionic villi in 
human). The ectoplacental cone develops into spongiotrophoblast (column 
cytotrophoblast in human), a layer existing between the labyrinth and the outer 
 3 
trophoblast giant cells. 
During implantation, the trophoblasts of the blastocyst stimulate the 
transformation of the stromal fibroblast cells of the uterine endometrium into decidual 
cells. The stored glycogen in these cells provides nourishment for the developing 
embryo 4. As development progresses, vascularity and vascular permeability are 
enhanced in the decidua. The predominant type of leukocyte within the decidua is the 
uterine natural killer cells, which is critical for appropriate endometrial angiogenesis 
in early implantation site development 5,6. As the maternal interface to the embryo, the 
decidua participates in the exchange of nutrients, gases, and waste products during 
gestation. The decidua also protects embryos from the maternal immune system. 
Finally, the decidua has to tightly control invasion of the trophoblasts into the uterine 
wall 7. 
At E8.5, the allantois from extraembryonic mesoderm makes contact with 
chorion in a process termed chorioallantoic fusion. The reciprocal interaction between 
allantoic mesoderm and chorionic trophoblast regulates subsequent placental 
development. The chorion begins to fold to form the villi, creating a space into which 
fetal blood vessels grow from the allantois 8. Trophoblasts along with the associated 
fetal blood vessels undergo extensive villous branching to form the labyrinth. At this 
time, the chorionic trophoblast cells differentiate into two labyrinth cell types, 
multinucleated syncytiotrophoblast cells surrounding the fetal capillary endothelium 
and mononuclear trophoblast cells lining the maternal blood sinuses.  
Invasive trophoblasts migrate to the maternal uterine spiral arteries and the 
trophoblasts replace the endothelial cells lining the spiral arteries and help dilate these 
blood vessels in a process referred to as spiral artery remodeling 9. In rodents and 
primates, the uterine epithelia are eroded and the endothelial cells of the maternal 
capillaries are broken down such that maternal blood comes into direct contact with 
 4 
 
 
 
Figure 1.1 Structure and development of mouse placenta. 
From Erica Watson & James Cross. Physiology. 2005, 20: 180-193. 
 
 5 
the trophoblast surface of the villi. This ensures the material exchange between the 
two blood systems of the mother and the fetus without direct mixing of blood in a 
classical hemochorial placenta 3. The developing fetus is connected to the placenta by 
the umbilical artery and vein.  
By E14.5, the well developed mouse placenta is composed of three major layers: 
1) the labyrinth, an inner layer of the placenta which is composed of highly branched 
villi; 2) the spongiotrophoblast, a middle junctional region which attaches the fetal 
placenta to the uterus. In this layer, trophoblasts invade into the uterine wall and 
maternal vessels; 3) the maternal decidua which is the outer layer including decidua of 
the uterus and maternal blood vessels that bring blood into or out of the implantation 
site 3. 
Until birth at approximately E19.5, the trophoblast and fetal vasculature generate 
more extensively branched villi within the labyrinth. To maximize nutrient transport, 
maternal blood flows within the placental labyrinth are arranged in a countercurrent 
direction to the fetal blood flows 10. If the labyrinth is not appropriately vascularized 
with branching and dilation, placental perfusion can be impaired leading to 
insufficient oxygen and nutrient exchange and growth restriction of the fetus. 
 
3. Function of the placenta 
The function of placenta is to exchange gases, nutrients and waste products 
between the mother and the fetus. In addition to material exchange, the placenta has 
many endocrine functions. Several hormones and growth factors are produced by the 
placenta such as placental lactogen (PL) in rodents 11, human chorionic gonadotropin 
(hCG) in primates 12, vascular endothelial growth factor (VEGF) 13 and placental 
growth factor (Pgf) 13,14.  
In mouse placenta, trophoblast giant cells produce PL. The protein structure and 
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function of PL is similar to prolactin and growth hormone. PL maintains the function 
of corpus luteum (CL) in mice. PL can modulate fetal and maternal metabolism during 
pregnancy. This hormone can stimulate lipolysis in the mother to provide fuel for the 
growing fetus. PL can lead to insulin resistance and carbohydrate intolerance in the 
mother 15. 
In human placenta, hCG is produced and secreted initially by the trophectoderm 
at first and later by syncytiotrophoblasts 16. This glycoprotein hormone can be 
detected in the maternal serum 9-10 days after ovulation, and its concentration 
increases exponentially soon thereafter, peaks at 10 weeks gestation and declines to a 
low plateau that persists throughout the remainder of pregnancy 17. By chemical 
structure, hCG is a glycoprotein with two subunits. The α subunit is same to 
luteinizing hormone, follicle-stimulating hormone and thyroid stimulating hormone. 
The β subunit is specific to hCG. Because of its early presence during the pregnancy, 
the β subunit of hCG has been widely used as a marker for detection of early 
pregnancy in women. hCG is required for the maintenance of progesterone secretion 
from the ovarian CL through engagement of the LH receptor on cells of the CL 18. 
Progesterone enhances the uterus with a thick lining of blood vessels and capillaries to 
sustain the growing fetus as well as inhibits the production and release of more 
oocytes. Furthermore, hCG may play a paracrine role in the uterine endometrium to 
facilitate uterine receptivity during implantation in primates 19. hCG inhibits the 
immune cells of the mother and facilitates the immune tolerance of the pregnancy, 
therefore regulating endometrial receptivity 20,21 and protecting the fetus from the 
maternal immune system during the first trimester 22. For example, hCG-treated 
endometrial cells induced an increase in T cell apoptosis 23. Thus, hCG supports fetal 
development through maintaining CL function and production of progesterone; 
facilitating trophoblast invasion; and can serve a paracrine regulator of the uterine 
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endometrium. 
Secreted factors like PL and hCG serve to regulate CL function and endocrine 
mechanisms related to implantation; however, normal development and function of 
the placenta require invasion of the maternal decidua by trophoblasts, followed by 
abundant and organized blood vessel growth. As such, vascular insufficiencies during 
placentation have been demonstrated to contribute to a number of obstetrical 
complications such as preeclampsia. Consistent with the research described in this 
dissertation, the following sections focus on pro-angiogenic factors such as VEGF and 
Pgf that control and direct placental vascular function.  
 
3.1 Vascular endothelial growth factor (VEGF)  
VEGF is a specific endothelial growth factor that stimulates endothelial cell 
growth and migration and increases vascular permeability 24. VEGF is expressed and 
secreted by various cell types including endothelial cells, skeletal and cardiac muscles, 
hepatocytes, osteoblasts, neutrophils, macrophages and keratinocytes. Mouse embryos 
with functional inactivation of one VEGF allele die at E11-12 during pregnancy due to 
abnormal blood vessel development 25,26. The placentas of these mouse embryos look 
more condensed and show degenerating endothelial cells in fetal capillaries 26. During 
embryogenesis, VEGF regulates blood vessel size and density. In postnatal life, VEGF 
appears to maintain endothelial cell integrity and promotes bone formation through 
recruitment of osteoblasts and chondroblasts 27.  
VEGF mediates its effects by interacting with three membrane-associated 
tyrosine kinase receptors, VEGF receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3 and 
two co-receptors of neuropilin (NRP) 28,29. VEGFR-1 is also known as fms-like 
tyrosine kinase (Flt-1); VEGFR-2 is known as fetal liver kinase (Flk-1), and in human, 
it is named kinase insert domain-containing receptor (KDR) 30. All three receptors are 
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composed of an immunoglobulin-like extracellular domain, a transmembrane domain, 
and an intracellular tyrosine kinase domain 31,32.  
Engagement of VEGFR-2 activates a number of signaling transduction pathways 
to mediate different endothelial cell functions such as survival, proliferation, migration 
and vascular permeability in a pathway-specific fashion as shown in Figure 1.2. For 
example, VEGF regulates endothelial cell survival through the phosphatidylinositol 3'-
kinase (PI3K) signaling pathway 33. Phosphorylation of VEGFR-2 is essential for 
VEGF-dependent endothelial cell proliferation via activation of phospholipase C-
gamma (PLC-γ), protein kinase C (PKC) and downstream extracellular signal 
regulated kinase (ERK) pathway 34. VEGFR-2 activation also triggers the activation of 
c-Jun N-terminal kinase (JNK), which mediates actin reorganization in endothelial 
cells leading to cell movement 35. 
Disruption of genes encoding VEGFRs results in severe abnormalities of blood 
vessel formation in mice. Embryos lacking the VEGFR-1 gene die at midgestation due 
to impaired development of functional blood vessels from the endothelial cells within 
the embryo 36, which is consistent with deletion of one VEGF allele 25. Disruption of 
the encoding gene of VEGFR-2 is embryonic lethal between E8.5 and E9.5 because of 
defects in the differentiation of endothelial cells and formation of blood vessels within 
the embryo 37. Consistent with this model, blockade of VEGFR-2 by using an 
immuno-neutralizing antibody in mice, results in dead and partially absorbed embryos 
and pale placentas at E8.0 of pregnancy. Thus, this indicates that VEGFR-2 is required 
for vascular development in both embryo and placenta 38.  
VEGF has been shown to stimulate angiogenesis under many pathological 
conditions including diabetic retinopathy, wound healing and tumor growth 24. VEGF 
is up-regulated in many tumors such as colon cancer, breast cancer, renal cell 
carcinoma and bladder cancer 39. Plasma VEGF is often elevated in cancer patients 
 9 
 
Figure 1.2 VEGF family members, receptors and VEGFR-2 signaling pathways. 
From Hiroyuki Takahashi & Masabumi Shibuya. Clinical Science. 2005, 109: 227-
241. 
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and it is a marker of poor clinical outcome 40,41. Blocking VEGF pharmacologically 
reduced tumor angiogenesis and growth in preclinical studies. A humanized 
monoclonal antibody to VEGF named bevacizumab has been approved for treatment 
of many cancers including metastatic colon cancer 42, non-small cell lung cancer 43,44 
and metastatic breast cancer 45,46. Bevacizumab has also been approved for use in 
metastatic renal cell carcinoma 47 and glioblastoma multiforme 48, a type of brain 
cancer. 
 
3.2 Placental growth factor (PGF) 
PGF is a member of VEGF family. It is an angiogenic growth factor that is 
expressed in the placenta, primarily by trophoblasts 49-51. In addition to the placenta, 
PGF is expressed in other tissues including microvascular endothelial cells, human 
umbilical vein endothelia, bone marrow, uterine natural killer cells and  
keratinocytes 14. Alternative splicing of the human PGF transcript generates four 
isoforms: PGF-1, 2, 3 and 4, all generated from a single gene 49,52,53. Differences 
among the four isoforms include the insertion of a heparin-binding domain in PGF-2 
and 4 that results in increased association with the cell membrane 14. In mouse, only 
one Pgf mRNA encoding the equivalent of human PGF-2 has been identified 54.  
PGF-2 specifically binds to VEGFR-1 with high affinity, and does not associate with 
VEGFR-2 and 3 55. PGF-1 shares approximately 42% amino acid sequence identity 
with VEGF 56 and both have significant structural similarity with platelet-derived 
growth factor (PDGF) and transforming growth factor (TGFβ) 57. These growth 
factors are characterized by a common motif of eight conserved cysteine residues that 
form a cysteine knot structure, which is involved in the dimerization of the growth 
factors 56,58. Although the three-dimensional protein structures of human PGF-1 and 
VEGF are remarkably similar, half of the residues located on the receptor-binding 
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domain are not conserved between these two growth factors 56.  
In comparison to VEGF, the role of Pgf in neovascularization is less clear. In 
mice, Pgf stimulates angiogenesis, leukocyte infiltration, tumor growth, stromal cell 
migration and revascularization of ischemic tissues 59. Pgf enhances the survival, 
growth and migration of endothelial cells in vitro and promotes vessel formation in 
certain model systems 60-62. For example, mice with overexpression of Pgf exhibit 
increased vascularization and vessel permeability 62.  
In endothelial cells and trophoblasts, PGF stimulation results in phosphorylation 
of different tyrosine residues on VEGFR and activation of different target genes as 
compared to VEGF stimulation 63,64. In trophoblast cells, the downstream signal 
transduction pathways activated by PGF include PLC-γ and JNK 65,66. Interestingly, 
embryogenesis appears to be normal in Pgf knockout mice, suggesting that its role in 
placental development is redundant or there are fundamental differences in the 
function of human and mouse Pgf 63.  
The Pgf knockout mouse reveals important functions of Pgf, independent of other 
angiogenic growth factors 63. Pgf is up-regulated under certain pathological conditions 
such as ischemia, wound healing and tumor formation 61. The Pgf knockout mice 
show significantly impaired angiogenesis during pathological conditions such as 
ischemia, inflammation, wound healing and tumor formation 63. Interestingly, 
inhibitors of Pgf reduce pathological angiogenesis in various cancers without affecting 
healthy blood vessels 38. One of the PGF inhibitors named TB403, a humanized 
monoclonal antibody against PGF, is currently in clinical trial in cancer patients 67. 
The pharmacological use of PGF inhibitor in conjunction with VEGF inhibitor 
enhances the anti-tumor activity compared to the VEGF inhibitor alone38 and 
decreases dose of the VEGF inhibitor for tumor treatment, therefore reducing side 
effects of the VEGF inhibitor such as thrombosis, hypertension, microvascular 
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pruning in healthy organs and interruption of pregnancy 68. 
Both VEGF and PGF are angiogenic factors and both have important roles in 
pathological angiogenesis. Combination of VEGF and PGF increases ischemic 
myocardial angiogenesis in a mouse model which is resistant to VEGF alone 64. In 
cultured human umbilical vein endothelial cells, VEGF actually induces the 
production of PGF protein through a post-transcriptional mechanism dependent on 
PKC signaling 69. PGF is, in turn, able to up-regulate the expression of VEGF 61. PGF 
synergistically enhances VEGF-induced angiogenesis and vascular permeability 55. 
Some of the mechanisms underlying PGF effects on the vascular endothelial cells 
include the following: 1) PGF has been shown to displace VEGF from VEGFR-1, 
thereby increasing the fraction of VEGF available to activate VEGFR-2; 2) PGF 
activates VEGFR-1, leading to intermolecular transphosphorylation of VEGFR-2 and 
enhancing the response of VEGFR-2 to VEGF; 3) PGF can induce downstream signal 
pathways through VEGFR-1, independently of cross talk with VEGFR-2; and 4) PGF 
can form heterodimers with VEGF and these heterodimers appear to stimulates 
angiogenesis by inducing the formation of VEGFR-1/ VEGFR-2 heterodimer  
receptor 64. Collectively, these studies demonstrated important interactions between 
PGF and VEGF in controlling blood vessel formation and physiology.  
 
3.3 Pro-angiogenic factors and placental diseases 
Many obstetric complications, such as preeclampsia, are associated with 
abnormal trophoblast function and inadequate or dysfunctional vasculature during 
placental development. Preeclampsia affects approximately 5% of all pregnancies and 
is manifested by maternal hypertension and proteinuria after 20 weeks of pregnancy 70. 
Preeclampsia may eventually progress to glomerular malfunction, thrombocytopenia, 
liver and brain edema, and associated life-threatening seizures 71. Circulating levels of 
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PGF in maternal serum fluctuate during normal human pregnancy. For example, PGF 
increases during the first two trimesters, peaks at 29-32 weeks of pregnancy and 
decreases thereafter 72. In women with preeclampsia and those who subsequently 
develop the disorder, the level of PGF in plasma follows the same secretion pattern; 
however, the total levels of PGF are shown to significantly decrease compared to 
normal pregnancy 14,72. PGF has been used as an important predictor of subsequent 
development of preeclampsia in pregnant women 72,73. 
Soluble FLT-1 (sFLT-1) is a variant splicing isoform of the VEGF receptor  
FLT-1, where sFLT-1 lacks the transmembrane and cytoplasmic domains 74. As such, 
sFLT-1 acts as a potent VEGF and PGF antagonist. Serum sFLT-1 concentrations 
have been shown to be increased in preeclampsia patient thus resulting in reduced 
circulating concentrations of free or bio-available PGF and VEGF 14,75-77. As discussed 
earlier, during normal pregnancy, cytotrophoblasts invade maternal spiral arteries and 
transform from an epithelial to an endothelial phenotype. This vascular remodeling 
increases the blood flow and the supply of oxygen and nutrients to fetus by the end of 
the first trimester 78,79. In the placenta of preeclamptic women, inadequate 
cytotrophoblast invasion of maternal spiral arteries causes reduced blood flow and 
placental insufficiency resulting in significant placental hypoxia 80. Placental hypoxia 
promotes increased release of sFLT-1 into maternal circulation, which reduces the 
circulating VEGF and PGF levels below a critical threshold required for maintaining 
the vasculature in the mother. The resultant systemic endothelial dysfunction causes 
maternal syndrome characterized by hypertension and proteinuria 75,77.  
 
3.4 Regulation of VEGF and PGF 
The VEGF gene is tightly regulated at the transcriptional level. Hypoxia is the 
major regulator via binding of hypoxia-inducible transcription factors to the hypoxia-
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responsive element located in the VEGF promoter 81. Some growth factors can induce 
VEGF transcription such as PDGF 82, TGFβ 83, epidermal growth factor (EGF) 84 and 
insulin-like growth factor (IGF-1) 85. In addition, cytokines such as IL-10 and IL-13 
inhibit the release of VEGF 86. Unlike VEGF, some studies have shown that PGF is 
not hypoxia-inducible in trophoblast cells 51 and mouse cornea 87, although this is 
controversial since other studies have reported that hypoxia can up-regulate Pgf 
expression during angiogenesis in fibroblasts 88. Thus, it is not fully understood 
whether hypoxia has a generalized effect on Pgf expression or if this is indeed tissue 
and/or cell type specific. In bovine retinal endothelial cells, high glucose increases 
expression of Pgf at both the mRNA and protein level 89. Pgf has been shown to be up-
regulated by forkhead/winged helix transcription factor FoxD1 in epithelial cells. 
FoxD1 binds to a conserved site in the Pgf promoter and activates its transcription 90. 
In human trophoblast cells, glial cell missing 1 (GCM1) has been shown to be a 
critical regulator of PGF gene transcription. In those studies, overexpression of GCM1 
increased human PGF promoter activity 91. Lastly, changes in chromatin structure to 
epigenetic regulatory mechanisms can impact PGF gene regulation. PGF expression is 
reduced through methylation of its promoter in human cell lines of lung and colon 
cancers, while demethylation of the PGF promoter appeared to restore its transcription 
in these tumor cells 92.  
In summary, VEGF and PGF are key angiogenic stimulators during normal 
development as well as in a variety of pathological conditions such as wound healing, 
ischemia and tumor formation. In diseases such as preeclampsia during human 
pregnancy, angiogenic balance appears to be an important determinant of disease 
outcome. In this situation the balance between VEGF and PGF may be antagonized by 
sFLT-1, this having a crucial impact on angiogenic potential within the developing 
placenta. Studies in this dissertation describe important mechanistic data suggesting 
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that regulation of the Pgf gene in mouse and likely in human trophoblasts required the 
trophoblast-specific transcription factor, Dlx3 (described in more detail below). 
Further, disruption of normal DLX3 and PGF expression appears to be an important 
factor associated with preeclampsia. 
 
4. Differences and similarities between mouse and human placenta 
Mouse placenta differs from human placenta in its morphogenesis and endocrine 
functions as shown in Figure 1.3. For example, villi of mouse and human are 
composed of different trophoblast cell layers. Mice have three trophoblast cell layers, 
two syncytial layers and a single mononuclear cell layer while humans have a single 
syncytial layer. Placental villi are grouped into round structures called cotyledons. 
Mice have a single cotyledon whereas humans have multiple cotyledons 2. In mouse, 
the pituitary gland is required for pregnancy and progesterone produced by the CL is 
essential throughout gestation. In early gestation, pituitary-derived prolactin regulates 
CL function. Later, trophoblast giant cells in the mouse placenta secrete PL supporting 
CL production of progesterone. In human, hormones from the pituitary gland are not 
required for the initiation and maintenance of pregnancy. Progesterone is produced 
first by the CL which is dependent on hCG and later progesterone is primarily 
produced by the placenta 93. 
Although there are some anatomic and physiologic differences between mouse 
and human placentas, their overall structures and the molecular mechanisms 
underlying placental development appear to be quite similar 2. The outer layer of the 
mouse placenta is composed of trophoblast giant cells whose function is similar to 
invasive extravillous cytotrophoblast cells in humans. The function of the middle layer 
of mouse placenta, the spongiotrophoblast, is analogous to the column cytotrophoblast 
that anchor the villi of the human placenta. The labyrinth layer of the mouse placenta 
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is similar in function to the chorionic villi of the human placenta 2. In both species, the 
villi are covered by syncytiotrophoblast cells that lie in direct contact with maternal 
blood. The key regulatory molecules during mouse placental development are 
expressed and functional in human placenta as well. Comparative analysis of the 
molecular similarities between the mouse and human placenta shows that over 80% 
genes known to cause placental phenotypes in mouse are expressed in human  
placenta 94. Because of the structural and molecular similarities between the mouse 
and human placentas, genetic studies in mice have provided important insights into the 
molecular bases of human placental disorders including preeclampsia in the mother 
and intrauterine growth retardation in the fetus. 
 
 
 
 
 
 
 
Figure 1.3 Comparative anatomies of the mouse and human placenta. 
From Janet Rossant & James Cross. Nat. Rev. Genet. 2001, 2: 538-548. 
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5. Targeted mutations and knockouts affecting mouse placental development 
The differentiation of trophoblast cell subtypes is regulated by distinct molecular 
mechanisms. A great number of knockout and transgenic mouse models have been 
generated to define genetic determinants required for developmental decisions in 
placental morphogenesis. For example, knockouts of extracellular matrix components, 
numerous receptors, signaling molecules or transcription factors have been shown to 
compromise placental morphogenesis. The following section describes key knockout 
models to illustrate the importance of these factors. 
 
5.1 Extracellular matrix components  
The extracellular matrix components, vascular cell-adhesion molecule 1 (Vcam1) 
and integrin α4 are required for chorioallantois fusion 95. Vcam1 is expressed at the tip 
of the allantois and binds to its receptor integrin α4 that is expressed on the basal 
surface of the chorion 96. The majority of Vcam-1 deficient mouse embryos die at an 
early gestational age due to the failure of allantois fusion to the chorion, resulting in 
abnormal placental development 95. In the minority of Vcam-1 deficient embryos, the 
allantois fuses with the chorion but the allantoic mesoderm is not distributed over the 
entire chorionic surface and formation of vascular structure is found to be abnormal 95. 
Knockout of integrin α4 in mice leads to embryonic death due to failure of fusion of 
the allantois with the chorion during placental development and abnormal 
development of epicardium and coronary vessels 96.  
 
5.2 Fibroblast growth factor (Fgf), Fgf receptor and downstream signaling 
molecules 
Studies in mice have shown that the main signaling pathway involved in the 
interaction between the trophoblast and inner cell mass was the Fgf signaling pathway. 
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Fgf4 is expressed by the inner cell mass at the blastocyst stage and subsequently in the 
embryonic ectoderm 2. Fgf4 is required for the proliferation and maintenance of 
trophoblast stem cell populations 97. Fgf4 knock out mouse embryos die at the time of 
implantation and poor development of all embryonic cell lineages is evident in these 
embryos98,99.  
All four Fgf receptors (Fgfr) are expressed at the blastocyst stage of mouse 
development and Fgfr2 is expressed in trophoblast cells immediately adjacent to the 
embryonic ectoderm 100,101. Disruption of Fgfr2 results in embryonic death a few 
hours after implantation and arrest of trophoblast differentiation 102. Fgfr signaling has 
also been demonstrated to be essential for chorioallantoic fusion and branching as well. 
Deletion of the immunoglobin-like domain of the Fgfr2 extracellular domain causes 
the mouse to die between E10-11 due to failure to form the chorioallantoic fusion and 
severe labyrinth defects 103. In addition to Fgfr2, mice deficient in Egf receptor also 
shows labyrinth defects 104.  
Many signal transduction components that act downstream of these growth factor 
receptors have been implicated during mouse embryogenesis. For example, growth 
factor receptor-bound protein 2 (Grb2) is a signaling adaptor protein downstream of 
Fgf. Grb2 null embryos die after implantation because of defects in inner cell mass 
survival and endoderm differentiation 105. Other signal transduction components 
downstream of Fgf including Grb2-associated binder 1 (Gab1), son of sevenless 
homologue 1 (Sos1), mitogen-activated protein kinase (MAPK) kinase 1 (Mek1) and 
Erk have been linked to the morphogenesis of placental labyrinth layer. The thickness 
of the labyrinth layer of the placenta in Gab1 knockout mice is shown to be severely 
reduced 106. The Sos-/- mouse placental labyrinth layer is also very thin and highly 
disorganized and vasculature in the labyrinth is incomplete 107. Targeted disruption of 
the mouse Mek1 gene results in embryonic lethality at E10.5 because vascular 
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endothelial cells in the labyrinth layer markedly decrease, leading to the reduced 
vascularization of the developing placenta 108. Erk2 knockout mouse embryos die at 
E11.5 due to the abnormality of the labyrinth layer of the placenta 109. Interestingly, 
Erk1 null mice appear to be completely normal with regard to placental function 
suggesting that during development, Erk1 and Erk2 do not appear to have redundant 
roles in the mouse 110,111.    
 
5.3 Transcription factors 
Fgf signaling regulates the expression of the homeobox transcription factors 
caudal-type homeobox (Cdx2) and eomesodermin homologue (Eomes), which are in 
turn required for maintaining the fate of trophoblast stem cells 112. The formation of 
the spongiotrophoblast or trophoblast giant cells from the ectoplacental cone is 
regulated by a balance among the actions of basic helix-loop-helix (bHLH) 
transcription factors at the transcriptional level. For example, mammalian achaete-
scute homologue 2 (Mash2) has shown to be an important regulator of trophoblast 
proliferation; its expression level diminished as mouse trophoblasts differentiate into 
giant cells. The targeted deletion of the Mash2 gene results in an increased number of 
trophoblast giant cells and diminished spongiotrophoblast layer 113. Contrary to the 
effect of Mash2, the other bHLH transcription factor Hand1 114 promotes 
differentiation of trophoblasts into giant cells.  
Gcm1 regulates the initiation of chorioallantoic branching and the differentiation 
of syncytiotrophoblast in mouse 115. Gcm1 expressing cells are localized precisely at 
sites of primary branch points and as the branches elongate, Gcm1 expression remains 
at the distal tip of the branches. In Gcm1 knockout mice, the allantois still fuses with 
the chorion, but subsequent steps of placental labyrinth formation appear to be 
inhibited, so the mouse embryos die at E10 due to absence of placental labyrinth 115. 
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Extraembryonic, spermatogenesis, homeobox-1 like protein-1 (Esx1) and distal less 3 
(Dlx3) are other transcription factors critical for development of the labyrinth layer. 
Esx1 is located on the distal arm of X chromosome 116. The Esx1 gene encodes a 
homeobox transcription factor that has been shown to be expressed only in trophoblast 
cells of the labyrinth. In the placenta of Esx1 mutant mouse, the chorioallantoic 
branching is shown to be normal but there are obvious deficiencies in fetal blood 
vessel growth into the labyrinth 117. Surprisingly, the Esx1 knockout mouse placenta is 
actually larger than normal suggesting an attempt to compensate for the reduced 
vascularization and nutrient transport. The other transcription factor Dlx3 is also 
shown to be required for normal labyrinth development. Dlx3 null mice die in uteri 
between E9.5-10 as a result of placenta defects that involve abnormal development of 
spongiotrophoblast and labyrinth layer, including defects in vascularization 118. The 
focus of the research presented in this dissertation is related to the role and regulation 
of Dlx3. As such, a more detailed discussion of this factor is warranted.   
 
6. Distal-less family members 
In Drosophila, the distal-less homeodomain gene Dll regulates the formation of 
appendages such as legs and antennae 119. Proteins of the Distal-less family are all 
related to this Drosophila distal-less homeodomain homolog 119,120. In mammals, the 
distal-less family includes six members, arrayed in pairs and aligned with the Hox 
gene clusters along different chromosomes 121. In mice and humans, Dlx1 and Dlx2 are 
linked with the Hox D gene cluster 122; Dlx3 and Dlx4 are linked to the Hox B  
cluster 123; and Dlx5 and Dlx6 are linked to the Hox A cluster 124. The relationship 
between convergently transcribed pairs of Dlx family members and specific Hox gene 
clusters suggests that these homeodomain-containing transcription factors are likely 
involved in important aspects of developmental morphogenesis 121. 
 21 
Table 1.1 Mouse mutant placental phenotypes mentioned in the context 
Gene Gene product Placental phenotype of mutant mice 
Vcam1 95 Adhesion molecule Failure of chorioallantoic attachment 
Integrin α4 96 Adhesion molecule (Vcam1 
receptor 
Failure of chorioallantoic attachment 
Fgf4 98,99 Fibroblast growth factor Failure of implantation 
Fgfr2 102,103 Fgf receptor Failure of chorioallantoic attachment 
or defective labyrinth formation 
Grb2 105 Adaptor protein Small labyrinth 
Gab1 106 Adaptor protein Small labyrinth 
Sos1 107 MAPK pathway Small labyrinth 
Mek1 108 MAPK kinase Small labyrinth 
Erk2 109 MAPK pathway Small labyrinth 
Cdx2 112 Homeodomain transcription 
factor 
Failure to maintain trophoblast stem 
cells 
Eomes 112 Homeodomain transcription 
factor 
Failure to maintain trophoblast stem 
cells 
Mash2 113 bHLH transcription factor Loss of spongiotrophoblasts, increased 
giant cell formation 
Hand1 114 bHLH transcription factor Block to giant cell differentiation 
Gcm1 115 Transcription factor Block to chorioallantoic branching 
morphogenesis, no labyrinth 
Esx1 117 Homeodomain transcription 
factor 
Placental hyperplasia, vascularization 
defects 
Dlx3 118 Homeodomain transcription 
factor 
Small labyrinth 
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Dlx genes are expressed in distinct but overlapping regions within the embryo, 
primarily in the forebrain, branchial arches and tissues derived from epithelial/ 
mesenchymal interactions during development 125,126. In mouse, all six Dlx genes are 
primarily expressed in ectodermal derivatives: the nervous system and the surface 
ectoderm. Dlx1, Dlx2, Dlx5 and Dlx6 were found to be expressed in the central 
nervous system, highly restricted to diencephalon and telencephalon 124. In situ 
hybridization studies have revealed a strict temporal sequence of the expression of Dlx 
gene in the forebrain. Dlx2 appears to be activated first, and then Dlx1 is subsequently 
transcribed in a subset of the Dlx2 expressing cells, followed by Dlx5 and Dlx6 127. 
Dlx2 knockout mice show abnormal development of proximal first and second 
branchial arches and abnormal differentiation in the forebrain 128. The Dlx1/Dlx2 
double mutants show a major blockage of neurogenesis within the subcortical 
telencephalon 129. Targeted disruption of Dlx5 in mouse leads to craniofacial defects, 
severe malformation of the vestibular organ and delayed ossification 130. The 
Dlx5/Dlx6 double mutants result in severe craniofacial and appendicular skeletal 
abnormalities 131. 
 
6.1 Dlx3 
 In contrast to other members of Dlx family, Dlx3 is not expressed in the central 
nervous system 125. Dlx3 has been shown to be tandemly and inversely arrayed with 
Dlx4 on human chromosome 17, separated by approximately 17.6 kb of intervening 
sequence 132. Dlx3 and Dlx4 show highly similar expression patterns. This concordant 
expression of genes suggests that they may be regulated by shared cis-control 
elements in their shared intermediate domains 133. Conserved elements exist in the 
intermediate domain of Dlx3-4 by sequence comparisons between mouse and  
human 134. During development, Dlx3 has been demonstrated to be involved in 
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developmental determination of multiple tissues, including the first and second 
branchial arches, dental tissues, epithelial derivatives and the placenta.  
Although all the Dlx genes are expressed in the first and second branchial arches, 
the expression Dlx3 is spatially and temporally distinct from the other members. It is 
the latest and most distally expressed in branchial arches 126. Expression of Dlx3 in the 
branchial arch appears to affect development of odontoblasts and craniofacial 
structures 135. The presence of Dlx3 mRNA in the tooth germ has been reported during 
bud, cap and bell stages of dental development 125,136. In addition, more recent studies 
have shown that Dlx3 was expressed in periosteum, osteoblasts, and chondrocytes of 
the developing limb and in osteogenic cell lineage, suggesting that Dlx3 may play a 
prominent role in bone physiology 137,138. 
Dlx3 is involved in the development of epithelial tissues such as skin, hair 
follicles, otic and olfactory placodes and limb buds 139. In the epidermis, Dlx3 is 
shown to be exclusively expressed in suprabasal cells, with transcription initiating 
shortly after cells exit the basal layer. Ectopic expression of Dlx3 in the basal cell 
layer of transgenic mouse skin induces cessation of proliferation and premature 
differentiation of keratinocytes, supporting a role for Dlx3 during epidermal 
differentiation 140. By the end of embryonic development in mice, Dlx3 expression has 
become restricted to the skin, where it is transcribed in the suprabasal cells of stratified 
epidermis and in the matrix cells of hair follicles 121. Dlx3 is also expressed 
throughout hair cycle and it is a crucial regulator of hair morphogenesis, 
differentiation and cycling 141. Conditional deletion of Dlx3 in the mouse epidermis 
results in complete alopecia, which is thought to be caused by failure of the hair shaft 
to form due to abnormal differentiation of the cortex of the hair shaft 141.  
In mouse placenta, Dlx3 is exclusively expressed in the ectoplacental cone and 
chorionic plate by E8.5, later in trophoblasts within the labyrinth layer by E10.5 118, 
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and Dlx3 continues to be expressed in the labyrinth throughout the remainder of 
gestation 142. Interestingly, Dlx3 does not appear to be expressed in trophoblast giant 
cells in mouse 142. Work from colleagues in the Roberson lab demonstrated that DLX3 
was nuclear localized in both cytotrophoblast and syncytial trophoblast within 
microvilli of first trimester human placenta at a time of peak hCG synthesis and 
secretion 143. In cultured human placental trophoblasts, DLX3 localizes to the nuclear 
compartment as well consistent with its role as a transcriptional regulator 144.   
 
6.2 Function of Dlx3  
The homeodomain within Dlx3 is a 60 amino acid conserved DNA binding motif 
that suggests that Dlx3 functions as a transcription factor and recognizes specific 
target sequences in the genome. Dlx3 also contains nuclear localization and 
transcriptional activation domains. Both mouse and human Dlx3 protein is composed 
of 287 amino acids with homeodomain located in residues 130-189 145. The sequence 
of Dlx3 protein is highly conserved between mouse and human with only five 
different amino acids and none of them is located at the homeodomain. The DNA 
binding domain of Dlx3 is located on the third α-helix of homeodomain which has 
been implicated in the direct binding with the major groove of DNA. The consensus 
DNA binding sequence for Dlx3, (A/C/G)TAATT(G/A)(C/G), was determined by 
random oligonucleotides binding selection in vitro 146. The activation domain of Dlx3 
includes two sites: residue 1-43 and residues 189-220 with the latter just downstream 
of the homeodomain 145.  
Dlx3 is thought to be a cell-type specific transcriptional activator in placental 
trophoblasts. In human trophoblast cell lines, DLX3 plays a key role in regulating cell-
specific expression of the α subunit of hCG, a key hormone of early pregnancy in 
primate placenta, as described earlier 143. Trophoblast-derived hCG plays a critical role 
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in the maintenance of progesterone secretion from the corpus luteum until the placenta 
can produce sufficient progesterone to maintain pregnancy 18. DLX3 binds to and 
transactivates the promoter of hCG gene via a cis acting element termed the junctional 
regulatory element (JRE). Mutations within the JRE markedly reduce basal expression 
of the α subunit of hCG because DLX3 cannot bind the mutant JRE 143.  
In addition to regulation of the α subunit of hCG, DLX3 is required for 
trophoblast-specific expression of the 3β-hydroxysteroid dehydrogenase type VI 
(3βHSD) gene 147. 3βHSD is an enzyme essential for the biosynthesis of all active 
steroid hormones including progesterone. 3βHSD is expressed in human placenta and 
is thought to be required for the biosynthesis of placental progesterone and thus the 
maintenance of pregnancy 148. In human placental cells, transfection studies have 
identified two novel trophoblast-specific enhancer elements within the 3βHSD VI 
gene promoter. These two enhancers bind DLX3 and activator protein (AP-2γ), a 
combination of cis elements and regulatory factors shared with regulation of the 
glycoprotein hormone α subunit promoter. Interestingly, the combined actions of 
DLX3 and AP-2γ appear to be necessary for the transcriptional regulation of both the 
glycoprotein hormone α subunit and 3βHSD VI genes in trophoblasts, suggesting 
commonality in transcription factor regulatory combinations or codes directing cell-
type specific gene expression 143,147,149. 
DLX3 also appears to regulate the gene expression of the bovine interferon-tau 
(IFNT) gene in ruminants. IFNT is secreted by ruminant trophoblasts and is thought to 
be a critical signal for maternal recognition of pregnancy in cattle and sheep 150. IFNT 
in ruminants has similar paracrine functions to those of hCG in primates. IFNT acts 
locally on the uterine endometrium to promote uterine implantation by increasing 
protein synthesis in endometrial glands 151. DLX3 transactivates the bovine IFNT 
promoter in human trophoblasts. In both human and bovine trophoblast cell line, 
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DLX3 is coexpressed with v-ets erythroblastosis virus E26 oncogene homolog 2 
(ETS2), the key regulator of IFNT expression. ETS2 and DLX3 have been shown to 
induce synergistic activation of IFNT promoter and deletion of the ETS2 binding site 
within the IFNT gene promoter eliminates the ability of DLX3 to transactivate the 
IFNT gene 152.  
Loss of Dlx3 in mice is associated with reduced expression of another homeobox 
gene, Esx1. The Esx1 gene encodes a homeobox transcription factor that appears to be 
expressed in visceral yolk sac, the ectoderm of the chorion, and trophoblast cells of the 
labyrinth in the mouse. In adult tissues, Esx1 expression was shown to be restricted to 
germ cells in testes 116. Thus, Esx1 has an important role in the differentiation of 
specific extraembryonic tissues and also in male germ cell development. Based on 
knockout studies, Dlx3 was identified as an important transcriptional regulator of Esx1 
gene promoter activity 118. While links to the Dlx3 gene program make important 
connections to Esx1; little is known about the larger group of Dlx3 responsive genes 
within the placenta. This dissertation focuses on microarray analyses and transcript 
profiling in comparing the placentas of wild type and Dlx3 null mice.  
Dlx3 is expressed in tissues in addition to placenta, such as epidermis, bone 
structure in mouse and human and Xenopus tissues. Dlx3 is an important regulator of 
epidermal differentiation. In normal epidermis, the profilaggrin and Dlx3 gene are co-
expressed in the granular layer which is the latest stage of epidermal differentiation. 
Ectopic expression of Dlx3 in the mouse basal cell layer causes the reduced expression 
of profilaggrin in the granular cells but increased expression in basal cells. Gel 
mobility shift experiment demonstrates the presence of a binding site for DLX3 within 
the proximal promoter region of the human profilaggrin gene 140. P63, a member of 
p53 family, is essential for the development and maintenance of the stratified 
epidermis. Dlx3 and p63 colocalize in the embryonic ectoderm throughout embryo 
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development, and Dlx3 expression is reduced in the embryos of p63 knock out mouse. 
P63 binds to the promoter of Dlx3 gene and transactivates Dlx3 gene expression in 
mouse keratinocytes 153. Once increased by p63, Dlx3 activates Raf1 kinase which 
mediates the phosphorylation of p63. This phosphorylation causes the degradation of 
p63 and thus the feedback regulatory loop is formed between p63 and Dlx3 154. 
Dlx3 has been shown to express in pre-osteoblasts, osteoblasts and osteocytes in 
bones 138. Runt-related transcription factor 2 (Runx2) is the earliest transcription factor 
that is essential for the formation of osteoblasts in response to bone morphogenetic 
protein 2 (BMP2) 137. BMP2 induces Runx2 gene transcription through activation of 
DLX3 protein expression 155. Dlx3 is up-regulated in differentiated osteoblasts and 
osteocytes, which implies that Dlx3 also plays a role in the late stage of osteoblast 
differentiation 156.   
In these cases, Dlx3 acts as a transcriptional activator. However, Dlx3 can also 
serve as a negative regulator of gene transcription in amphibians. During Xenopus 
development, Dlx3 is activated at the beginning of gastrulation and it is not expressed 
in the dorsal region of the embryo, which is the future neural plate. Dlx3 represses the 
activation of genes which are specific to the nascent central nervous system through 
blocking the activation of zinc finger proteins, Zic3. By the neurula stage, Dlx3 is 
essentially expressed specifically in epidermis 157. 
The activation/repression ability of Dlx3 may depend on different cell contexts 
and physiological states by interacting with variable heterodimeric partners. This 
dissertation examines the binding partners of DLX3 in human trophoblast cells and 
demonstrates that a DLX3 partner is mothers against decapentaplegic homolog 6 
(SMAD6). 
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6.3 Importance of Dlx3  
The importance of Dlx3 arises from its function in different biomedical systems 
of disease states. Dlx3 null mice die in utero by E10 due to placental failure 118. This is 
failures due to abnormal development/morphogenesis of the labyrinth layer in the 
mouse placenta. The early death of Dlx3 knock out mice makes it difficult to study 
Dlx3 function in later development; however, there is additional genetic evidence in 
humans implicating the function of DLX3 in hair, tooth, and craniofacial 
morphogenesis 138.  
Mutation in human DLX3 gene has been linked to tricho-dento-osseous (TDO) 
syndrome, an autosomal dominant disorder manifested by kinky, curly hair at birth, 
enlarged pulp chambers in the teeth (taurodontism), enamel defects that cause tooth 
loss by adulthood and increased thickness and density of the cranial bones 158,159. 
Consistent with these observations, transgenic mice with the human TDO mutant have 
markedly increased trabecular bone volume and bone mineral density in the femoral 
bone 160. The TDO defect is a four nucleotides deletion just downstream of the DNA-
binding homeodomain in DLX3 158. This deletion causes a frameshift mutation 
resulting in a premature stop codon and ultimately the deletion of the carboxy-terminal 
32 amino acids of DLX3 protein 159,161. The mutated DLX3 TDO has a dominant 
negative effect on wild type DLX3 in that the TDO mutant appears to be unable to 
bind DNA alone but can form a heterodimer with wild type DLX3 and subsequently 
inhibits wild type DLX3 transcriptional activity 162.    
Amelogenesis imperfecta (AI) with taurodontism in human has similar 
phenotypic characteristics to TDO. AI is an autosomal dominant trait leading to dental 
enamel defects and enlarged pulp chambers. The mutation is a deletion of two 
nucleotides in the DLX3 coding sequence that causes a frameshift altering the last two 
amino acids of the homeodomain. This results in a mutant protein that is 88 amino 
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acids shorter than the normal DLX3 protein 163. The carboxyl terminal change 
downstream of the AI mutant is not the same as the TDO mutant.   
In addition to TDO and AI, DLX3 mutations have been associated with some 
forms of craniofacial abnormalities, including cleft palate 164. The putative 
involvement of DLX3 in the occurrence of cleft palate is also supported by the mouse 
model deficient in endothelin-1 receptor, which results in cleft palate and hypoplasia 
of the mandible 165-167. In this model, Dlx3 expression is shown to be dependent upon 
endothelin-1 through a Gαq/Gα11-dependent signaling mechanism. In the Gαq/Gα11-
deficient mouse, Dlx3 is also specifically down-regulated, supporting the speculation 
of the importance of Dlx3 in cranio-facial morphogenesis 168.  
Collectively, these studies of TDO, AI and craniofacial abnormalities underscore 
the biomedical significance of studying Dlx3, its mechanism of action and 
downstream gene program. The focus of this dissertation is to dissect the role of Dlx3 
in gene regulation in the mouse placenta.   
 
6.4 Regulation of Dlx3 gene expression 
The expression of Dlx3 has been shown to be regulated by a number of growth 
factors and hormones including BMP2, endothelin-1 and transcription factors for 
example CCAAT box/enhancer-binding protein β (C/EBPβ) and Msh homeobox 
homolog 1 (Msx1). The following sections briefly described studies that defined the 
role of these factors in the regulation of Dlx3 transcript and protein abundance. 
BMP2 
Expression of Dlx3 was demonstrated to be BMP2-dependent in early 
gastrulation 169 and for cellular differentiation of both keratinocytes 141 and  
osteoclasts 169. BMP2 is expressed in proliferative basal and differentiated suprabasal 
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keratinocytes. In cultured keratinocytes, the transcription of Dlx3 is induced within 12 
hours and remains activated up to 48 hours by BMP2 treatment in vitro 141. This 
transactivation is appeared to be mediated through a member of the Smad family of 
transcriptional regulators. Smad proteins can be subdivided into three classes: 
regulated Smads (Smad 1, 2, 3, 5 and 8), common Smads (Smad 4) and inhibitory 
Smads (Smad 6 and 7) 170-172. Smads integrate BMP action following BMP2 binding 
to its type I and II receptors, Smad1 becomes phosphorylated. Phosphorylated Smad1 
then interacts with common Smad4 and subsequently the Smad dimer translocates into 
the nucleus. Finally, the Smad1/4 complex activates BMP2-specific target genes such 
as Dlx3 173. In osteoblasts, DLX3 is shown to be continuously up-regulated during 
BMP2 induced osteogenesis. BMP2 induced DLX3 also activates gene transcription 
of Runx2, the transcription factor essential for the formation of osteoblasts 155.  
Endothelin-1 
Endothelin-1 is expressed in the epithelium of pharyngeal arches. Activation of 
endothelin-1 has shown to be required for proper development of craniofacial 
structures 166. As indicated earlier, targeted deletion of the endothelin-1 ligand or its 
receptor causes cleft palate and hypoplasia of the mandible. Dlx3 expression is shown 
to be significantly reduced in endothelin-1 receptor knock out mice 165. Gαq/Gα11 
signaling pathway is the downstream signal of endothelin-1. In the Gαq/Gα11 
deficient mouse, Dlx3 is specifically down-regulated in pharyngeal arches 168. These 
studies implied that Dlx3 is dependent upon endothelin-1 through Gαq/Gα11-mediated 
mechanism. 
CCAAT box and C/EBPβ 
In mouse epidermis, a CCAAT box enhancer located within the 5’-flanking 
sequences of the Dlx3 promoter appears to be responsible for the majority of the Dlx3 
promoter activity. Additionally, the Sp1 binding site located immediately upstream of 
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transcription start site acts as a positive regulatory element of the Dlx3 promoter, 
independent of the CCAAT box 174. The Roberson lab has also shown that the 
CCAAT box enhancer is required for regulation of basal expression of the Dlx3 gene 
promoter in choriocarcinoma cells, a model for human placental trophoblasts 174. In 
placental cells, the CCAAT box sequence specifically binds C/EBPβ. Interestingly, 
Dlx3 and C/EBPβ were shown to be coexpressed in human primary trophoblasts 
derived from normal term pregnancy 144. These studies suggested a central role for 
C/EBPβ in the basal regulation of the Dlx3 promoter in placental trophoblasts.  
Msh homeobox homolog 1 (Msx1) 
The other homeodomain-containing transcription factor family, Msx, is closely 
related to Dlx family. Dlx proteins have been shown to be transcriptional activators, 
while Msx proteins appear to function as transcriptional repressors that antagonize Dlx 
function 175. The Msx1 protein binds a DNA sequence containing TAAT, which is 
also recognized by the Dlx3 homeobox 157. Thus, the preferred DNA binding sites for 
Dlx3 and Msx1 are essentially the same 157. During mouse embryogenesis, the 
expression patterns of Msx1 and Dlx3 genes overlap in the limb bud and during 
craniofacial development suggesting that this putative antagonism may be essential to 
these developmental processes 175. In the adult mouse, Dlx3 and Msx1 protein have 
also been shown to be coexpressed in the differential layers of epidermal tissues. In 
this scenario, the transcriptional activity of Dlx3 is thought to be regulated by the 
transcriptional repressor protein Msx1 175. Msx1 can form a heterodimer with Dlx3 
therefore competing for DNA binding and effectively inhibiting the function of  
Dlx3 145.  
This dissertation investigates proteins within the human placental cells that can 
interact with DLX3 and then may further affect its transcriptional activity. The binding 
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partner of DLX3 is SMAD6. This dissertation also examine the mechanisms of 
SMAD6 regulating the transcriptional effect of DLX3 on its target genes such as Esx1 
and Pgf. 
   
7. Summary 
During mammalian embryogenesis, the placenta provides maternal nutrition, 
facilitates fetal respiration, eliminates fetal waste, and protects the fetus from maternal 
immune system. The placenta is also an important source of hormones and growth 
factors that are essential for normal embryonic development and maintenance of the 
reproductive cycles necessary for successful and productive pregnancy. Dlx3 plays an 
important role in the development of placental labyrinth in the mouse and the 
regulation of hormones critical to pregnancy (such as hCG) in the primate. My 
hypothesis in this dissertation is that Dlx3 plays a critical role in placental 
development by regulating its related genes. The research described in Chapter 2 
sought to examine the mechanisms associated with DLX3 as a transcriptional activator 
by characterizing binding partners of DLX3 in trophoblast cells. In Chapter 3, I 
described the gene profile regulated by Dlx3 in the mouse placenta and Pgf is one of 
the Dlx3 dependent genes. Specific control of Pgf gene expression may be of 
particular importance in disease situations like preeclampsia, where PGF appears to be 
a significant component and a marker of the progression of the disease. In Chapter 4, I 
analyzed the role of Dlx3 in Pgf gene regulation in trophoblast cells. My studies 
demonstrated that Dlx3 directly affects transcriptional regulation of Pgf. By 
unraveling Dx3-dependent mechanisms related to placenta development in the mouse, 
we may better understand the human placenta and diseases such as preeclampsia in 
women and fetal growth retardation that compromise both maternal and fetal health.  
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SMAD6 REPRESSES DLX3 TRANSCRIPTIONAL ACTIVITY THROUGH 
INHIBITION OF DNA BINDING 
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Abstract 
Dlx3 is a homeobox-containing transcription factor required for normal placental 
development in mice. Here we demonstrate that DLX3 interacts with SMAD6, a 
member of a larger family of transcriptional regulators generally thought to regulate 
transforming growth factor β/bone morphogenetic protein signaling. 
Immunocytochemical and immunoprecipitation studies demonstrate overlapping 
nuclear localization and physical interaction between DLX3 and SMAD6 in human 
choriocarcinoma cells and in differentiated trophoblasts from human placenta. In vitro 
protein interaction studies mapped the SMAD6 interaction domain within DLX3 to 
residues 80-163, a region of DLX3 that includes a portion of the homeodomain. DLX3 
and DLX4 share homology within this region, and DLX4 was also found to bind 
SMAD6. Using the Esx1 gene promoter as a model for a Dlx3-responsive gene, 
studies demonstrate two near consensus Dlx3 binding sites within the proximal 2.3 kb 
of the transcription start site. Interestingly, binding of DLX3 to one of these two sites 
was inhibited by interaction with SMAD6. Consistent with this result, expression of an 
Esx1 promoter luciferase reporter was increased by overexpression of DLX3; this 
effect was reversed with co-expression of SMAD6. Further, small interfering RNA 
mediated knockdown of endogenous SMAD6 increased DLX3-dependent expression 
of the Esx1 gene promoter. Thus, SMAD6 appears to functionally interact with DLX3, 
altering the ability of DLX3 to bind target gene promoters. SMAD6 appears to play a 
modulatory role in the regulation of DLX3-dependent gene transcription within 
placental trophoblasts. 
 
Introduction 
The Dlx family of transcriptional regulators includes six members in mammals, 
arrayed in pairs and aligned with the Hox gene clusters along different  
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chromosomes 1,2. DLX3 is tandemly arrayed with DLX4 on human chromosome 17 
and is involved in developmental determination of multiple tissues, including the first 
and second branchial arches, teeth, bone, and multiple epithelia, including the skin, 
mammary gland primordia, and the placenta 3. The relationship between convergently 
transcribed pairs of Dlx family members and specific Hox gene clusters has suggested 
that, although independent of Hox gene expression patterns, these homeodomain-
containing transcription factors are clearly involved in important aspects of 
developmental morphogenesis (reviewed in Ref. 2). The importance of Dlx3 during 
development and in the adult arises from several different observations of disease 
states. Mutations in DLX3 are believed to be causally related to TDO, a genetic 
disorder manifested by taurodontism, hair abnormalities, and increased bone density in 
the cranium 4-6. The defect in DLX3 leading to TDO appears to be associated with a 
four-nucleotide deletion just downstream of the homeodomain, resulting in a 
premature truncation of the protein. AI with taurodontism has similar characteristics as 
TDO and has also been associated with mutations with DLX3 in some families 
investigated, albeit distinct from the four nucleotide deletion/mutation described  
above 7. AI is an autosomal dominant trait leading to dental enamel defects and 
enlarged pulp chambers and has been associated with a two-nucleotide deletion within 
the homeodomain of DLX3. This deletion again results in a frameshift and premature 
truncation of DLX3 in the carboxyl terminus, primarily downstream of the homeobox. 
In addition to TDO and AI, Dlx3/Dlx4 have been identified in the gene interval 
thought to be involved in some forms of craniofacial abnormalities, including cleft 
palate 8. The putative involvement of Dlx3 in the occurrence of cleft palate is also 
supported by the murine model deficient in endothelin-A receptor, which results in 
cleft palate and hypoplasia of the mandible 9-11. In this model, Dlx3 expression is 
thought to be dependent upon endothelin-1 through a Gαq/Gα11-dependent 
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mechanism. In the Gαq/Gα11-deficient mouse, Dlx3, among other factors, is 
specifically down-regulated, supporting the speculation of the importance of Dlx3 in 
cranio-facial morphogenesis 12. Thus, the role and importance of Dlx3 in morphogenic 
aspects of development and in epithelial differentiated function is rather far reaching. 
The Dlx3 null mouse dies in utero by E10 due to putative placental failure 13. 
This was associated with a failure in the development/morphogenesis of the placental 
labyrinth compartment of the murine placenta. Further, genetic loss of Dlx3 was 
correlated with reduced expression of an additional homeobox factor, Esx1, 
suggesting that Dlx3 may be an important transcriptional regulator of Esx1 promoter 
activity. Studies from our laboratory identified DLX3 as a cell type-specific 
transcriptional activator in placental trophoblasts. DLX3 binds to and transactivates 
the promoter for the glycoprotein hormone α subunit gene via a cis-acting element 
required for full basal activity of this gene 14. The glycoprotein hormone α subunit is a 
subunit of the heterodimeric glycoprotein hormone, CG. Trophoblast-derived CG has 
been identified in primates and equine and appears to play a critical role in the 
maintenance of early pregnancy in women, providing early gonadotropic support to 
the CL and maintenance of progesterone production 15-17. Both for the case of the α 
subunit promoter and regulation of Esx1 in the Dlx3 null mouse, Dlx3 appears to 
function as a putative transcriptional activator. However, it has also been proposed 
that Dlx3 can serve as a negative regulator of gene transcription in amphibian models 2. 
This apparent activation/repression capability may be due to variable heterodimeric 
partners of Dlx3 (as proposed in Ref. 2), dependent upon cell context and 
physiological state. This observation was the impetus for us to examine potential 
binding partners of DLX3 in the context of the human placenta. The present studies 
identify SMAD6 as a binding partner for DLX3 using a yeast two-hybrid screen of a 
human term placental cDNA library. DLX3 and SMAD6 are co-localized in the 
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nucleus of cells of trophoblast origin including cytotrophoblasts and syncytial 
trophoblasts from fully differentiated human term placenta. Interaction between DLX3 
and SMAD6 alters the DNA binding properties of DLX3 such that SMAD6 serves as 
a negative regulator of DLX3-dependent gene transcription of the Esx1 promoter. 
 
Materials and Methods 
Plasmids and cDNAs 
    All plasmids used in these studies were prepared by two cycles through cesium 
chloride using standard protocols. Expression vector for human DLX3 was generously 
provided by Dr. Maria Morasso (National Institutes of Health, Bethesda MD). A series 
of deletion mutants of the DLX3 cDNA were constructed by PCR. To facilitate 
cloning into the pKH3 vector (generously provided by Dr. Jun-Lin Guan, Cornell 
University, Ithaca, NY), EcoR I and Cla I restriction sites were added to the forward 
and reverse primers, respectively. The forward primers used in these reactions were as 
follows: forward 1, 5’-TCAGGAAT TCAAATGAGCGGCTCCTTCGATCGC-3’, 
forward 40, 5’-TCAGGAATTCAACTGGGC TATTACAGCGCTCCTCAG-3’, 
forward 80, 5’-TCAGGAATTCAATACTCGCCCAAGT CGGAATATACC-3’, 
forward 121, 5’-TCAGGAATTCAAATGGTGAACGGCAAGCCCAAAAAG-3’, and 
forward 195, 5’-TCA GGAATTCAACTGGAACACAGCCCCAACAACAGT-3’. 
The reverse primers used in these reactions were as follows: reverse 128, 5’-
GTACATCGATCACGGCTTTCGGACC TTCTTGGGCTTCCC-3’, reverse 163, 5’-
GTACATCGATCAAGCTAGCTCGGCGCGCTCAGGCAA-3’, reverse 202, 5’-
GTACATCGATCAACTGTATTGGGACTGTGCTCCAG-3’, and reverse 287, 5’-
GTACATCGATTCAGTACACAGCCCCAGGGTT-3’. PCR products were cloned 
initially into the pGEM T-Easy vector (Promega Corp., Madison, WI). Once verified 
by nucleotide sequence analysis, fragments were subcloned into the pKH3 vector for 
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use in studies. SMAD6 expression plasmid was a gift from Dr. Ali Hemmati-
Brivanlou (The Rockefeller University, New York, NY). SMAD4 expression vector 
was a gift from Dr. Colin Clay (Colorado State University, Fort Collins, CO). The 
human DLX4 cDNA was obtained by PCR from RNA isolated from JEG3 cells using 
the following primers: 5’-TCAGGAATTCAAATGACCTC TTTACCCTGTCCC-3’ 
and 5-GTACATCGA TCACATCATCTGAGGCAG TGC-3’. The resulting DLX4 
cDNA was cloned into pKH3 and verified by nucleotide sequence analysis. Esx1-
2.3kb promoter was obtained by PCR using mouse genomic DNA and the following 
primers: 5’ primer (5’-GGTACCAGCACCGAGCTATCACAACCATCA-3’) and 3’ 
primer (5’-GCTAGCTACCAGCTGCTTCTCCCGTA-3’). To facilitate cloning, Kpn I 
and Nhe I restriction enzyme sites were engineered at the end of the 5' primer and 3’ 
primer respectively. The PCR products were cloned into pGEM T-Easy vector. After 
Kpn I and Nhe I digestion, the promoter fragment was subcloned into a luciferase 
reporter vector. The fidelity of the construct was confirmed by nucleotide sequence 
analysis. PCR-based site-directed mutagenesis was used to disrupt the distal DLX3 
binding site within the Esx1 luciferase reporter. This mutation substituted a Not I 
restriction site for the near consensus DLX3 binding site. The mutation was confirmed 
using nucleotide sequence analysis. The human α subunit gene promoter luciferase 
reporter has been reported previously 14. 
 
Yeast two-hybrid screen 
To investigate novel protein-protein interactions, full-length DLX3 served as the 
bait protein with a human term placental cDNA library serving as the target. The bait, 
human DLX3 cDNA was cloned into the vector pGBKT7 and transformed in the yeast 
strain AH109. A pretransformed human term placental Matchmaker cDNA library was 
in yeast strain Y187 (BD Biosciences/Clontech, Palo Alto, CA). The bait and library 
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plasmids were expressed as GAL4 fusion proteins. 3-amino-1,2,4-triazole was titrated 
(5-35 mM) using the bait strain to control background yeast growth. A concentration 
of 12 mM 3- amino-1,2,4-triazole was used in the library screen. The bait and library 
strains were mated with an efficiency of approximately 4%. The bait strain required 
Leu- Synthetic Dropout (SD) minimal medium, and the library strain required Trp- SD 
minimal medium. Mating was carried out in YPDA media containing 0.003% adenine 
hemisulfate. Following mating of the bait strain with the human placental library, 
yeast was initially plated on medium stringency SD media (His-/Leu-/Trp-) plates. 
When colonies were of sufficient size, colonies were replicate plated on high 
stringency SD medium (Ade-/His-/Leu-/Trp-/X-α-Gal) plates to verify that they 
maintained the correct phenotype. A colony filter lift assay was performed to access β-
galactosidase activity to identify and rank the strength of potential interactions. Once 
identified, yeast plasmids were isolated using disruption with glass beads and plasmids 
rescued/purified using the Qiagen Miniprep reagents and spin column (Qiagen Inc., 
Valencia, CA). Identity of the rescued plasmids was verified by nucleotide sequence 
analysis. The interaction between DLX3 and target genes was examined using a 
reconstitution assay where both plasmids were co-transformed into the AH109 yeast 
strain and plated on high stringency SD medium.   
 
Preparation of JEG3 cell nuclear extracts 
Subconfluent JEG3 cells were used for the preparation of nuclear extracts. Cells 
were washed twice with ice-cold Dulbecco’s Phosphate Buffered Saline (PBS; 
Invitrogen Corp., Carlsbad, CA). Cells were collected by scraping in ice-cold PBS 
supplemented with 1:1000 dilution of protease inhibitor cocktail (referred to as 
protease inhibitor cocktail; Sigma-Aldrich Corp., St. Louis, MO), 5 mM benzamidine, 
and 0.2 mM phenylmethylsulfonyl fluoride (PMSF). Cells were pelleted by 
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centrifugation and resuspended in a hypotonic buffer consisting of 120 mM potassium 
chloride, 30 mM sodium chloride, 30 mM Hepes (pH 8.0), 0.3 M sucrose, protease 
inhibitor cocktail, 5 mM benzamidine, and 0.2 mM PMSF and allowed to swell for 15 
min on ice. Cells were lysed by douncing and nuclei were isolated by layering the 
broken cell lysate over a sucrose cushion (0.9 M sucrose) followed by centrifugation 
at 2000×g for 30 min at 4˚C. The nuclear pellet was resuspended in a buffer 
containing 10 mM Tris (pH 7.5), 50 mM NaCl, 5% glycerol, 1 mM ethylenediamine 
tetraacetic acid (EDTA), protease inhibitor cocktail, 5 mM benzamidine, and 0.2 mM 
PMSF. Additional sodium chloride was added to a final concentration of 450 mM and 
nuclear proteins were extracted with constant rocking at 4˚C for 30 min. Nuclear 
extracts were clarified by centrifugation (85,000×g for 60 min) and the nuclear extract 
was stored in aliquots at –80˚C until later use. Protein concentrations of the nuclear 
extracts were determined by Bradford assay. 
 
Immunoprecipitation (IP) from JEG3 nuclear extracts and Western blotting 
analysis 
JEG3 cell nuclear extracts (200µg) were suspended in 1ml of 0.1% Triton X 
buffer (50 mM Tris (pH 7.6), 50 mM sodium chloride, 0.1% Triton X, protease 
inhibitor cocktail, 5 mM benzamidine, and 0.2 mM PMSF). To pre-clear the nuclear 
extracts, protein A/G-agarose (Santa Cruz Biotechnology Inc., Santa Cruz, CA) was 
added to each suspension and allowed to mix for 1 h at 4˚C with gentle rocking. 
Following centrifugation (1200×g for 1 min) to remove protein A/G-agarose, 
antibodies were added at the following dilutions: normal rabbit serum at 1:1000; Dlx3 
antibody at 1:1000; SMAD6 antibody (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA) at 1:100. Following 2 h at 4˚C of gentle rocking, protein A/G-agarose (Santa 
Cruz Biotechnology Inc., Santa Cruz, CA) was added and allowed to mix for an 
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additional 2 h. Complexes were then washed four times with 0.1% Triton X buffer. 
Samples were then suspended in an equal volume of 2×SDS loading buffer (100mM 
Tris (pH 6.8), 4% SDS, 20% glycerol and 200 mM dithiothreitol). Protein samples 
were boiled for 3 min and chilled for 5 min on ice. Proteins were resolved by SDS-
polyacrylamide gel electrophoresis and transferred to polyvinylidine difluoride 
membranes by electroblotting. Membranes were blocked with nonfat dried milk (5%) 
in Tris-buffered saline [10 mM Tris (pH 7.6), 150mM sodium chloride] containing 
0.1% Tween 20 (TBST). For western blots, the DLX3 antibody was used at 1:5000 in 
TBST, 5% nonfat dried milk. The reciprocal western blot from IPs using the SMAD6 
antibody was not possible since the IP heavy chain IgG blocked visualization of 
SMAD6 on western blot due to similar molecular size. In other western blot studies, 
the SMAD6 antibody was used at 1:500 and the actin antibody (Santa Cruz 
Biotechnology Inc., Santa Cruz CA) was used at 1:1000 dilution. Proteins bands were 
visualized by chemiluminescence reagents (PerkinElmer Life Sciences, Wellesley, 
MA).  
 
Immunocytochemistry 
JEG3 cells were cultured on glass slides or coverslips for 24 h, rinsed one time 
with potassium phosphate buffered saline (KPBS), then fixed for 20 min with 4% 
paraformaldehyde. Slides or coverslips were then stored in 70% ethanol until used. 
Prior to use, slides were rinsed in KPBS seven times over 1 hour. JEG3 cells were 
incubated with primary antibody (SMAD6 at 1:100; DLX3 at 1:500) overnight at 4˚C. 
Slides were again rinsed with KPBS followed by incubation with a fluorescent-
conjugated secondary antibody (Alexa 594, Molecular Probes, Eugene OR; and Cy2, 
Jackson Immunoresearch Labs, Westgrove, PA) in KPBS-Triton X at 37˚C for 2 h. 
Cells were rinsed in KPBS, dehydrated through a graded series of ethanol, cleared 
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with xylene and coverslips attached with Krystalon (EM Science, Gibbstown NJ). 
Samples of human term placenta (derived from elective caesarian section) were 
obtained from Cayuga Medical Center, Ithaca, NY under the guidelines and approval 
of the Cornell University and the Cayuga Medical Center Committees on the Use of 
Human Subjects in Research. Samples were collected, fixed with 4% 
paraformaldehyde for 48 h and transferred to 70% ethanol until processing. Tissues 
were paraffin embedded and 5 µm sections were obtained. Immunocytochemistry was 
performed as previously described 14, except that fluorescent-conjugated secondary 
antibodies were used as described above. 
 
Recombinant proteins and immuno-precipitation analysis 
Recombinant SMAD6, SMAD4, DLX4, DLX3 and deletions of DLX3 were 
prepared using a coupled transcription and translation Wheat Germ Extract System 
(Promega Corp., Madison, WI) following the prescribed protocol. Proteins were 
radioactively labeled using 35S methionine (1,000Ci/mmol at 10mCi/ml; Amersham, 
Piscataway, NJ). A portion (10%) of each recombinant protein was saved for input 
analysis. Protein combinations were added at a 1:1 (by volume) mixture to a 0.1% 
Triton X buffer along with appropriate antibody at specified concentrations (DLX3 at 
1:1000; SMAD6, Santa Cruz Biotechnology Inc., Santa Cruz, CA at 1:100; and 
SMAD4, Santa Cruz Biotechnology Inc., Santa Cruz, CA at 1:500). Following 2 h of 
gentle rocking at 4˚C, protein A/G-agarose (Santa Cruz Biotechnology Inc., Santa 
Cruz, CA) was added and allowed to mix for an additional 2 h. Complexes were then 
washed four times with 0.1%Triton X buffer. Proteins were resolved by SDS-
polyacrylamide gel electrophoresis, the gel was fixed in 25% methanol, and 15 % 
glacial acetic acid for 1 h with gentle rocking at room temperature. The gel was then 
washed three times in 40% isopropanol solution, dried and bands visualized by 
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autoradiography. 
 
Electrophoretic mobility shift assay 
Electrophoretic mobility shift assays (EMSA) were carried out as described 
previously 14,18 using the indicated antibodies. Reactions (without probe) were 
maintained at room temperature for 30 min followed by addition of 32P-labeled 
oligonucleotide DLX3 binding site probes (the junctional regulatory element or JRE 
from the glycoprotein hormone α subunit promoter 14 and two putative DLX3 binding 
sites identified within the Esx1 promoter). The binding reactions were maintained an 
additional 30 min then resolved on native polyacrylamide gels. To determine if 
SMAD6 could displace prebound DLX3 in EMSA, binding reactions containing 
DLX3 alone were allowed to incubate with probe for 30 min to reach equilibrium. 
SMAD6 protein was then added and the reactions were incubated for an additional 30 
min. These reactions were compared to binding reactions where both DLX3 and 
SMAD6 were added together and incubated for the full 60 min. Following 
electrophoresis, the gels were dried and DNA-protein complexes were visualized by 
autoradiography. All DNA binding studies were conducted at least three times with 
similar results. The nucleotide sequences for probes were as follows (only one strand 
indicated): JRE: 5’-ACGTCATGGTAATTACACCAAG-3’ Distal binding site: 5’-
ACA AGGAGCTAATTTACTTCCT-3’ Proximal binding site: 5’-
TTAGGGCTCTAATTCAGACTCT-3’. 
 
Cell culture and transient transfection studies 
JEG3 cells were cultured in monolayer using Dulbeco’s Modified Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS). Before 
transfection studies, cells were split to 35 mm dishes and sub-confluent cultures were 
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used. JEG3 cells were transiently co-transfected with an Esx1 promoter luciferase 
reporter construct, DLX3 expression vector at a constant dose (2.0 µg) and increasing 
doses of SMAD6 expression vector using lipofection (FuGENE 6 transfection reagent; 
Roche Diagnostics Inc., Indianapolis, IN). All transfections were carried out with a 
constant amount of DNA by supplementing reactions with the parent vector pKH3. 
Luciferase activity was determined after 24 h of transfection using reagents from the 
Luciferase Reporter Assay System (Promega Corp., Madison, WI), and luciferase 
activity was standardized by total cell protein amount (luciferase/1.0 µg) as 
determined by Bradford assay. All transfection studies were conducted in triplicate on 
at least three separate occasions with similar results. Data are shown as means (n=3) ± 
standard errors of the mean of a representative experiment. 
 
Preparation of stable cell lines expressing small interference RNA (siRNA) 
The mammalian expression vector, pSUPER-retro-neo (pSR; OligoEngine, 
Seattle, WA) was used for preparation of retrovirus containing specific siRNAs and 
expression of siRNAs in JEG3 cells following viral infection. Each gene-specific 
insert targeted a 19-nucleotide sequence within the human SMAD6 mRNA. The 
siRNA sequences were as follows: SMAD6-#1: 5’CACATTGTCTTACACTGAA 
SMAD6-#2: 5’TCAAGGTGTTCGACTTCGA SMAD6-#3: 
5’GCCACTGGATCTGTCCGAT The plasmids were referred to as SMAD6 siRNA #1, 
#2 and #3. A control siRNA vector (also prepared in pSR) was constructed using a 19-
nucleotide sequence (5’TTCTCCGAAC GTGTCACGT) putatively without 
significant similarity to any mammalian gene sequence and therefore served as an 
appropriate negative control (OligoEngine, Seattle, WA). The forward and reverse 
strands of oligonucleotides containing the siRNAs and nonsense sequence also 
contained Bgl II and Hind III sites at the 5’end of the forward and reverse 
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oligonucleotides, respectively. The oligonucleotides were annealed and inserted into 
the pSR vector after digestion of the vector with Bgl II and Hind III. These siRNAs 
were a self-contained hairpin loop for the double stranded siRNA. All siRNA 
sequences were confirmed by nucleotide sequencing.  
 
Cell culture, transfection and retroviral infection of siRNAs 
HEK293 Phoenix Ampho packaging cells (American Type Culture Collection; 
Manassa, VA) were cultured in DMEM containing 10% FBS and were transfected 
with the pSUPER-retro-neo siRNA plasmids using FuGENE 6 transfection reagent 
(Roche Diagnostics Inc., Indianapolis IN). Forty-eight hours following transfection, 
the culture media containing the retrovirus for individual siRNAs and control siRNA 
were filtered through a 0.45-μm filter, and the viral supernatant was used for infection 
of JEG3 cells in the presence of 8 μg/ml polybrene. JEG3 cells were exposed to the 
retrovirus overnight, cell were then washed with fresh medium and allowed to recover 
for 24 h. Following infection, stable cell lines were selected using neomycin at 500 
μg/ml for 7 days (time until untransfected cells all died) then cultures were maintained 
in medium containing 500 µg/ml neomycin. Transient transfections of the siRNA cell 
lines were carried out as described above. 
 
Statistical analysis 
Luciferase data were subjected to analysis of variance and differences between 
treatments were determined using Tukey’s Studentized Range Test. Probability of less 
than 0.05 (p<0.05) was considered statistically significant. 
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Results 
DLX3 and SMAD6 functionally interact in a yeast two-hybrid screen 
Full-length human DLX3 was used as a bait protein in a yeast two-hybrid screen 
of a human term placental library. The screen included coverage of approximately 
3.4×106 independent clones. Once colonies were identified from the original screen 
and library plasmids were rescued, plasmids were retransformed in a reconstitution 
assay with the bait vector into the AH109 yeast strain. The library plasmid resulting in 
the most robust interaction (as measured by β-galactosidase activity) with DLX3 was a 
cDNA containing the entire coding region of SMAD6. Transformation of the SMAD6 
library vector alone did not support yeast growth on high stringency SD medium (Ade-
/His-/Leu-/Trp-/X-α-Gal) plates in the presence of 12 mM 3-amino-1,2,4-triazole. 
Transformation of Dlx3 bait vector minimally supported yeast growth under the same 
conditions. Co-transformation of DLX3 bait and SMAD6 library plasmid resulted in 
rescue of yeast growth (Figure 2.1A).  
 
DLX3 and SMAD6 are co-localized in the nucleus in choriocarcinoma cells and in 
human placental trophoblasts 
Initially, studies focused on examining localization of DLX3 and SMAD6 
proteins in cells of trophoblast origin. DLX3 and SMAD6 were expressed and 
localized primarily in the nuclear compartment in JEG3 cells (Figure 2.1B), a 
choriocarcinoma cell line of trophoblast origin. Consistent with this observation, 
DLX3 and SMAD6 were nuclear localized to both cytotrophoblast and syncytial 
trophoblast within microvilli of fully differentiated term human placenta. Localization 
of DLX3 in term placenta provided additional insight into the expression pattern of 
DLX3 during gestation in primates. We have previously shown DLX3 in placental 
trophoblasts in human placenta obtained at 8 weeks gestation during peak production 
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Figure 2.1. DLX3 and SMAD6 interact in yeast two hybrid and co-localize in 
placental trophoblasts. A. Yeast two-hybrid screen of a human term placental library 
was carried out using full length DLX3 as bait. Following plasmid rescue, Gal4 DNA 
binding domain-DLX3 bait was co-transformed along with Gal4 activation domain-
SMAD6 into the AH109 yeast strain and plated on (-His, -Leu,  
-Trp) media as described in Methods. B. JEG3 cells were plated on glass slides and 
fixed as described in Materials and Methods. Double labeled immunocytochemistry 
was used to determine localization of DLX3 (green) or SMAD6 (red). The merged 
images demonstrate overlapping expression patterns. Human term placenta was 
obtained, fixed and sectioned as described in Materials and Methods. Similar double 
labeled immunocytochemistry was used to localize DLX3 and SMAD6. The white 
arrow head identifies nuclei in syncytial trophoblasts while the black arrow head 
identifies nuclei in cytotrophoblasts. Bar = 20 µm. 
This figure is kindly provided by Dr. Kathie A. Berghorn. 
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of hCG 14. The current studies support the conclusion that DLX3 expression may be 
maintained within trophoblast cell populations until term in the human placenta. 
Since both DLX3 and SMAD6 were expressed endogenously in the JEG3 
horiocarcinoma cell model, we sought to use this model for subsequent analyses. We 
have used JEG3 cells previously for molecular analysis of gene regulatory processes 
related to glycoprotein hormone and DLX3 gene promoter expression 14,18,19. IP studies 
using nuclear extracts from JEG3 cells and SMAD6 antibody revealed that DLX3 and 
SMAD6 interact in mammalian cells (Figure 2.2A). The reciprocal study using DLX3 
antibody to IP SMAD6 was not possible due to the molecular size of SMAD6 and 
interference with the IgG heavy chain used in the IP studies. However, this constraint 
was overcome with preparation of DLX3 and SMAD6 as recombinant proteins labeled 
with [35S] methionine. IP of recombinant DLX3 and SMAD6 with the DLX3 antibody 
revealed specific association with SMAD6 but not Smad4 (Figure 2.2B). Thus, the 
original interaction defined in the yeast system was supported by IP studies in 
choriocarcinoma cells that endogenously express these two proteins and in vitro using 
recombinant DLX3 and SMAD6 proteins. 
 
Structure/function analysis of the DLX3/SMAD6 interaction interface 
To further understand the mechanism of the DLX3/SMAD6 interaction, we 
constructed a series of deletion mutants of DLX3 (Figure 2.3A). The rationale for 
these mutations was predicated on existing understanding of important domains within 
DLX3 defined by others 20,21, centering upon the homeodomain (residues 130-189; 
Figure 2.3A), the centrally located DNA binding domain. DLX3 deletion mutants 
were prepared in vitro along with full-length DLX3 and SMAD6. SMAD6 IP was then 
used to determine the domains sufficient to support interaction with DLX3. Initially, 
we identified the importance of DLX3-(1-202), which bound SMAD6 at levels similar  
Figure 2.2. DLX3 and SMAD6 interact in the JEG3 choriocarcinoma cell 
model. A. JEG3 cell nuclear extracts were used in immunoprecipitation (IP) 
studies. IPs included the use of normal rabbit serum (NRS) or antisera (ab) 
directed against DLX3 or SMAD6. Recombinant DLX3 (rDLX3; without HA 
epitope tag) and IPs were resolved by SDS-PAGE and Western blots for DLX3 
were carried out (IB DLX3).  Molecular size standards (MW) are depicted to the 
left of the panel. B. Recombinant DLX3, SMAD6 and SMAD4 were produced 
using wheat-germ lysates in a coupled transcription/translation reaction containing 
35S methionine (Input).  DLX3 and either SMAD6 or SMAD4 were combined 
followed by IP with the DLX3 antibody (DLX3 IP). The input and IPs were 
resolved by SDS-PAGE, the gels fixed and dried and autoradiography was used to 
visualize bands.
This figure is kindly provided by Ms. Patricia A.Clark.
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Figure 2.3. Deletion mutants of DLX3 reveal interaction interface with SMAD6.   
A. A series of DLX3 deletions (characterized in schematic form) were prepared using 
PCR. The numbers represent amino acid designations for the termini of wild type 
DLX3 and each mutant. B. Wild type DLX3, SMAD6 and the DLX3 deletion series 
were prepared as recombinant proteins as described in Figure 2B (Input) and subjected 
to IP studies using the SMAD6 antibody (SMAD6 IP) and recombinant SMAD6 and 
the combination of deletions mutants indicated. The input and IPs were resolved by 
SDS-PAGE, gels were fixed and bands visualized by autoradiography. Asterisks (*) 
designate bands consistent with protein-protein interactions. 
This figure is kindly provided by Ms. Patricia A.Clark. 
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to DLX3-(1-287) (Figure 2.3B). DLX3-(121-287) bound SMAD6 as well, suggesting 
that SMAD6 interaction domain required at least a portion of the homeodomain 
(Figure 2.3B). Based upon these results, we predicted that DLX3-(121-202) mutant 
would also bind SMAD6. This was not readily interpretable in our studies since 
putative degradation fragments/products of these recombinant deletion mutants were 
of similar molecular size as the DLX3-(121-287) mutant. Subsequent DLX3 deletion 
mutants defined a region of DLX3-(80-163) that was sufficient to bind SMAD6 in 
vitro (Figure 2.3B). These studies again supported the conclusion that at least the 
amino-terminal portion of the homeodomain was sufficient for interaction with 
SMAD6 in vitro. Alignment of DLX3 with DLX4 (another member of the DLX 
family expressed in placenta 22) revealed approximately 37% amino acid conservation 
within this region (residues 80-163; Figure 2.4A), with higher levels of homology 
particularly clustered within the homeodomain, supporting the prediction that DLX4 
may also bind SMAD6. Based upon in vitro studies, recombinant full-length DLX4 
bound SMAD6 similar to DLX3-(1-287) (Figure 2.4B). DLX3-(195-287), previously 
shown not to bind SMAD6 (Figure 2.3B), was used in these studies as a negative 
control.  
 
DLX3 binds to the 5’-flanking sequence of the Esx1 promoter 
To begin to examine the functional significance of the DLX3/SMAD6 interaction 
on gene transcription, we cloned 2.3 kilobases of the 5’-flanking sequence of the Esx1 
promoter. The report of the Dlx3 null mouse provided evidence that the loss of Dlx3 in 
vivo was correlated with a loss of Esx1 mRNA in mouse placenta 13. Taking advantage 
of this observation, we identified two near consensus Dlx3 binding sites within the 
2.3-kb promoter fragment. The distal site was located at -2135 and the more proximal 
site at -585 relative to the transcription start site of the Esx1 promoter, as previously  
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Figure 2.4. DLX4 binds SMAD6. A. Alignment of DLX3 and DLX4 between 
residue 80 and 198 reveals regions of conserved sequence within the SMAD6 
interaction domain (residue 80-163). The consensus amino acid sequence is listed in 
bold below the alignment. B. Wild type DLX31-287, DLX3195-287, SMAD6 and DLX4 
were prepared as recombinant proteins as described in Figure 2 (Input) and subjected 
to IP studies using the SMAD6 antibody (Smad6 IP) and recombinant SMAD6 and 
combinations of DLX3 or DLX4 as indicated. The input and IPs were resolved by 
SDS-PAGE, gels were fixed and bands visualized by autoradiography. Asterisks (*) 
designate bands consistent with protein-protein interactions. 
This figure is kindly provided by Ms. Patricia A.Clark. 
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Figure 2.5. Two putative Dlx3 binding sites are present within the Esx1 promoter.  
A. The junctional regulatory element (JRE), a consensus Dlx3 binding site from the 
glycoprotein hormone α subunit promoter was compared to the distal (position -2135) 
and proximal (position -585) binding sites from the Esx1 promoter. The central core of 
the binding site is underlined. B. Electrophoretic mobility shift assays (EMSA) were 
used to compare binding complexes formed on the JRE, the distal and proximal Dlx3 
binding sites within the Esx1 promoter using JEG3 cell nuclear extract and 
recombinant DLX3. Equal amounts of nuclear extracts or recombinant DLX3 were 
added to each binding reaction. Recombinant DLX3 in these studies was epitope 
tagged with three copies of the HA epitope (3xHA-DLX3). Binding reactions were 
resolved on native polyacrylamide gels. The gels were dried and bands visualized by 
autoradiography. Free probe is designated by an arrow at the bottom of the gel. 
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defined 23. At both of these two sites, the central core of the binding site (TAATT) was 
conserved; however, the two nucleotides present on the 3’ termini of this central core 
were not conserved (Figure 2.5A). These nucleotides varied from the consensus Dlx3 
binding site 24 we defined in the human glycoprotein hormone α subunit promoter 14. 
Using EMSAs, we compared the DNA binding complexes formed when using the 
distal (-2135) and proximal (-585) putative Dlx3 binding sites from the Esx1 promoter 
and nuclear extracts from JEG3 cells (Figure 2.5B). As a positive control, the JRE 
from the α subunit promoter was used. Figure 2.5B depicts direct comparison of 
complexes formed with all three of these binding sites. The distal site was more 
similar to the JRE binding complex electrophoretic mobility when compared to the 
proximal site. When using recombinant DLX3 in EMSA (Figure 2.5B), all three sites 
were sufficient to bind DLX3; however, clear differences in the relative binding of 
DLX3 for these binding sites were revealed. The recombinant DLX3 was slightly 
larger in molecular size due to the presence of the three hemagglutinin (HA) epitopes 
engineered into the recombinant protein. The rank order of relative binding for 
recombinant DLX3 was the JRE (highest) > the distal site > the proximal site (lowest). 
We focused our attention on the distal DLX3 binding site within the Esx1 gene 
promoter. EMSA studies using nuclear extracts and antiserum against DLX3 provided 
direct evidence that endogenous DLX3 can bind to this site (Figure 2.6A). The 
addition of the DLX3 antibody to EMSA binding reaction resulted in supershifted 
complexes that were not evident using preimmune normal rabbit serum (NRS). The 
addition of the SMAD6 or the C/EBP antiserum to these binding reactions did not 
appreciably alter complex formation in EMSA, suggesting that SMAD6 may not 
directly participate in DNA binding with DLX3 and that DLX3 antibody interactions 
were specific. To determine the importance of this site to DLX3-induced Esx1 gene 
transcription, the distal site was mutagenized to a Not I restriction site and examined   
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Figure 2.6. The distal binding site of the Esx1 promoter binds DLX3 and is 
necessary for full DLX3-induced gene transcription. A. Using only the distal 
binding site for DLX3 and JEG3 cell nuclear extract (JEG3 NE), studies examined if a 
DLX3 antibody would disrupt binding of endogenous proteins including DLX3 to this 
site. Binding reactions were resolved on native polyacrylamide gels, the gels were 
dried and bands visualized by autoradiography. Addition of a DLX3 antibody (DLX3 
ab) to binding reactions resulted in the formation of a super shifted complex as 
indicated (supershift). Normal rabbit serum was used as a control for the DLX3 
antibody. In some binding reactions, the JEG3 NE was boiled and then added to 
reactions containing the DLX3 ab as a negative control. Free probe is designated by an 
arrow at the bottom of the gel. B. Transient transfection studies were used to 
determine the relative importance of the distal DLX3 binding site on expression of the 
Esx1 promoter luciferase reporter gene. JEG3 cells were transiently transfected with 
either wild type Esx1 luciferase reporter or an Esx1 luciferase reporter containing a 
mutation within the distal DLX3 binding site. Cells were cotransfected with control 
plasmid or a DLX3 expression vector (2 µg; designated – or +). Data are reported as 
relative luciferase activity standardized for protein for a representative study 
(n=3/treatment). The designations a, b and c indicate significant differences (p<0.05).   
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using a luciferase reporter gene approach in transient transfection studies (Figure 
2.6B). The wild type Esx1 promoter was strongly induced by DLX3. The mutation in 
the distal putative DLX3 binding site reduced DLX3-induced Esx1 expression by 
>50% (p<0.05), suggesting that this site was important for promoter activity induced 
by DLX3. 
We then sought to determine the impact of SMAD6 on DLX3 DNA binding. 
Reconstitution EMSAs using recombinant DLX3 and SMAD6 demonstrated that the 
DLX3/SMAD6 interaction effectively reduced/ blocked association of DLX3 with the 
distal DLX3 binding site within the Esx1 promoter (Figure 2.7A). In this experiment, 
SMAD6 alone did not form a complex with the distal DLX3 binding site. When 
SMAD6 was titrated into the binding reactions containing DLX3, the DLX3 binding 
complex was diminished in a dose-dependent manner. Using the JRE as probe, a 
similar titration of SMAD6 protein reduced DLX3 binding, albeit to a lesser extent 
compared to the distal site of the Esx1 promoter. Studies then focused on determining 
if prebound DLX3 could be displaced by SMAD6 in EMSA binding reactions (Figure 
2.7B). Binding reactions compared addition of DLX3 concurrent with SMAD6 and 
reactions where DLX3 binding was allowed to reach equilibrium then SMAD6 was 
added. These studies revealed that for the distal probe, SMAD6 competed for DLX3 
binding regardless of order of protein addition. Similar levels of competition were not 
observed using the JRE (stronger relative binding), suggesting that SMAD6 can 
compete for DLX3 binding particularly on gene targets that have relatively weaker 
DLX3 binding sites, like those characterized within the Esx1 gene promoter. 
To assess the functional consequences of the DLX3/SMAD6 interaction on the 
Esx1 promoter, we again used the Esx1 promoter-luciferase reporter construct (Figure 
2.8). Based upon the binding studies described above, our prediction was that SMAD6 
overexpression would probably repress expression of the Esx1 promoter induced by  
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Figure 2.7. SMAD6 attenuates DLX3 DNA binding. A. To examine the effects of 
SMAD6 on DLX3 binding, recombinant DLX3 and SMAD6 were prepared in vitro 
and used in electrophoretic mobility shift assays (EMSA) with the distal DLX3 
binding site within the Esx1 promoter and the JRE. As observed earlier, DLX3 bound 
this site while increasing doses of SMAD6 (as represented by the grey triangle) did 
not bind.  Binding reactions containing a constant dose of DLX3 and increasing 
doses of SMAD6 resulted in a dose dependent reduction in DLX3 binding for the 
distal site and to a lesser extent for the JRE. B. EMSA studies were carried out to 
determine if order of protein addition had an impact on the ability of SMAD6 to 
interfere with DLX3 binding. Using the distal and JRE probes, binding reactions were 
assembled where DLX3 was added and allowed to reach equilibrium (DLX3) then 
SMAD6 was added (DLX3 > SMAD6). This was compared to binding reactions 
where DLX3 and SMAD6 were added concurrently (DLX3 + SMAD6). For both A. 
and B., free probe and DLX3 complexes are designated by arrows. 
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DLX3. Using transient transfection in JEG3 cells, overexpression of DLX3 and 
SMAD6 resulted in increased levels of ectopically expressed DLX3 and SMAD6 
(Figure 2.8A). Further, DLX3 overexpression increased Esx1 luciferase activity 
(p<0.05; Figure 2.8B). Titration of SMAD6 into this system resulted in reduced basal 
activity of the Esx1 reporter gene (p<0.05). Consistent with our prediction, o-
transfection with increasing doses of SMAD6 expression vector along with DLX3 
resulted in a marked inhibition (p<0.05) of DLX3-induced Esx1 promoter activity. 
DLX3-induced activation of the α subunit gene promoter was also reduced by 
overexpression of SMAD6 (data not shown). In an effort to determine the specificity 
of SMAD6 action on gene transcription in general, we examined the effects of 
SMAD6 on the trophoblast Kunitz domain protein (TKDP) 1 (Figure 2.8C) and Rous 
sarcoma virus promoters (data not shown). TKDP1 promoter expression 25,26 is 
trophoblast-specific but not dependent upon DLX3 expression (Figure 2.8C). The 
Rous sarcoma virus promoter is constitutively active in trophoblast cells. In contrast to 
the effects of SMAD6 on DLX3-induced expression of the Esx1 and α subunit 
promoter, SMAD6 had no appreciable effect on the TKDP promoter and actually 
increased expression of the Rous sarcoma virus promoter in a dose-dependent manner. 
These studies support the conclusion that SMAD6 does not confer global non-specific 
transcriptional repression and probably the effects of SMAD6 on Esx1 and α subunit 
promoter activity are specific. 
 
siRNA-mediated knockdown of SMAD6 resulted in increased expression of the Esx1 
gene promoter.  
Whereas overexpression studies can be informative, interpretation of such studies 
must be cautious. To examine the effects of SMAD6 on DLX3-dependent gene 
expression, we developed stable cell lines expressing specific SMAD6 siRNA hairpin  
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Figure 2.8. SMAD6 attenuates DLX3-dependent promoter activation in JEG3 
cells. A. To determine the levels of ectopic expression of DLX3 and SMAD6 in 
overexpression studies, JEG3 cells were transiently transfected with expression 
vectors for DLX3 (+DLX3; 2 µg) or SMAD6 (+SMAD6; 2 µg). Whole cell lysates 
were prepared and western blot analyses were carried out using the DLX3 and 
SMAD6 antibodies. B. Transient transfection studies in JEG3 cells were used to 
investigate the functional relevance of SMAD6 on DLX3-dependent gene expression. 
Co-transfection of the Esx1 gene promoter-luciferase reporter with DLX3 (constant 
dose, 2 µg) and increasing doses of SMAD6 expression vector (0, 0.5, 1.0 and 2.0 µg; 
represented by the grey triangle) resulted in a dose dependent decrease in expression 
of the Esx1 luciferase reporter. C. Similar studies were carried out using the TKDP-1 
gene promoter luciferase reporter. As a control for DLX3 action, the Esx1 promoter 
was also used. TKDP-1-Luc activity was unaffected by DLX3 or increasing doses of 
SMAD6 expression vector. Data for all panels are reported as relative luciferase 
activity standardized for protein from representative studies (n=3/treatment). For B. 
and C. The designations a, b and c indicate significant differences (p<0.05) within 
experiment; ns = not significantly different. 
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Figure 2.9. siRNA-mediated knockdown of SMAD6 results in enhanced DLX3-
dependent expression of the Esx1 Luc reporter. A. Stable cell lines were selected 
using neomycin resistance following infection with retrovirus expression empty vector 
(Vector Control), three separate, independent siRNAs specific for SMAD6 (SMAD6 
siRNA #1-3) or a control siRNA (Control siRNA). Following selection, cell lysates 
were prepared and western blot analysis was used to determine SMAD6 protein levels. 
The cell lines were also assayed for DLX3 and ACTIN using specific antibodies. 
SMAD6 protein levels were reduced approximately 57% with siRNAs #1 and 3.   
B. The Control siRNA and SMAD6 siRNA#1-3 cell lines were used in transient 
transfection studies using the Esx1 Luc reporter in the absence or presence of DLX3 
expression vector (2 µg). Data are reported as relative luciferase activity standardized 
for protein from representative studies (n=3/treatment). The designations a, b, c and d 
indicate significant differences (p<0.05). 
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loops (Figure 2.9A). Two of the three siRNA cell lines examined were found to have 
specific reductions in SMAD6 protein expression (SMAD6 siRNAs #1 and #3; 57% 
reduction compared to control siRNA) but not expression of DLX3 nor ACTIN 
(internal controls; Figure 2.9A). Transfection studies in the control siRNA and the 
SMAD6 siRNA cell lines using the Esx1 luciferase reporter demonstrated that basal 
activity of this promoter was elevated (p<0.05) in the siRNA#1 and siRNA#3 cell 
lines but not in the control and siRNA#2 cell lines. In response to DLX3, Esx1 
luciferase promoter activity was enhanced (p<0.05) in SMAD6 siRNA#1 and 
siRNA#3 cell lines but not in control or siRNA#2 cell lines [control siRNA (5.0-fold) 
versus siRNA#1 (7.3-fold) and siRNA#3 (8-fold)] in a manner highly correlated with 
the percentage loss of SMAD6 in these cell lines (Figure 2.9B). Thus, consistent with 
the overexpression studies, loss of endogenous SMAD6 was highly correlated with 
enhanced DLX3-dependent transcription of the Esx1 gene promoter. 
 
Discussion 
The present studies provide novel evidence for the functional association between 
DLX3, a distal-less class homeobox factor required for normal placental development 
in the mouse, and an inhibitory Smad, SMAD6. The role of DLX3 as a transcriptional 
activator is clear based upon studies in mammalian systems, such as the glycoprotein 
hormone α subunit gene promoter 14, the expression of the homeobox factor Esx1 in 
the Dlx3 null mouse 13, and the role of Dlx3 in the regulation of the osteocalcin gene 27. 
Moreover, Dlx3 has been linked to transcriptional activation as well as transcriptional 
repression in Xenopus (reviewed in Ref.2). The ability of Dlx3 to serve in several 
different ways as a transcriptional modulator may be best explained by the presence of 
variable tissue- and cell type-specific binding partners. The present study provides 
important evidence that DLX3 and SMAD6 form a complex in a yeast system, in 
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mammalian cells in culture and in vitro using recombinant proteins. DLX3 and 
SMAD6 also display overlapping expression in the nucleus of differentiated human 
term placental trophoblasts, suggesting that a functional interaction between these two 
proteins may be important in vivo. The finding that one DLX3 interacting partner is an 
inhibitory Smad may also reflect important cross-talk between the transforming 
growth factor (TGF) β/bone morphogenetic factor (BMP) signaling system and 
important developmental determinants that require DLX3. 
    Smad proteins are transcriptional regulators that can be subdivided into 
essentially three classes (reviewed in Refs. 28-30). Regulated or R-Smads (Smad 1, 2, 3, 
5 and 8) are substrates of the serine/threonine kinase catalytic activity of TGFβ/BMP 
type I receptors. Phosphorylation of R-Smads promotes the association with a 
common or C-Smad (Smad4) and subsequent nuclear translocation of the R- and C-
Smad complex to affect TGFβ/BMP/Smad-specific target genes. Others have 
demonstrated an interaction between Smad4 and Dlx1 in the context of cytokine 
regulation of hematopoietic cells 31. A third unique subclass of this family is the 
inhibitory or I-Smads (Smad 6 and 7). In the context of TGFβ/BMP signaling, I-
Smads essentially oppose the activity of the stimulatory R- and C-Smads at several 
levels. I-Smads have been shown to compete for R-Smad binding to the type I 
TGFβ/BMP receptor, providing an inhibitory mechanism for R-Smad activity 32. In 
addition, Smad6 has been shown to interfere with the ability of Smad1 to form a 
complex with Smad4, independent of Smad1 phosphorylation state 33. I-Smads also 
form complexes with Smurfs, E3 ubiquitin ligases that appear to be involved in I-
Smad nuclear export and marking target proteins (for example the TGFβ/BMP 
receptors and I-Smads themselves) for degradation by the proteosome, again 
contributing to an inhibitory action 28-30. 
In the nuclear compartment, Smad6 appears to recruit the transcriptional co-
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repressor C-terminal binding protein to target genes related to BMP action 34. Based 
upon the present studies, DLX3 and SMAD6 were localized to the nucleus of 
placental trophoblasts independent of apparent TGFβ/BMP signaling. Smad6 has been 
shown to serve as a transcriptional co-repressor following interaction with another 
homeodomain transcription factor, Hox c-8 35,36. In these studies, Smad6 complexed 
with Hox c-8 appeared to be sufficient to recruit histone deacetylase activities to Hox 
c-8-dependent genes thus repressing transcription via altered organization of 
chromatin structure. Our studies suggest that the interaction between DLX3 and 
SMAD6 may utilize an entirely different mechanism for transcriptional repression in 
human placental cells. SMAD6 interaction clearly resulted in a reduction of DLX3 
DNA binding activity, probably via steric interference. Our results demonstrate that 
the SMAD6 interaction interface includes the first two α helices of the homeodomain. 
SMAD6 interaction would then potentially interfere with DLX3 DNA binding, since 
these two α helices are central to DNA binding as well. This mechanism potentially 
alleviates a need for recruitment of transcriptional co-repressor activities, since a 
DLX3-SMAD6 complex association may preclude association of DLX3 with specific 
target gene promoter elements. Increased SMAD6 protein levels using overexpression 
inhibited DLX3-dependent gene expression. Conversely, reductions in the expression 
of endogenous SMAD6 using siRNA knockdown provides important evidence that 
DLX3-dependent gene expression may be particularly sensitive to relatively modest 
changes in SMAD6 protein levels in placental cells. These complementary approaches 
underscore the potential importance and sensitivity of DLX3-dependent genes to 
SMAD6 regulation. This may be largely true of Dlx3 target genes with binding sites 
that have low relative binding affinity, like Esx1.   
The Dlx3 homeodomain is centrally located and serves as a DNA binding domain, 
one of the defining characteristics of all homeobox transcription factors 37,38. The 
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domain structure of Dlx3 has been examined in studies defining a bipartite nuclear 
localization signal (residues 124-150) in a region adjacent to and including a portion 
of the homeodomain; transcriptional activation domains have been ascribed to 
residues 1-43 and 189-220; and Ser138 within the homeodomain is an apparent 
substrate for protein kinase C isozymes 20,21,24. The deletion mutagenesis carried out in 
the present studies defined residues 80-163 within DLX3 as the SMAD6 interaction 
domain in vitro. This region of DLX3 contains the first full α helix and approximately 
two-thirds of helix 2 within the homeodomain. In addition, this interaction interface 
contains Ser138, a substrate for PKC activity. Several possibilities exist for how DLX3-
SMAD6 association may alter DNA binding. Perhaps the most obvious is a steric 
interference model, since the interaction interface includes a portion of the 
homeodomain. In addition, the presence of Ser138 in this interaction domain lends 
itself to potentially interesting speculation. The equivalent of this serine residue is 
conserved in all six Dlx family members 1, consistent with the observation that, like 
DLX3, DLX4 is also a SMAD6 interacting protein. Using recombinant Dlx3, Morasso 
and co-workers demonstrated that phosphorylation at Ser138 by PKC (most strongly by 
PKCα) resulted in partial inhibition of Dlx3 DNA binding 21, consistent with the 
potential effects of SMAD6 on DNA binding. This supports speculation that 
phosphorylation of Dlx3 at Ser138 may alter or increase Smad6 binding leading to 
reduced DNA binding at Dlx3 target genes. Studies are currently underway to address 
this possibility.   
R- and C-Smads appear to be constitutively expressed in most cell types whereas 
I-Smads are subject to regulation by a number of growth factors, such as EGF, TGFβ 
and BMPs. In many cases the effects of these growth factors are mediated through R- 
and C-Smad-dependent transcriptional mechanisms. This has led to a hypothesis 
implicating an intracellular negative feedback loop, whereby positive TGFβ/BMP 
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signals are modulated over time by accumulation of induced I-Smads (reviewed in Ref. 
39). Interestingly, Dlx3 expression patterns during Xenopus development depend in 
part upon BMP signaling gradients 40,41. Inhibition of these gradients using the BMP 
receptor antagonist chordin resulted in a dose-sensitive inhibition of Dlx3, Dlx5 and 
Dlx6 mRNA expression. Dlx3 expression in mouse keratinocytes was also reported to 
be subject to regulation by BMPs 42 in a manner potentially coordinate with I-Smad 
expression. This supports speculation that not only might BMP-regulated Smad6 
expression serve as a negative feedback mechanism controlling the duration of Smad 
signaling but increased BMP-dependent Smad6 expression may lead to important 
modulation of Dlx3-dependent gene expression. BMPs have been shown to regulate 
early embryogenesis during the perimplantation period, such that these types of 
ligands are probably present and important during placental morphogenesis 43. 
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CHAPTER THREE 
 
ANALYSIS OF THE GENE REGULATORY PROGRAM INDUCED BY THE 
HOMEOBOX TRANSCRIPTION FACTOR DISTAL-LESS 3  
IN MOUSE PLACENTA 
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Abstract 
    Dlx3, a homeodomain transcription factor, is essential for placental development 
in the mouse. The Dlx3-/- mouse embryo dies at E9.5-10 due to placental failure. To 
develop a more comprehensive understanding of the gene profile regulated by Dlx3, 
microarray analysis was used to determine differences in gene expression within the 
placenta of Dlx3+/+ and Dlx3-/- mice. Array analysis revealed differential expression of 
401 genes, 33 genes in which signal to log ratio values of null/wild type were lower 
than -0.5 or higher than 0.5. To corroborate these findings, quantitative real-time PCR 
was used to confirm differential expression for 11 genes, nine of which displayed 
reduced expression and two with enhanced expression in the Dlx3-/- mouse. Loss of 
Dlx3 resulted in a marked reduction (>60%) in mRNA expression of Pgf, a member of 
the vascular endothelial growth factor family. Consistent with these results, Pgf 
secretion from placental explants tended to be reduced in the Dlx3-/- mice compared 
with wild type. To investigate mechanisms of Dlx3 regulation of Pgf gene 
transcription, we cloned 5.2 kb of the Pgf 5’ flanking sequence for use in reporter gene 
assays. Expression of the Pgf promoter luciferase reporter containing at least three 
Dlx3 binding sites was increased markedly by overexpression of Dlx3 supporting the 
conclusion that Dlx3 may have a direct effect on Pgf promoter activity. These studies 
provide a novel view of the transcriptome regulated by Dlx3 in mouse placenta. Dlx3 
is specifically required for full expression and secretion of Pgf in vivo. Moreover, in 
vitro studies support the conclusion that Dlx3 is sufficient to directly modulate 
expression of the Pgf gene promoter in placental cells. 
 
Introduction 
    The complex process of determination of trophoblast cell lineages within the 
placenta is integral to the successful establishment of the maternal-fetal interface. 
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Remarkably, these tissues functionally give rise to cell populations that control fetal 
nutrient and gas exchange, participate in maternal-fetal immunological dialog and are 
critical sources of endocrine factors that communicate to the mother the presence of 
the conceptus. Failures associated with establishment of the maternal/fetal interface 
can result in fetal mortality or lead to intrauterine fetal growth abnormalities 
associated with fetal morbidity and the potential to contribute to the adult onset of 
diseases such as type 2 diabetes (recently reviewed in Refs 1-3). Thus, a more 
comprehensive understanding of the genetic mechanisms that underlie the 
development and morphogenesis of the placenta will provide the foundation for 
understanding mechanisms of fetal morbidity and mortality during early pregnancy 
and potentially a better understanding of aspects of the origins of adult disease. 
    A great number of mouse knockout models have been instrumental in defining 
genetic determinants required for developmental decisions during placental 
morphogenesis. These have been recently reviewed in elegant detail 4. For example, 
knockouts of numerous receptors, signaling molecules and transcription factors have 
been shown to compromise syncytial trophoblast differentiation and morphogenesis of 
the placental labyrinth, a key site within the mouse placenta of interdigitations 
between fetal vascular beds and maternal blood spaces 5. Our laboratory has developed 
a keen interest in one of these transcription factors, Dlx3, based on two important 
observations. First, in human trophoblast cell lines DLX3 plays a critical role in the 
basal regulation of the glycoprotein hormone α subunit gene, a key subunit of the 
heterodimeric placental borne hormone, CG 6. CG is expressed exclusively in primate 
and equine trophoblasts and is an important luteotropin during early human pregnancy. 
CG also appears to be an important ligand in the regulation of endometrial receptivity 
7-9 through changes in MAPK signaling activity to affect morphology and function of 
epithelial and stromal compartments of the receptive endometrium 10. Second, in 
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mouse models, disruption of the Dlx3 loci in knockout experiments resulted in fetal 
death at E9.5-10 due to failed placental labyrinth development 11. Dlx3 expression is 
largely restricted to trophoblasts within the labyrinth of the mouse placenta, and loss 
of Dlx3 appears to affect the expansion of the labyrinth during midgestation 12. Thus, 
Dlx3 appears to be playing a critical role in facilitating biosynthesis of a key placental 
hormone that serves as a luteotropin and a modulator of uterine receptivity in primates 
as well as being instrumental in facilitating organizational aspects of the mouse 
labyrinth morphogenesis and the establishment of the maternal-fetal interface. 
    In the present studies, we have furthered our understanding of Dlx3 expression 
within the mouse placenta. We have identified a rather large Dlx3-dependent 
transcriptome by microarray analyses comparing Dlx3+/+ and Dlx3-/- mice. Pgf 
transcript levels and secretion appear to be markedly reduced by the loss of Dlx3 in 
these studies. The present studies provide important new evidence that Dlx3 may 
directly affect transcriptional regulation of Pgf through interactions of Dlx3 and the 
Pgf gene promoter in choriocarcinoma cells. 
 
Materials and Methods 
Histological staining of mouse placental sections 
    Implantation sites from Dlx3+/+ and Dlx3-/- placentas at E9.5 were fixed in 4% 
paraformaldehyde and embedded in paraffin. Sections were then cut and stained in 
hematoxylin and eosin to characterize relative differences in labyrinth expansion and 
morphogenesis. 
 
Microarray 
All experimental paradigms using animals in this research were approved by the 
Cornell University Institutional Animal Care and Use Committee. Male and female 
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Dlx3+/- (heterozygous) mice were time mated and killed 9.5 d after conception. Gravid 
uteri were dissected free and fetal tissues were harvested for genotyping as previously 
described 12. The placental disks (with some maternal decidua) were carefully 
removed and immediately frozen in liquid nitrogen pending completion of genotyping. 
Total RNA was extracted by homogenizing dissected, thawed tissues in Trizol reagent 
(Invitrogen, Carlsbad, CA) using a TissueLyser (Qiagen, Valencia, CA). The RNA 
was examined for quality and degradation through an Agilent BioAnalyzer by the 
microarray core facility (Cornell University, Ithaca, NY). Double-stranded cDNA was 
synthesized from mRNA and in vitro transcription reactions were then used to produce 
biotin labeled cRNA from the cDNA using GeneChip IVT labeling kit (Affymetrix, 
Santa Clara, CA). The labeled cRNA was hybridized with GeneChip mouse genome 
430 2.0 Array (Affymetrix, Santa Clara, CA) and scanned by GeneArray 3000 scanner 
(Affymetrix, Santa Clara, CA). The raw array data of three pairs of Dlx3-/- versus 
Dlx3+/+ samples were analyzed using Affymetrix GCOS software to obtain signal, 
signal log ratio values, change call and associated p values, using the wild-type sample 
in each pair as baseline. Paired t test was performed on signal to log ratio values 
versus mean of zero for each gene. Multiple test correction was not used because of 
the heterogeneous nature of the tissue samples, the relatively small differences in gene 
expression levels observed between samples, and the limited number of replicates that 
were performed. We therefore chose an arbitrary p value of 0.05 to generate an initial 
set of genes for further validation. A set of 401 differentially expressed genes were 
selected which had t test p value of less than 0.05 and maximum signal value of at 
least 512. Gene networks were identified by database analyses (Ingenuity Pathway 
Analysis; Ingenuity Systems, Redwood City, CA) using all 401 identified genes in the 
array analysis.  
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Quantitative real-time PCR 
    Quantitative (q) real-time PCR using probe based chemistry was used to confirm 
differential expression of genes identified by array experiments. Briefly, a total of 9.0 
μg of total mRNA from individual Dlx3+/+ and Dlx3-/- mouse placentas (n=3/genotype) 
was reversed transcribed using a high-capacity cDNA archive kit (Applied Biosystems, 
Foster City, CA). TaqMan universal PCR master mix (Applied Biosystems, Foster 
City, CA) with uracil-N-glycosylase was used to set up PCRs containing forward and 
reverse primers, amplicon specific probes and 20.0 ng of cDNA template in a total 
volume of 20.0 μl. All PCRs were performed in triplicate. Forward and reverse 
primers flanking an exon junction were designed by ProbeFinder version 2.10 (Roche 
Applied Science, Indianapolis, IN) and synthesized by Integrated DNA Technologies 
Inc (Coralville, IA). The amplicon specific fluorogenic probes used were identified 
from the Roche universal probe library that were labeled with 6-carboxy fluorescein 
(FAM) and 6-carboxy-tetra-methyl rhodamine (TAMRA) for the 5’ reporter and 3’ 
quencher, respectively. The oligonucleotide sequences of primers and identification 
number for the corresponding Roche mouse universal probe library are listed in Table 
3.1. PCRs were performed on an ABI 7500 real-time PCR system and analyzed with 
sequence detection software version 1.3 (Applied Biosystems). Negative controls were 
run with each sample set, in which the template was replaced by PCR-grade water. β-
actin was used as the endogenous control for normalization of cDNA input. Relative 
quantification of gene expression was determined by the 2-(ΔΔCt) method after first 
determining that the amplification efficiency of all targets and β-actin was identical 13. 
We also used commercially available ABI TaqMan gene expression assays to quantify 
synuclein-α (Snca) expression levels as well as confirm the specificity of the Roche 
probe sets to the hemoglobin gene family members Hba-a1, Hba-x, and Hbb-y (listed 
in Table 3.2).  
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Table 3.1. Primers and probes used for qPCR analysis 
Gene 
symbol 
GeneBank 
accession no. 
Forward primer Reverse primer Roche
Probe 
no.  
Pgf NM_008827 ctgggttggctgtgcatt ggcaccacttccacttctgt 03 
Hba-a1 NM_008218 gagctgaagccctggaaag tggcttacatcaaagtgaggaa 60 
Hba-x NM_010405 tgagagagctatcatcatgtcca ggggtagctgcagaagagc 07 
Hbb-y NM_008221 cttgccatcatggtgaacttt ggtccatgggtacacaacaa 73 
Hbb-bh1 NM_008219 tggatcctgagaacttcaagc attggccactccaatcacc 29 
Mmp9 NM_013599 acgacatagacggcatcca gctgtggttcagttgtggtg 19 
Ceacam11 NM_023289 aggggatcctgctcacagt tctgggtggtagttggaatca 62 
Psx1 NM_008955 gggtgtggatgaatgtgatg gcactctcctgtttctctgg 91 
Lum NM_008524 ggatggcaatcctctcactc tcatttgctacacgtagacactcat 16 
Thbs2 NM_011581 ggctttctgggcaatggta atatctgtgaccacagcacactc 85 
 
Table 3.2. Applied Biosystems TaqMan gene expression assays 
 
Gene 
symbol 
Gene name GeneBank 
accession no. 
Assay ID 
Snca Synuclein-α NM_009221 Mm00447333_m1 
Hba-a1 Hemoglobin-α, adult chain 1 NM_008218 Mm00845395_s1 
Hba-x Hemoglobin X, α-like embryonic 
chain in Hba complex 
NM_010405 Mm00439255_m1 
Hbb-y Hemoglobin Y, β-like embryonic 
chain 
NM_008221 Mm00433936_g1 
 
Northern blotting 
    The Pgf cDNA was amplified from E9.5 mouse placenta using PCR, the PCR 
product was cloned into pGEM T-Easy vector (Promega Corp., Madison, WI) and 
nucleotide sequence analysis was used to confirm the Pgf cDNA. Male and female 
Dlx3+/- (heterozygous) mice were time mated and euthanized 9.5 d after conception. 
Gravid uteri were dissected free and embryos were harvested for genotyping as 
described above. The placental disk (with some maternal decidua) was removed and 
immediately frozen in liquid nitrogen pending completion of genotyping. Total RNA 
was extracted from E9.5 placenta using Trizol reagent (Invitrogen, Carlsbad, CA). 
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RNA samples (15 μg) from different genotypes were separated in conventional 
denaturing formaldehyde-containing agarose gel electrophoresis, ribosomal bands 
documented, and then RNA transferred to nylon membranes using capillary action. 
The membranes were prehybridized in Church’s hybridization buffer [7% (wt/vol) 
sodium dodecyl sulfate, 0.5 M sodium phosphate buffer (pH 7.2) and 10 mM EDTA] 
overnight. Radiolabeled [32P] Pgf cDNA probe was prepared by random primer 
labeling to high specific activity and then added to the hybridization buffer. 
Hybridizations were carried out at 65°C overnight. Membranes were then washed 
under high stringency and bands were visualized by autoradiography. Densitometry 
analyses of band intensity were performed using ImageJ (National Institutes of Health, 
Bethesda, MD). 
 
Placental explant studies and Pgf ELISA 
    Male and female Dlx3+/- (heterozygous) mice were time mated and pregnant 
females were killed 9.5 d after conception. Gravid uteri were dissected free and 
embryos were harvested for genotyping as described above. The placental disks with 
some maternal decidua [Dlx3+/+ (n=5) and Dlx3-/- (n=7)] were removed and 
immediately placed into explant culture as described previously (12). Media samples 
were collected at time 0 and after 3 h in this culture system. Media samples were then 
analyzed for secreted Pgf protein levels using a mouse Pgf ELISA based immunoassay 
commercially available (R & D Systems, Minneapolis, MN) as per the manufacturer’s 
instructions. Media samples were assayed in duplicate in two separate assays. In 
media samples collected at time 0, Pgf concentrations were below detectable limits of 
the assay. According to the manufacturer, interassay coefficient of variation for this 
assay was 5.6%. Within-assay variation was reported as 9.5%. The sensitivity of this 
assay (minimum detectable dose) was 1.49 pg/ml. 
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Cloning the Pgf promoter sequences 
    Mouse Pgf (5.2 kb) promoter was obtained by PCR using mouse genomic DNA 
and the following primers: 5’ primer, 5’-
GGTACCGATGAGAGAGGGCGGAAGAGAA-3’ and 3’ primer, 5’-
GGTACCTTCAAGGCACAATCACCATGC-3’. To facilitate cloning, a Kpn I 
restriction enzyme site was incorporated at the end of both 5’ and 3’ primers. The PCR 
product was cloned into pGEM T-Easy vector (Promega Corp., Madison, WI). The 
nucleotide sequence was verified by sequence analysis. After Kpn I digestion, the 
promoter fragment was subcloned into a luciferase reporter vector and orientation 
confirmed using restriction analysis. The Pgf promoter-luciferase reporter gene 
plasmid was prepared by two cycles through cesium chloride using standard protocols. 
 
Cell culture and transient transfection studies 
    JEG3 cells were cultured in DMEM supplemented with 10% FBS. Before 
transfection studies, cells were split to 35-mm dishes and subconfluent cultures were 
used in all experiments. The Pgf promoter-luciferase reporter (Pgf-Luc) containing 5.2 
kb 5’ flanking sequences as described above was used in these studies. The Pgf-Luc 
reporter was transiently cotransfected into JEG3 cells with increasing doses of Dlx3 
expression vector (pKH3-Dlx3) using FuGENE 6 transfection reagent (Roche 
Diagnostics Inc., Indianapolis, IN) as per the manufacturer’s instructions. All 
transfections were carried out with an equivalent amount of total DNA by 
supplementing reactions with the parent vector (pKH3). Twenty-four hours after 
transfection, luciferase activity was determined using reagents from the dual-luciferase 
reporter assay system (Promega Corp., Madison, WI). Luciferase activity was 
standardized by total cell protein content as determined by Bradford assay. All 
transfection studies were performed in triplicate on at least three separate occasions 
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with similar results. Data are shown as means (n=3) ± SEM of representative 
experiments. To determine ectopic DLX3 expression level in transfected cells, 
Western blot analysis was performed on cell lysates obtained for luciferase assay. 
Equal protein amounts of cell lysate were resolved by SDS-PAGE and transferred to 
nitrocellulose membranes using electroblotting. Membranes were blocked using Tris-
buffered saline [10 mM Tris (pH 7.6) and 150 mM NaCl] containing 0.1% Tween20 
(TBST) and 5% nonfat dried milk. After 1h of blocking, membranes were incubated 
with a rabbit polyclonal DLX3 antiserum or β-ACTIN as previously described 13, and 
protein bands representing ectopic expression were visualized using enhanced 
chemiluminescence (Perkin Elmer, Boston, MA).  
 
Identification of putative Dlx3 binding sites within the Pgf 5’ flanking sequences 
and DNA binding assays 
    Inspection of the Pgf 5’ flanking sequences revealed three putative Dlx3 binding 
sites based upon comparison to the consensus binding site sequence A/C/GTAATT 
G/AC/G. These sites were located at positions -4297, -3061 and -1716 relative to the 
start site of transcription. The site at position -4297 was a consensus site, whereas the 
sites at positions -3061 and -1761 were near consensus (a single nucleotide mismatch 
in the 3’ termini of the site). Oligonucleotides (top and bottom strands) were 
synthesized for each of these sites, annealed and labeled for use in EMSAs. 
Recombinant DLX3 was prepared by in vitro transcription and translation using a 
wheat germ lysate kit commercially available (Promega, Madison, WI) for use in 
EMSA studies. Nuclear extracts were prepared from JEG3 choriocarcinoma cells and 
used in EMSA as described previously 13,14. 
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Statistical analyses 
    Statistical methods for the array analyses are described above. Where appropriate 
for Pgf secretion data and all luciferase data, paired t tests were used to examine 
statistical differences between means. Statistical significance is reported for each 
experiment. 
 
Results 
Genetic perturbation of Dlx3 in knockout mice results in a failure to expand the 
placental labyrinth 
    In the mouse, Dlx3 has been shown to be required for normal placental 
development and morphogenesis 11. Dlx3 is expressed within the trophoblasts of the 
labyrinth beginning sometime after E8.5 and is clearly detectable by 
immunohistochemistry on E9.5 12. Dlx3 was not detectable in giant cell trophoblasts. 
Targeted deletion of Dlx3 resulted in embryonic lethality at E9.5-10 characterized by a 
failure in the development of the murine placenta. Consistent with previous 
observations by Morasso et al. 11, histological examination of the murine placenta on 
E9.5 revealed a reduction in the thickness of the labyrinth in Dlx3-/- implantation sites, 
compared to wild type (Figure 3.1A). 
 
Gene profiling of the Dlx3-/- mouse placenta 
    The Dlx3-/- mouse placenta is characterized by a putative failure in the expansion 
of the labyrinth compartment, a key developmental step effectively enlarging the fetal 
vascular compartment and thus the maternal-fetal interface (Figure 3.1A). To better 
understand the transcriptome regulated by Dlx3 within the labyrinth, we used 
microarray analysis of placental tissues from the Dlx3-/- mouse model. Our studies 
focused on the gene profile at E9.5, a time when the placenta appears to be causal in 
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the demise of the developing embryo 11. Mouse Genome 430 2.0 arrays containing 
45,000 probe sets analyzing the expression level of approximately 39,000 transcripts 
were used. From this analysis, we identified 401 differentially expressed genes (for 
detailed information, see Appendix 1). Of these 401 genes, RNA levels from 194 
genes were shown to be reduced, whereas RNA levels from the remaining 207 genes 
were increased. Using the criteria of a significant paired t test and a signal to log ratio 
value of lower than -0.5 and higher than 0.5 when comparing Dlx3-/- to Dlx3+/+ mice, 
analyses of array data demonstrated differential expression of 33 genes in three pair-
wise comparisons (Figure 3.1B). RNA levels from 25 of the 33 genes were reduced, 
whereas the remaining eight genes were expressed at elevated levels in the placenta of 
Dlx3-/- mice, compared with Dlx3+/+ mice. 
    To confirm these array findings, 12 selected genes were examined by qPCR 
methods (Table 3.3). Selection of these genes was made from the entire set of 401 
differentially expressed genes; however, the majority was selected from the list of 33 
genes with the greatest fold change in transcript level (Figure 3.1B). qPCR results 
confirmed the fidelity of the array analysis for 11 of 12 genes with consistent fold 
changes in RNA levels (Table 3.3). For example, four hemoglobin genes (Hba-a1, 
Hba-x, Hbb-y and Hbb-bh1) examined were all reduced in the Dlx3-/- placenta to 
approximately 30-40% of wild type RNA levels, whereas lumican and 
thrombospondin 2 were both elevated 1.8- to 2.2-fold using these two assays. 
Remarkably we did not obtain consistent results for only 1 (insulin-like growth factor 
binding protein 5) of the 12 genes examined. We attribute this inconsistency to a lack 
of an effective mouse universal probe library assay in the qPCR approach rather than 
true differences between the assays used. Therefore the qPCR results confirm the 
accuracy of the array analysis in determining differential gene expression in the 
placenta in the absence of Dlx3. 
 104 
 
 
 
 
 
 
 
Figure 3.1. Effect of Dlx3 on labyrinth morphology and gene profile of 33 
differentially expressed genes in Dlx3-/- mouse placenta. A. Hemotoxylin and eosin 
staining of E9.5 mouse Dlx3-/- and Dlx3+/+ implantation sites identifying labyrinth (lab; 
demarcated by dashed lines). Bar = 200 µm. B. Thirty-three genes from microarray 
analysis whose magnitude of log ratio was lower than -0.5 or higher than 0.5 are 
depicted. Genes were identified by Affymetrix ID (Gene ID), symbol and gene name. 
Each column represents a pair wise sample comparison. The signal to log ratio values 
of Dlx3-/-/Dlx3+/+ from Affymetrix GCOS software were used in the cluster analysis. 
The shades of green indicate repressed genes and the shades of red are induced genes. 
Colored pixels represent the magnitude of the gene response (log fold change).  
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Table 3.3. Comparison of changes in transcript levels using array  
analysis and qPCR 
 
Gene 
symbol 
Gene name Gene Bank 
accession 
number 
Microarray 
fold change 
(Mean±SEM) 
qRT-PCR 
fold change 
(Mean±SEM)
Pgf Placental growth 
factor 
NM_008827 0.50 ± 0.08 0.60 ± 0.14 
Snca Synuclein, alpha NM_009221 0.31 ± 0.08 0.48 ± 0.06 
Hba-a1 Hemoglobin alpha, 
adult chain 1 
NM_008218 0.40 ± 0.05 0.45 ± 0.08 
Hba-x Hemoglobin X, alpha-
like embryonic chain 
in Hba complex 
NM_010405 0.39 ± 0.03 0.44 ± 0.03 
Hbb-y Hemoglobin Y, beta-
like embryonic chain 
NM_008221 0.37 ± 0.02 0.44 ± 0.07 
Hbb-bh1 Hemoglobin Z, beta-
like embryonic chain 
NM_008219 0.44 ± 0.03 0.52 ± 0.14 
Mmp9 Matrix 
metalloproteinase 9 
NM_013599 0.52 ± 0.01 0.68 ± 0.12 
Ceacam11 CEA-related cell 
adhesion molecule 11 
NM_023289 0.37 ± 0.01 0.60 ± 0.06 
Psx1 Placenta specific 
homeobox 1 
NM_008955 0.66 ± 0.03 0.75 ± 0.04 
Lum Lumican NM_008524 1.81 ± 0.24 2.03 ± 0.22 
Thbs2 Thrombospondin 2 NM_011581 1.60 ± 0.14 2.16 ± 0.12 
 
    To gain further insight into how these differentially regulated genes may be 
organized into specific gene networks, the entire array data set (401 differentially 
expressed genes) was subjected to gene network analysis using Ingenuity pathway 
analysis (Ingenuity.com). This analysis revealed two interrelated gene networks 
strongly impacted by the loss of Dlx3 (Figure 3.2). Loss of Dlx3 resulted in the altered 
expression of 11 genes within a cell-to-cell signaling and interaction gene network. 
This network is composed of a number of important signaling ligands/receptors (Pgf 
and EGF receptor), signaling enzymes (the low molecular weight GTP binding protein 
ras, phospholipase D, protein kinase C inhibitor) and extracellular matrix-related 
molecules [matrix metalloproteinase 9 (Mmp9), thrombospondin 2 (Thbs2)]. This 
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cell-to-cell signaling and interaction gene network was linked to a second network 
composed of genes related to hematological disease. These two networks were linked 
via the putative regulation of hemoglobin genes though EGF receptor signaling. 
Within the hematological disease network, loss of Dlx3 resulted in the down-
regulation of five specific hemoglobin genes, some of which were embryonic/fetal 
hemoglobin forms (i.e. Hbb-bh1). Regulation of embryonic/fetal forms of hemoglobin 
in fetal, nucleated erythrocytes may be consistent with the role of Dlx3 in supporting 
an emerging fetal vascular compartment associated with the placental labyrinth 11,12. 
Thus, changes in the Dlx3-modulated cell-to-cell signaling and interaction network 
affects another gene network related to hematological disease. These types of gene 
network relationships provide an important opportunity to examine the specific impact 
of related genes more broadly on the functional development and morphogenesis of 
the mouse placenta. 
 
Pgf gene appears to be an important target of Dlx3 action in placental cells  
Examination of our array data immediately drew our attention to changes in 
expression of the Pgf gene, a member of the VEGF family. Consistent with qPCR 
results, Northern blot analysis revealed a decrease in a single 1.7-kb mRNA in the 
placental tissue when using mouse Pgf cDNA as the probe (Figure 3.3A). 
Densitometric analysis indicated that the expression level of Pgf mRNA in placenta of 
Dlx3-/- mice was 43% of that in wild type mice (Figure 3.3B). To determine whether 
changes in Pgf transcript level were functionally coupled to reduced Pgf secretion, we 
performed placental explant studies 12 using implantation sites from Dlx3+/+ and Dlx3-/- 
mice. After 3h in explant culture, concentrations of Pgf detected in explant culture 
medium tended to be reduced by more than 50% (P = 0.063) in Dlx3-/- placentas, 
compared with Dlx3+/+ (Figure 3.3C) providing an indication of coupled Pgf  
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Figure 3.2. Dlx3 impact on gene networks. The microarray data (401 
differentially expressed genes) were subjected to Ingenuity pathway analysis. Two 
networks were identified; one was related to hematological disease and the other 
was related to cell-to-cell signaling and interaction. The genes identified by circles 
are Dlx3-dependent.
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Figure 3.3. Pgf expression and secretion in placenta of Dlx3+/+ and Dlx3-/- mice.
A. Total RNA was isolated from placenta of different genotypes. RNA (15 μg) 
was hybridized with Pgf cDNA probe. Ethidium bromide staining of 28s and 18s 
ribosomal RNAs was used as the lane loading control. B. Band intensity from the 
Pgf Northern blots was quantified using ImageJ software and depicted as a 
histogram. (a and b reflect statistical differences, p<0.05) C. Dlx3-/- and Dlx3+/+
implantations were prepared and placed in explant cultures for 3 hours. Media 
samples were assayed for Pgf using a commercially available ELISA-based assay   
(a and b reflect statistical tendency, p=0.063).
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gene expression and secretion. 
   
The Pgf gene 5’ flanking region is responsive to Dlx3 overexpression in 
choriocarcinoma cell. 
    To examine the hypothesis that the Pgf gene promoter may be regulated by Dlx3 
at the transcriptional level, we cloned a portion of the Pgf promoter into a luciferase 
reporter gene construct. The promoter fragment was based upon studies previously 
reported 15 and additional sequences obtained from Ensembl genome browser. Initial 
studies compared basal expression of the Pgf promoter-luciferase reporter gene 
activity with other promoter fragments known to be expressed in placental 
trophoblasts [Esx-1 and Dlx3 13,14 or constitutively expressed (thymidine kinase)]. The 
luciferase reporter containing 5.2 kb of the Pgf gene 5’ flanking region displayed 
transcriptional activity approximately 10-fold higher that the parent luciferase reporter 
gene. Basal Pgf promoter activity was greater than Esx-1 promoter activity 13 but less 
than the Dlx3 or thymidine kinase promoters 14 when transfected as luciferase 
reporters into the JEG3 choriocarcinoma cell line (a trophoblast cell model).  
    Examination of the nucleotide sequences of this Pgf promoter fragment revealed 
three consensus or near consensus Dlx3 binding sites (using A/C/G TAATT G/A C/G 
consensus sequence for a Dlx3 binding site). For identification of near-consensus sites, 
a single nucleotide mismatch outside of the central TAATT core of the binding site 
was considered. These sites were located on the sense strand at positions -4297 
(consensus site), -3061 and -1761 (both near consensus sites). We synthesized 
oligonucleotide probes for the putative Dlx3 binding sites for use in EMSA using 
recombinant DLX3 and nuclear extracts purified from JEG3 choriocarcinoma cells to 
determine whether DLX3 could bind these elements in vitro (Figure 3.4A and B). 
EMSA revealed that all of these sites were sufficient to bind recombinant DLX3. The 
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junctional regulatory element (JRE; a consensus DLX3 binding site) from the 
glycoprotein hormone α subunit promoter was used as a positive control in these 
studies (Figure 3.4A). Binding sites at -4297 and -1761 bound recombinant DLX3 in a 
manner consistent with the JRE; whereas the site located at -3061 appeared to be a 
higher relative affinity binding site compared to the others despite being a near 
consensus site. 
    Using the -3061 binding site, we examined DNA binding complex formation 
using nuclear extracts from JEG3 choriocarcinoma cells (Figure 3.4B). These binding 
reactions resulted in the formation of discrete complexes with an electrophoretic 
mobility consistent with recombinant DLX3. Further using DLX3 antiserum, these 
studies demonstrated a DLX3-like immunoreactivity within the DNA binding 
complex as measured by a more retarded electrophoretic mobility often referred to as a 
supershift. In these studies, normal rabbit serum (NRS) and the CCAAT/enhancer-
binding protein (C/EBP) antisera were used as negative controls. Similar results were 
observed using the -4297 and -1761 binding sites and JEG3 nuclear extracts. These 
studies support the conclusion that DLX3 or a highly similar epitope is present in the 
binding complexes formed using these sites and JEG3 nuclear extracts. Moreover, 
these studies support speculation that DLX3 may have a direct effect on Pgf promoter 
activity in cells of the trophoblast lineage. 
    To determine the effect of DLX3 on the expression of Pgf promoter-luciferase 
reporter, cotransfection studies in JEG3 choriocarcinoma cells were used. 
Overexpression of DLX3 resulted in a dose-dependent increase in expression of 
epitope tagged DLX3 (Figure 3.5A). Addition of three hemagglutinin (HA) epitopes 
in frame with the DLX3 coding sequence resulted in expression of HA-DLX3, which 
was slightly larger in molecular size relative to endogenous DLX3. Recombinant  
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Figure 3.4. DLX3 binds to sites within the Pgf gene promoter. A. EMSAs were 
used to determine DLX3 DNA binding to three putative DLX3 binding sites found 
within the Pgf 5’ flanking region. The positions of these sites (designated as probes) 
were at -4297 (a consensus site), -3061 (a near consensus site) and -1761 (a near 
consensus site) relative to the start site of transcription for the Pgf promoter. The JRE 
from the glycoprotein hormone α-subunit was used as a positive control. Recombinant 
(r) DLX3 was added in increasing doses (gray triangles) and DLX3 complexes are 
designated by the arrow. Free probe at the bottom of the gel is also designated. B. 
EMSAs were performed using JEG3 nuclear extracts (NE) and the -3061 probe as 
described above. All binding reactions received the same amount of JEG3 NE. In 
some binding reactions, NRS, DLX3 or C/EBP antisera were added in an effort to 
perturb the DLX3 binding complex. NRS and C/EBP antisera served as negative 
controls. To identify the electrophoretic mobility of the DLX3 containing complex, 
rDLX3 was added as a standard. Free probe, the DLX3 complex, and the DLX3 
complex bound to the DLX3 antibody (DLX3 supershift) are designated with arrows. 
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Figure 3.5. DLX3 overexpression is sufficient to activate the Pgf gene 
promoter in JEG3 cells. A. Transient overexpression studies were carried out 
using the vector control (2.0 µg) or increasing doses of an expression vector for 
HA epitope-tagged human Dlx3 (HA-DLX3). Whole cell lysates were prepared 
and subjected to Western blot analysis using the DLX3 antibody to determine the 
extent of ectopic expression of HA-DLX3. HA-DLX3 migrates slightly slower 
than endogenous DLX3 due to the addition of three HA epitopes. Recombinant (r) 
human DLX3 was used as a positive control for the Western blot. To control for 
lane loading, the samples were reprobed with an antibody to ACTIN. B. Transient 
transfection studies in JEG3 cells were used to determine the effect of DLX3 on 
Pgf promoter activity. Cotransfection of the Pgf gene promoter-luciferase reporter 
with increasing doses of DLX3 expression vector (0, 0.5, 1.0, 1.5, 2.0 µg) resulted 
in a dose dependent increase in expression of the Pgf luciferase reporter. Data are 
reported as relative luciferase activity standardized by total cellular protein content 
from representative studies (n=3/treatment) (a and b reflect statistical differences, 
p<0.05).
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DLX3 was used as a positive control in these studies. Importantly, DLX3 
overexpression increased Pgf promoter luciferase activity in a dose-dependent manner 
(Figure 3.5B). At the highest dose of DLX3 expression vector, Pgf promoter-
luciferase reporter expression was increased greater than 7-fold. These studies provide 
clear evidence that DLX3 is sufficient to modulate expression of the Pgf promoter in 
cells of trophoblast origin and support the conclusion that the loss of Dlx3 in vivo 
likely impacts Pgf production at the transcriptional level. 
 
Discussion 
    Dlx3 is a member of a larger group of homeobox containing transcription factors 
within the Dlx family 16. Pairs of Dlx family members are grouped in clusters aligned 
with Hox genes on separate chromosomes in mouse and human. For example, DLX3 
and DLX4 (also referred to as DLX7) are tandemly arrayed on human chromosome 17 
separated by approximately 17.6 kb of intervening sequence and aligned with the Hox 
B cluster 17. DLX3 and 4 are both expressed within placental trophoblasts 18. The 
Dlx3-/- mouse dies in utero at E9.5-10, presumably due to failed placental development 
11. Morphologically, the labyrinth of the Dlx3-/- placenta appears compact and does not 
appear to enlarge at a similar rate, compared with wild type mice potentially reflecting 
a defect in the expansion of the fetal vascular bed (Figure 3.1A). Morasso et al. 11 
found that defects in both yolk sac and fetal vasculature within the labyrinth were 
evident in the Dlx3-/- placenta; however, it remains unclear whether this is causal in 
the demise of the developing embryo. Placental trophoblast expression of DLX4 18 is 
likely not simply redundant because the presence of Dlx4 in the Dlx3-/- mouse embryo 
cannot rescue the placental phenotype providing evidence for the distinct role of Dlx3 
in placental morphogenesis. In primate species, DLX3 expression is conspicuous 
throughout gestation within syncytial and cytotrophoblasts in microvilli in human 
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placenta 14 and baboon placental samples obtained throughout gestation (Fazleabas, A., 
and M.S. Roberson, unpublished observations). This is consistent with the endocrine 
role of DLX3 in directing transcriptional regulation of the glycoprotein hormone α-
subunit of CG, whose expression is restricted to trophoblasts of primates and horses. 
The mouse placenta does not produce a similar placental borne gonadotropin; as a 
consequence questions regarding a potential role of Dlx3 in regulating placental 
endocrine function have not been fully explored. 
    The present studies are the first to provide insight into the underlying 
transcriptome modulated by Dlx3 in the developing placenta. The loss of Dlx3 impacts 
the expression of a functionally diverse group of genes. For example, genes affected 
by Dlx3 can be categorized as ligands (such as reduced expression of Pgf), cell 
signaling molecules (such as down-regulation of Rab6B, Rac/Cdc42 guanine 
nucleotide exchange factor 6 and up-regulation prostaglandin E receptor 3), regulators 
of cytoarchitecture (such as down-regulation of keratin complex 2 and phosphatase 
and actin regulator 1) and extracellular matrix related molecules (such as down-
regulation of Mmp9 and up-regulation of lumican and thrombospondin 2). These 
changes in gene expression point to a spectrum of distinct cellular processes 
dependent on transcriptional activity and regulation by Dlx3. Focusing on more global 
changes, we identified a potential impact of loss of Dlx3 on gene networks related to 
cell-to-cell signaling and interactions and a cohort of hemoglobin genes related to 
hematological disease. This gene network analysis lends support to the conclusion that 
Dlx3 may be involved in development of the fetal vascular bed consistent with a 
reduction in labyrinth depth. During mouse development, initial hematopoiesis begins 
in the yolk sac around E7.0 within extraembryonic blood islands 19. Later (E11.0/12.0), 
fetal liver becomes the primary site of hematopoiesis. Because it is unlikely that the 
fetal hemoglobin genes observed in our array analysis are specifically expressed in 
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labyrinth trophoblasts (the specific site of Dlx3 expression), it seems more likely that 
hemoglobin mRNA expression occurs in fetal nucleated erythrocytes gradually 
populating the labyrinth vascular bed primarily from yolk sac at E9.5. Consistent with 
this notion, fetal erythrocytes were greatly reduced within the labyrinth vasculature in 
the Dlx3-/- mouse at E12.5 11. Thus it is reasonable to suspect that loss of the 
hemoglobin mRNAs in the Dlx3-/- placenta in our array analysis is consistent with 
reduced fetal vasculature and potential for reduced fetal erythrocytes within the 
labyrinth of the midgestation placenta. 
    One of the more notable gene transcripts identified by our array analysis was Pgf. 
Array analysis, qPCR and Northern analysis all consistently demonstrated a reduced 
expression of the Pgf transcript in the Dlx3-/- placenta. Consistent with coupled 
biosynthesis and secretion, the Dlx3-/- implantation sites tended to secrete less Pgf than 
wild type placentas in explant cultures, suggesting a functional consequence of 
reduced Pgf gene expression in vitro. Our additional studies based on the array results 
implicate DLX3 as a putative direct activator of the Pgf gene promoter in studies using 
a choriocarcinoma cell model. Examining the initial 5.2 kb of the mouse Pgf 5’ 
flanking sequence revealed the consensus or near consensus Dlx3 binding sites (Figure 
3.4). All of these sites could bind DLX3 in vitro, albeit with variable relative affinity 
and overexpression of DLX3, was sufficient to increase transactivation of the Pgf 
luciferase reporter gene (Figure 3.5). Interestingly, the extent of DLX3 overexpression 
necessary to induce Pgf promoter-luciferase reporter transcriptional activation was 
higher than expected. This may be related to our recent observations that the inhibitory 
SMAD, SMAD6, can functionally interact with DLX3 and prevent DLX3 DNA 
binding and thus transactivation of target genes in choriocarcinoma cells 13. In our 
DLX3 overexpression studies, high doses of DLX3 expression vector leading to 
relatively high levels of DLX3 may have been necessary to overcome the negative 
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effects of SMAD6 interaction. As the dose of DLX3 increased, the stoichiometry 
between DLX3 and SMAD6 would be shifted in favor of unbound DLX3 and a 
positive transcriptional signal. Thus, our in vivo Dlx3-/- mouse implicates Dlx3 as a 
necessary factor for the expression and secretion of Pgf. Using in vitro and cell culture 
models, our studies provide direct evidence that DLX3 is sufficient to bind to and 
transactivate the Pgf gene promoter. 
    As discussed earlier, PGF is a member of the VEGF gene family and is thought 
to play a role in placental and endometrial angiogenic potential 20,21. The PGF receptor 
is expressed within the endothelial compartment of the labyrinth and in placental 
trophoblasts, suggesting a complex role of PGF in placental cell biology. In the human, 
alternative splicing of the PGF transcript generates four isoforms: PGF-1, PGF-2, 
PGF-3 and PGF-4 22-25. In mouse, only one Pgf mRNA encoding the equivalent of 
human PGF-2 has been identified 24. Structurally related to VEGF, PGF binds to 
VEGFR-1 and appears to be involved in modulation of vascular permeability during 
pathological angiogenesis 26. The mechanistic role of PGF and VEGFR-1 during 
placental development and angiogenesis has not been fully elucidated. Pgf -/- mice 
appear to be fertile without evidence of placental vascular pathologies 26; however, 
PGF has been found to be an important marker for preeclampsia in women, a 
syndrome of late pregnancy characterized by maternal hypertension, proteinuria, 
insufficient trophoblast invasiveness, a reduction of PGF levels, and increased soluble 
anti-angiogenic fms-like tyrosine kinase activity during mid- to late gestation. All of 
these symptoms are resolved with expulsion of the placenta 27-32. An important mouse 
model recapitulating many of the cardiovascular symptoms of preeclampsia has 
recently been described 33,34. Pgf expression is markedly reduced in this mouse model 
of preeclampsia as well. The possibility exists that DLX3-dependent changes in PGF 
may be related to the molecular determinants driving the progression of events leading 
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to preeclampsia. Additional studies will be required to fully appreciate this possibility.   
    Dlx3-dependent biosynthesis and secretion of Pgf also affords a potential 
mechanism for the indirect actions of Dlx3 on target gene expression. Because Pgf is a 
secreted angiogenic/growth factor and the VEGFR-1 is expressed in cell types that do 
not necessarily express Dlx3, it is conceivable that Dlx3-dependent loss of Pgf would 
have a marked impact on other genes within the Dlx3-dependent transcriptome 
through activation of VEGFR-1. We would predict that some proportions of the genes 
identified by our array analysis are indirectly regulated by Dlx3 through Pgf-induced 
signaling and transcriptional activation. This may be of particular importance in 
situations like preeclampsia where PGF appears to be a significant component of the 
progression of this disease in women. 
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Abstract 
Distal-less 3 (Dlx3), a homeodomain containing transcription factor, is essential 
for chorionic gonadotropin α subunit gene transcription in primates and placental 
development in the mouse. The Dlx3-/- mouse embryo dies at E9.5-10 due to placental 
failure. Loss of Dlx3 in the mouse also results in a marked reduction in the synthesis 
and secretion of Pgf, a member of the vascular endothelial growth factor family and an 
important marker of preeclampsia. The current studies examine the molecular 
mechanisms involved in Dlx3-regulated expression of the Pgf gene promoter. To 
investigate the functional importance of Dlx3 in the regulation of Pgf gene 
transcription, we identify and mutate the two putative Dlx3 binding sites in the 5.2 kb 
of 5’ flanking sequence of the mouse Pgf gene. Pgf promoter activity is markedly 
increased with Dlx3 overexpression and reduced by the combined mutation of both of 
the Dlx3 binding sites. Thus, these putative Dlx3 binding sites are required for 
regulation of Dlx3-induced Pgf gene promoter activity in placental trophoblast cells. 
DNA binding studies of the two putative Dlx3 binding sites using electrophoretic 
mobility shift assays and recombinant DLX3 or JEG cell nuclear extracts demonstrate 
that DLX3 can bind these two sites in vitro albeit with site-specific relative affinity. 
The role for DLX3 is further implicated in the regulation of the Pgf promoter by 
overexpression of the DLX3 interacting protein, SMAD6. We have previously 
demonstrated that SMAD6 represses DLX3-dependent gene promoters by blocking 
DLX3-DNA binding through SMAD6-DLX3 interactions. Consistent with this notion, 
SMAD6 overexpression results in a dose-dependent inhibition of DLX3-induced up-
regulation of the Pgf gene promoter. siRNA-mediated knock-down of endogenous 
DLX3 results in a reduction in human PGF mRNA levels and PGF secretion from 
JEG3 cells. Thus, DLX3 appears to be an important determinant for PGF gene 
promoter activity and ultimately secretion in human placental trophoblasts. Since 
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reduced expression of PGF is an important marker of preeclampsia, we next examined 
the possibility that Dlx3 and Pgf are mis-regulated in a mouse model of preeclampsia 
using the BPH/5 mouse line. Implantation sites from control C57 and BPH/5 mice 
were collected at different gestational ages and transcript abundance for Dlx3 and Pgf 
was determined. At early gestational stages, Dlx3 and Pgf transcripts were reduced in 
the BPH/5 mouse placenta compared to controls; while at later gestational ages, both 
transcripts are overexpressed in the placentas of BPH/5 mouse. When similar 
preliminary studies were carried out using normal human placentas paired (by age, 
ethnicity and health status) with placentas collected from patients experiencing 
preeclampsia, we found that DLX3 and PGF transcript abundance was reduced in the 
term placentas of preeclampsia patients. These combined studies lead us to conclude 
that Dlx3 is an important transcriptional activator of the Pgf gene promoter. Moreover, 
mis-regulation of DLX3 is correlated with altered PGF gene expression during 
preeclampsia suggesting that DLX3 may be a new and important early genetic 
determinant regulating the etiology of this critical disease. 
 
Introduction 
Dlx3, a homeodomain-containing transcription factor, is essential for placental 
development in the mouse 1. Both mouse and human Dlx3 protein is composed of 287 
amino acids with homeodomain located in residues 130-189 2. The sequence of Dlx3 
protein is highly conserved between mouse and human with variation in only five 
different amino acids, none of which are located within the homeodomain. The Dlx3 
null embryo dies between E9.5 and E10, a time when there is remarkable 
morphogenesis and expansion of the placental labyrinth. The failure of Dlx3 null 
embryos to survive past mid-gestation is thought to be a failure in the establishment of 
the fetal-maternal vascular interface within the labyrinth 1. However, Dlx3 dependent 
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mechanisms involved in this process have not been fully elucidated. Our previous 
gene profiling analysis demonstrated that Pgf mRNA expression was lower in the 
Dlx3 null mouse placenta at E9.5 and that Pgf secretion was reduced by the loss of 
Dlx3 3. Thus, Dlx3 may be an important determinant for Pgf gene promoter activation 
within placental trophoblasts.  
Pgf is a member of vascular endothelial growth factor (VEGF) family, consistent 
with its role as an angiogenic growth factor 4. Pgf is synthesized within the placenta 
primarily by cytotrophoblasts and syncytiotrophoblasts 5-7. Additionally, Pgf is 
expressed in other tissues including microvascular endothelial cells and human 
umbilical vein endothelia 4. In women who subsequently develop preeclampsia, the 
level of PGF in plasma decreases significantly during gestation compared to normal 
pregnancy 4,8. As such, PGF has been used as a predictor for risk of subsequent 
development of preeclampsia in pregnant women 8,9. Preeclampsia affects 
approximately 5% of all human pregnancies and is manifested by onset of maternal 
hypertension and proteinuria after 20 weeks of pregnancy 10. The BPH/5 mouse has 
been reported to be an important animal model for preeclampsia in women 11,12. The 
BPH/5 mouse is an inbred strain that spontaneously exhibits clinical features of human 
preeclampsia such as hypertension and proteinuria during the third trimester of 
gestation 11. The BPH/5 mouse also displays reduced serum concentrations of Pgf 
suggesting that mechanisms involved in the onset and progression of preeclampsia in 
women and BPH/5 mice may share a common basis 12. 
In the present studies, we have furthered our understanding of the effect of Dlx3 
on the Pgf promoter by studying the effects of mutation of putative Dlx3 binding sites 
within the Pgf gene promoter. Mutation of these Dlx3 binding sites reduces Pgf 
promoter activity in transfected JEG3 choriocarcinoma cells, an in vitro model for 
human trophoblasts. DLX3 is capable of binding to two sites within the mouse Pgf 
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promoter. Engagement of these sites can be functionally disrupted by overexpression 
of SMAD6, a known inhibitor of DLX3 binding activity. Knockdown of endogenous 
DLX3 was correlated with reduced the mRNA and protein expression of endogenous 
PGF in JEG3 cells. These results suggest that Dlx3 is an important regulator of mouse, 
and likely human PGF gene expression in trophoblast cells. Perhaps most importantly, 
we demonstrate that Dlx3 is mis-regulated in the BPH/5 mouse model throughout 
gestation and at term in human placentas from patients with preeclampsia and these 
transcript profiles correlate well with altered PGF transcript levels in these models. 
 
Materials and Methods 
Cell culture and transient transfection studies 
JEG3 cells were cultured in DMEM supplemented with 10% FBS. Before 
transfection studies, cells were split to subconfluent (approximately 60%) cultures 24 
h prior to all experiments. The Pgf promoter-luciferase reporter containing 5.2kb 5’ 
flanking sequences was used in these studies (referred to as Pgf-Luc). PCR-based site-
directed mutagenesis was used to disrupt the two Dlx3 binding sites within the Pgf 
luciferase reporter. This mutation substituted a Not I restriction site for the near 
consensus Dlx3 binding site. The mutations were confirmed using nucleotide 
sequence analysis. The SMAD6 expression plasmid was a gift from Dr. Ali Hemmati- 
Brivanlou (The Rockefeller University, New York, NY). The Pgf-Luc reporter was 
transiently cotransfected into JEG3 cells with Dlx3 expression vector (pKH3-Dlx3) 
using GeneJuice transfection reagent (Novagen, Darmstadt, Germany) as per the 
manufacturer’s instructions. All transfections were carried out with an equivalent 
amount of total DNA by supplementing reactions with the parent vector (pKH3). 
Twenty-four hours after transfection, luciferase activity was determined using reagents 
from the dual-luciferase reporter assay system (Promega Corp, Madison, WI). 
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Luciferase activity was standardized by total cell protein content as determined by 
Bradford assay. All transfection studies were performed in triplicate on at least three 
separate occasions with similar results. Data are shown as means ± SEM (n=3) of 
representative experiments.  
 
Electrophoretic Mobility Shift Assay 
EMSA was carried out as described previously 13,14. Recombinant human DLX3 
was prepared by in vitro transcription and translation using a commercially available 
wheat germ lysate kit (Promega Corp, Madison, WI) as described previously 14. 
Nuclear extracts were prepared from JEG3 cells as described previously 14. The 
nucleotide sequences for EMSA probes were as follows (only the forward strand 
indicated): -3061 binding site, 5’- GTGGGAGTAATTAAAACCTA -3’; Mutant -
3061 binding site, 5’-GTGGGAGCGGCCGCAACCTA-3’; -1761 binding site, 5’-
ACACAGATAATTAAGAATAC -3’; mutant -1761 binding site, 5’-ACACAGGC 
GGCCGCGAATAC-3’. Binding reactions (without labeled probe) were maintained at 
room temperature for 30 min followed by the addition of 32P-labeled oligonucleotide 
Dlx3 binding site probes. The binding reactions were maintained an additional 30 min 
and then resolved on native polyacrylamide gels. Following electrophoresis, the gels 
were dried, and DNA-protein complexes were visualized by autoradiography. In 
competition studies using EMSA, DNA competitors included a 10-fold molar excess 
of wild type or mutant Dlx3 binding sites from the Pgf promoter to determine the 
specificity of the protein-DNA interactions. All DNA binding studies were conducted 
at least three times with similar results.  
 
Preparation of cell lines expressing siRNAs 
The mammalian expression vector, pSuper-retro-neo (OligoEngine, Seattle, WA) 
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was used for preparation and expression of DLX3 siRNA. Each gene-specific insert 
targeted a 19- nucleotide sequence within the human DLX3 mRNA. The siRNA 
sequences were as follows: siDLX3-#1: 5’-TGCTGCGGTTTCCTATTTA-3’; 
siDLX3-#2: 5’-GAAAGCCGCGTACGATCTA-3’; siDLX3-#3: 5’-
CCTAGCCACTCAGGAATCA-3’. A control siRNA vector (also cloned into 
pSUPER-retro-neo) was constructed using a 19-nucleotide sequence (5’-
TTCTCCGAACGTGTCACGT-3’) putatively without significant similarity to any 
mammalian gene sequence and therefore served as an appropriate negative control. 
The forward and reverse strands of oligonucleotides containing the siRNA and 
nonsense sequence were annealed and cloned into the pSuper-retro-neo vector. All 
siRNA sequences were confirmed by nucleotide sequencing. JEG3 cells were 
transfected with the pSUPER-retro-neo siRNA plasmids using GeneJuice transfection 
reagent as outlined above. Following transfection, stable cell lines were selected using 
neomycin at 500 μg/ml for 7 days (time until untransfected cells all died) then cultures 
were maintained in DMEM/10% FBS medium containing 500 µg/ml neomycin.  
 
Western blotting 
Cells were collected and lysed in RIPA buffer containing protease inhibitors as 
described previously 15. Protein content was determined in all samples using Bradford 
assay and samples were then suspended in an equal volume of 2×SDS loading buffer 
[100mM Tris (pH 6.8), 4% SDS, 20% glycerol and 200 mM dithiothreitol]. Protein 
samples were boiled for 3 min and chilled for 5 min on ice. Proteins were resolved by 
SDS-polyacrylamide gel electrophoresis and transferred to polyvinylidine difluoride 
membranes by electroblotting. Membranes were blocked with 5% nonfat milk in Tris-
buffered saline. For Western blots, a Dlx3 antibody was used at 1:1000 in TBST, 5% 
nonfat milk as described previously 14. The β-actin antibody (Santa Cruz 
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Biotechnology, Santa Cruz, CA) was used at 1:1000 dilution under identical 
conditions as the Dlx3 antibody. Secondary horseradish peroxidase coupled secondary 
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA) were used at 1:5000 dilution. 
Protein bands were visualized by chemiluminescence using commercially available 
reagents (PerkinElmer Life Sciences, Waltham, MA). 
 
Human PGF-1 ELISA 
Stably transfected JEG3 cells expressing control or DLX3 siRNAs were split and 
cultured in DMEM containing 10% FBS and neomycin. After 48 h of cell culture, 
media were changed to serum free OptiMEM media (Invitrogen, Carlsbad, CA). 
OptiMEM media samples were collected at 0, 1, 4 and 8 h and all media samples were 
analyzed as per the manufacturer’s instructions for secreted PGF protein levels using a 
human PGF-1 ELISA-based immunoassay commercially available (R & D Systems, 
Minneapolis, MN). Media samples were assayed in triplicate in two separate assays. In 
OptiMEM media samples collected at time 0, PGF-1 concentrations were below 
detectable limits of the assay. According to the manufacturer, intra-assay coefficient of 
variation for this assay was 5.9%. Inter-assay variation was reported as 13.6%. The 
sensitivity of this assay (minimum detectable dose) was typically less than 7 pg/ml. 
 
RNA isolation 
Total RNA was isolated from both C57 (control) and BPH/5 mouse placenta. 
Briefly, at the specified gestational ages, the placental disk was dissected free from 
uterine wall and decidua. Total RNA was extracted from all samples using Trizol 
reagent (Invitrogen, Carlsbad CA) as per the manufacturer’s instructions. Human term 
placental tissues (without patient identifiers) were obtained from Dr. Monique Ho at 
University of Rochester Medical Center (Rochester, NY) under the guidelines and 
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approval of Cornell University and University of Rochester Medical Center 
Committees on the Use of Human Subjects in Research. Full thickness, radial samples 
from the placental disk were collected, placed in RNA preservation medium, 
RNALater (Qiagen, Valencia, CA) and stored at -80°C until use. Approximate 30 mg 
of placental tissues were disrupted by TissueRuptor (Qiagen, Valencia, CA) for 30 
seconds at full speed with disposable probes to prevent contamination between 
samples. Total RNA was extracted using RNeasy Plus Mini Kit (Qiagen, Valencia, 
CA). RNA samples were also obtained from stable JEG3 cell lines using similar 
approaches with samples being homogenized by passing the lysate 6-8 times through a 
20-gauge needle. For all samples, RNA quality and concentration were determined by 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific, Wilmington, DE). A ratio 
of A260/A280 ≥ 2.0 confirmed the RNA quality.  
 
Quantitative real-time PCR 
Quantitative real-time PCR using probe-based chemistry (outlined below) was 
used to determine differential expression of genes. Briefly, a total of 2.0 μg total RNA 
from mouse or human placental tissues (n = 3 each for control and BPH/5 mouse 
tissues; n = 6 each for control and preeclampsia) or cultured JEG3 cells (n = 3) was 
reversed transcribed using a high-capacity cDNA synthesis kit (Applied Biosystems, 
Foster City, CA). Forward and reverse primers flanking an exon junction were 
designed by ProbeFinder version 2.45 (Roche Applied Science, Indianapolis, IN) and 
synthesized by Integrated DNA Technologies Inc (Coralville, IA). The amplicon-
specific fluorogenic probes used were identified from the Roche universal probe 
library that were labeled with 6-carboxy fluorescein (FAM) and 6-carboxy-tetra-
methyl rhodamine (TAMRA) for the 5’ reporter and 3’ quencher, respectively. The 
oligonucleotide sequences of primers and identification number for the corresponding 
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Roche mouse universal probe library are listed in Table 4.1. TaqMan universal PCR 
master mix (Applied Biosystems, Foster City, CA) with uracil-N-glycosylase, 
commercially available ABI TaqMan gene expression assays (containing forward and 
reverse primers and amplicon-specific probes) and 20.0 ng cDNA templates were used 
to set up PCRs in a total volume of 20 μl. All PCRs were performed in triplicate. The 
ABI TaqMan probes are listed in Table 4.2. PCRs were performed on an ABI 7500 
real-time PCR system and analyzed with sequence detection software version 1.3 
(Applied Biosystems). Negative controls were run with each sample set, in which the 
template was replaced by PCR-grade water. Mouse β-actin or human 18s RNA probe 
sets were used as the endogenous control for normalization of mouse or human 
placenta tissue cDNA input, respectively. Relative quantification of gene expression 
was determined by the 2-(ΔΔCt) method 3. 
 
Table 4.1 Mouse primers and Roche universal probes used for  
qPCR analysis 
 
 Gene 
symbol 
GenBank 
accession 
no. 
Forward primer Reverse primer Roche 
probe no. 
Dlx3 NM_010055 ggggatcctataggcagtacg cctctttcaccgacactgg 32 
Pgf NM_008827 ctgggttggctgtgcatt ggcaccacttccacttctgt 3 
 
 
Table 4.2 Human primers and TaqMan probes used for qPCR analysis 
 
Gene symbol Gene name GenBank accession no. Assay ID 
DLX3 Distal-less homeobox NM_005220 Hs00270938_m1
PGF-2 Placental growth factor NM_002632 Hs00182176_m1
 
Statistical analysis 
Luciferase data were subjected to analysis of variance and differences between 
treatments were determined using Tukey’s Studentized Range Test. Human placenta 
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samples were subjected to analysis of paired t-test. Probability of less than 0.05 
(p<0.05) was considered statistically significant.  
 
Results 
Mutation of Dlx3 binding sites reduces Pgf promoter activity 
We previously reported the transcriptional activity of a 5.2 kb fragment of the 
mouse Pgf gene 5’ flanking sequence, fused with a luciferase reporter gene 3. 
Bioinformatic comparison of 5 kb promoter sequences of human and mouse Pgf genes 
revealed three regions of > 75% evolutionarily conserved sequence. Two near-
consensus Dlx3 binding sites (at -3061 and -1716 relative to the transcription start site) 
were identified within the mouse promoter. The more distal site (at -3061) is located 
in one of these highly conserved regions. To investigate the functional importance of 
these Dlx3 binding sites in regulating Pgf gene transcription, we mutated the two sites 
individually or in combination in the context of the 5.2 kb promoter of the mouse Pgf 
gene. The basal activity of either of the individual Pgf mutant promoters was modestly 
reduced compared to the wild type promoter. Basal activity of the Pgf promoter was 
reduced to approximately 50% of wild type levels by double-mutation of both Dlx3 
binding sites. HA-DLX3 overexpression increased wild type Pgf gene promoter 
activity approximately 4 fold consistent with previous results 3 (Figure 4.1). HA-
DLX3 overexpression was confirmed by Western blot using HA antibody (Figure 4.1; 
shown in the inset). When analyzed separately, the individual mutations in the Pgf 
promoter reduced the response to HA-DLX3 overexpression by approximately 30-
40% compared to the wild type. The double-mutation of both putative Dlx3 binding 
sites nearly abrogated the response to HA-DLX3 overexpression suggesting that both 
sites were required for promoter activity induced by Dlx3. 
Figure 4.1. Mutation of Dlx3 binding sites reduces Pgf promoter activity. 
Transient transfection studies were used to determine the relative importance of 
the Dlx3 binding site on expression of the Pgf promoter luciferase reporter gene. 
JEG3 cells were transiently transfected with wild type Pgf luciferase reporter or 
Pgf luciferase reporter containing one or double mutations within the Dlx3 
binding sites. Cells were cotransfected with control plasmid or a DLX3 
expression vector. Data are reported as relative luciferase activity standardized 
for protein for a representative study (n=3/treatment). The designations a, b, c, d, 
e and f reflect statistical differences, p<0.05. Same numbers mean no statistical 
significance while different numbers mean statistical significance. The inset is a 
Western blot using anti-HA antibody. 1-4 lanes were cells transfected with wild 
type or mutant Pgf gene promoter alone; 5-8 lanes were cells with 
overexpression of HA tagged DLX3 protein. 
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Dlx3 binds specifically cis elements within the Pgf gene promoter  
Our previous studies demonstrated that the two Dlx3 binding sites within the Pgf 
5.2 kb promoter could bind recombinant human HA-DLX3 protein and nuclear extract 
from JEG3 choriocarcinoma cells 3; however, the specificity of these interactions was 
not examined fully. To determine whether DLX3 interaction at these sites was indeed 
specific, we carried out additional EMSAs with competitive binding to determine the 
specificity of these interactions (Figure 4.2). The core DNA sequence for DLX3 
binding, (A/C/G)TAATT(G/A)(C/G), the -3061 and -1761 sites are depicted in Figure 
4.2A. Mutations at these sites reflected substitution of a Not I restriction site 
effectively disrupting the TAATT central core of the site. EMSA were carried out 
using recombinant (r) human DLX3 and nuclear extracts purified from JEG3 cells. 
Consistent with previous reports 3, EMSA revealed that the two wild type sites were 
sufficient to bind DLX3. Addition of ten-fold molar excess of wild type binding site to 
these reactions competitively interfered with binding to the radio-labeled probe; 
however, addition of ten-fold molar excess of the mutant binding sites failed to 
compete for the binding of HA-DLX3 (Figure 4.2B and C). These results support the 
conclusion that the DLX3 protein (either recombinant or from nuclear extracts) binds 
specifically these sequences within the Pgf promoter.  
 
SMAD6 inhibits DLX3-dependent Pgf promoter activation in JEG3 cells 
To further corroborate the required role for DLX3 binding at these elements, we 
made use of a SMAD6 overexpression paradigm. SMAD6 has been shown previously 
to interact directly with DLX3 14. The DLX3-SMAD6 protein-protein interaction 
domain involves a region within DLX3 adjacent to the homeobox domain that is 
critical for protein-DNA interaction (14; see Chapter 2 of this dissertation). In previous 
studies, SMAD6 overexpression repressed DLX3 transcriptional activity 
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Figure 4.2. Dlx3 binding to Dlx3 binding sites within the Pgf gene promoter is 
specific. A. Two Dlx3 binding sites within the Pgf 5.2 kb promoter are located at 
position -3061 and -1761 relative to the start site of Pgf gene transcription. The central 
core of the binding site is underlined. Oligonucleotide probes for these binding sites 
were synthesized and used in electrophoretic mobility shift assays (EMSA). Mutations 
(shown in italics) within these binding sites are also shown and used in EMSA 
competition experiments. EMSA was used to detect binding complexes formed on the 
Dlx3 binding sites using recombinant human DLX3 protein (rDLX3) (B) or JEG3 
nuclear extracts (C). Banding reactions were resolved on native polyacrylamide gels, 
the gels were dried, and bands were visualized by autoradiography. Free probe and the 
DLX3-DNA complex are designated with arrows at the bottom or in the middle of the 
gel respectively.  
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Figure 4.3. SMAD6 inhibits DLX3-dependent Pgf promoter activation in 
JEG3 cells. Transient transfection studies in JEG3 cells were used to investigate 
the functional relevance of SMAD6 on DLX3-dependent gene expression. Pgf 
gene promoter-luciferase reporter was cotransfected with DLX3 (constant dose, 2 
µg) and increasing amount of SMAD6 expression vector (0, 0.5, 1.0, 2.0 µg). Data 
are reported as relative luciferase activity standardized for protein from 
representative studies (n=3/treatment). See previous figures for the designations a, 
b, c, d and e. 
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on the Esx1 gene promoter through inhibition of DLX3 binding to DNA 14. To 
investigate the effect of SMAD6 on DLX3-dependent Pgf promoter activation, we 
overexpressed SMAD6 and DLX3 in JEG3 cells along with Pgf-Luc reporter. In these 
studies, DLX3 increased Pgf promoter activity as previously observed. 
Overexpression of SMAD6 repressed basal expression of Pgf promoter activity in a 
dose-dependent manner and essentially blocked DLX3-induced Pgf promoter 
transactivation (Figure 4.3). These studies provide compelling evidence that these two 
DLX3 cis regulatory elements are required for DLX3-dependent gene activation and 
that DLX3 occupancy at these sites is central to this regulation. 
 
Stable knockdown of human DLX3 results in suppression of the endogenous PGF 
gene transcript and PGF secretion 
Thus far, we have investigated the role and requirement for Dlx3 on the mouse 
Pgf gene promoter activity based largely on our observations from the Dlx3 null 
mouse model and microarray analyses 3. However, PGF appears to play a critical role 
as an angiogenic factor within human placenta and reduced PGF in maternal 
circulation is an important marker of preeclampsia 8,9. To examine the effect of DLX3 
on human PGF gene expression, we developed stable cell lines expressing 21- 
nucleotide siRNAs in an effort to knock down DLX3 in JEG3 cells. Initially, we 
prepared three separate siRNA constructs and tested each individually in stably 
selected cell populations compared to a control siRNA as described in Materials and 
Methods. Preliminary studies indicated that DLX3 siRNA#1 and 3 were modestly 
effective at knocking down DLX3 protein levels while siRNA#2 was not effective. 
Subsequently, an additional stable cell line was prepared with siRNAs #1 and #3 co-
expressed resulting in significant knockdown of DLX3 as determined by Western blot 
analysis (Figure 4.4A). To investigate the effect of knockdown of endogenous Dlx3
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Figure 4.4. Stable siRNA-mediated knockdown of DLX3 reduces endogenous 
expression and secretion of human PGF in JEG3 cells. siRNA was used to knock 
down DLX3 in JEG3 cells. The control siRNA was constructed using a 19-nucleotide 
sequence without significant similarity to any mammalian gene sequence. The empty 
pSUPER-retro-neo vector (Vector control) and the control siRNA were used as the 
negative controls. A. DLX3 protein levels were determined by Western blot analysis 
in siRNA cell lines. Recombinant (r) Dlx3 protein was used as a positive control. β-
ACTIN was used as the lane loading control. B. Mouse Pgf 5.2kb promoter was 
transfected into different siRNA cell lines. Promoter activity was measured in 
different siRNA cell lines. C. DLX3 and PGF-2 transcript levels were detected using 
q-PCR. Human 18s RNA was used as the internal control. Transcript level of DLX3 
and PGF-2 in pSuper-retro-neo vector control was set at 1.0. D. Control and siRNA 
stable cell lines were prepared and placed in OptiMEM media, samples were collected 
at 1, 4, 8 hours and assayed for PGF-1 using a commercially available ELISA-based 
assay. See previous figures for the designations a, b, c, d, e and f.  
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Figure 4.4 (Continued)
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on mouse Pgf promoter activity, we transfected the siRNA cell lines with Pgf-Luc and 
found that basal Pgf promoter activity was markedly reduced by knocking down 
DLX3 (Figure 4.4B). Then, we determined endogenous transcript levels of human 
PGF in the siRA stable cell lines using qPCR. Both DLX3 and PGF-2 transcript levels 
in control siRNA and DLX3 siRNA were compared to pSuper-retro-neo vector control. 
Human PGF transcript level in the DLX3 siRNA cell line was reduced to 
approximately 58% of the control siRNA cell line consistent with the level of siRNA-
mediated knockdown of DLX3 in this cell line (Figure 4.4C). Thus, knocking down 
endogenous DLX3 reduced PGF mRNA expression. To determine if this DLX3/PGF 
knockdown was correlated with a reduction in PGF-1 secretion in these cell lines, cell 
culture media were collected at different time points (1, 4, 8 hours) from both control 
and DLX3 siRNA cell lines. PGF-1 protein concentration in the media was examined 
using an ELISA-based assay. PGF-1 secretion was increased with increasing time of 
culture at both control siRNA and DLX3 siRNA cell lines. PGF-1 protein 
concentration in DLX3 siRNA cell line was significantly reduced compared to control 
siRNA cell line at all time points tested (Figure 4.4D). These studies provide 
important evidence that the human PGF gene may be regulated by DLX3, similar to 
what we observed the effect of Dlx3 on mouse Pgf gene transcription. This may have 
important implications regarding the role of PGF in the pathogenesis of preeclampsia. 
 
Dlx3 and Pgf gene expression is mis-regulated in BPH/5 mouse placenta. 
To examine the possibility that Dlx3 and Pgf transcript levels are mis-regulated in 
the BPH/5 mouse preeclampsia model, quantitative PCR was used to determine 
placental disk mRNA levels for Dlx3 and Pgf at gestational day E9.5, 12.5, 14.5 and  
18.5 in control C57 and BPH/5 mice. For these studies, transcript levels determined in 
the C57 controls were standardized to 1.0 at equivalent gestational ages for direct 
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Figure 4.5. Dlx3 and Pgf transcript abundance in BPH/5 mouse placenta.
Quantitative PCR was used to determine placental mRNA levels for Dlx3 and Pgf
at gestational day E9.5, 12.5, 14.5 and 18.5 in control C57 and BPH/5 mice 
(n=3/group/gestational age). Transcript level of Dlx3 and Pgf in C57 mouse 
placenta was set at 1.0. 
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comparison to BPH/5 transcript levels. Changes in Dlx3 and Pgf transcript levels were 
found to follow very similar trends throughout gestation. At E9.5, Dlx3 and Pgf were 
reduced to 20-30% of control levels. At E12.5, Dlx3 gene expression in the placenta 
was reduced to 60% compared to the C57 mouse and Pgf expression was reduced to 
75% of the control level. At E14.5, Dlx3 gene expression was increased, while Pgf 
gene transcript was modestly reduced in BPH/5 mouse placenta. However, at E18.5, 
both transcripts were overexpressed 2.0-2.5 fold in BPH/5 mouse placentas compared 
to the C57 controls (Figure 4.5).  
 
DLX3 and PGF-2 transcript levels tend to be reduced in term placenta of 
preeclampsia patients compared to control patients.  
Preliminary studies of placental samples from both control (n = 6) and 
preeclampsia (n = 6) patients were collected by Dr. Monique Ho from University of 
Rochester Medical Center. For this study, the diagnosis of preeclampsia was defined 
as two diastolic blood pressure measurements ≥90 mm Hg measured 4 hour to 1 week 
apart and proteinuria of ≥300 mg on a 24 hour urine collection 10. Control patients 
were pregnant women without history of hypertension of any kind. Exclusion criteria 
for patients in this preliminary study included evidence of intra-uterine growth 
retardation, prior chronic hypertension, chorioamnionitis, fetal anomaly or 
chromosome abnormality, multiple gestation and maternal diabetes. Control and 
preeclampsia patients were paired at the same gestational age, labor status, maternal 
ethnicity, age and parity (nullipara or multipara). Quantitative PCR demonstrated that 
PGF-2 gene expression in preeclampsia patients was significantly reduced to 
approximately 50.2% of control patients; while DLX3 mRNA expression was 
significantly reduced to about 66.9% of control patients (Figure 4.6). Taken together 
with the transcript profiling in the BPH/5 mouse model, these studies suggest that both  
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Figure 4.6. Preliminary studies of DLX3 and PGF-2 transcript abundance in 
term human placenta of control and preeclampsia patients. Quantitative PCR 
was used to determine term placental mRNA levels for DLX3 and PGF-2 in 
control (open circles) and preeclampsia patients (black dots) (n=6/group). 
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DLX3 and PGF-2 are coordinately mis-regulated during preeclampsia. 
 
Discussion  
In mice, Dlx3 is a homeodomain-containing transcription factor that is essential 
for placental development. Dlx3 is exclusively expressed in ectoplacental cone and 
chorionic plate in mouse placenta at E8.5, and later in trophoblasts within the 
labyrinth layer at E10.5 1. Dlx3 continues to be expressed in the labyrinth throughout 
later gestation 15. In primate species, DLX3 is nuclear localized to both 
cytotrophoblasts and syncytial trophoblast within microvilli in human placenta at 
approximately 8 weeks gestation and at term 16. Dlx3 null mouse embryos die at E9.5-
10.5 due to defects in the development of labyrinth layer of the placenta 1. Microarray 
analysis of the gene profile regulated by Dlx3 revealed Pgf is one of the genes with 
reduced expression in Dlx3 null mouse placenta suggesting that Dlx3 may be an 
important regulator of Pgf gene expression 3.  
Pgf belongs to a group of proangiogenic peptides within the VEGF family 4. Few 
studies have been carried out to examine the regulation of Pgf gene expression in any 
cell type. Hypoxia is the major regulator of VEGF transcription via binding of 
hypoxia-inducible transcription factors to the hypoxia-responsive element located in 
the VEGF promoter 17. Some studies have shown that, in contrast to VEGF, Pgf is not 
hypoxia-inducible 7,18, but other studies have reported that both hypoxia and hyperoxia 
can up-regulate Pgf expression during angiogenesis in certain tissues 19. Thus, it is not 
fully understood how oxygen tension affects Pgf gene expression. In retinal 
endothelial cells, high glucose increases expression of Pgf at both the mRNA and 
protein level suggesting that Pgf may play a role in the retina during diabetes 20. In 
epithelial cells, Pgf is up-regulated by forkhead/winged helix transcription factor 
FoxD1. FoxD1 binds to a conserved site in the Pgf promoter and activates its 
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transcription 21. In human trophoblast cells, GCM1 regulates PGF gene transcription. 
Overexpression of GCM1 increases human PGF promoter activity 22. In the mouse, 
Gcm1 plays a critical role in the developmental organization of the labyrinth layer of 
the placenta. The Gcm1 knockout mouse is characterized by a distinct reduction or 
absence of labyrinth development 23. In addition to specific integration of PGF gene 
expression by cell-type specific transcription factors, expression of the PGF gene is 
also regulated at the epigenetic level. PGF expression is reduced by promoter 
methylation in lung and colon cancer cell lines and demethylation at these sites 
restores PGF gene transcription 24. 
Our previous results demonstrated that overexpression of DLX3 increased Pgf 
promoter activity in cultured trophoblast cells 3. The present studies demonstrated that 
mutation of DLX3 binding sites within the Pgf promoter reduced the Pgf promoter 
activity, suggesting that these mutations interfered with DLX3-DNA interactions. 
Consistent with these mutagenesis studies, activation of the Pgf promoter by DLX3 
could be inhibited by SMAD6, an inhibitory binding partner of DLX3 (see Chapter 2 
of this dissertation). The repressive effect of SMAD6 is likely due to inhibition of 
DLX3-DNA binding. In siRNA cell line with knockdown of endogenous DLX3 
expression, human PGF mRNA expression and protein secretion were reduced, 
consistent with the hypothesis based on the Dlx3 null mouse model. These 
experiments help to confirm previous studies in mouse and perhaps more importantly 
provide key evidence that DLX3 is a regulator of human PGF expression in placental 
trophoblasts.    
As discussed earlier, PGF is a VEGF family member and appears to be 
synthesized primarily by placental trophoblasts 5-7. In addition to the placenta, PGF is 
also expressed in other tissues including microvascular endothelial cells, human 
umbilical vein endothelia, bone marrow, uterine natural killer cells and keratinocytes 4. 
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Alternative splicing of the human PGF transcript generates four protein isoforms: 
PGF-1, PGF-2, PGF-3 and PGF-4 5,25,26. Differences among the four isoforms include 
the insertion of a heparin-binding domain in PGF-2 and PGF-4 that results in 
increased association with the cell membrane or altered affinity for PGF receptors 4. In 
the mouse, only one Pgf mRNA has been identified, which encodes the homolog of 
human PGF-2 27. PGF-2 specifically binds to VEGFR-1 with high affinity 28. In 
trophoblast cells, the downstream signal transduction pathways activated by PGF 
include PLC-γ and JNK 29,30. Interestingly, embryogenesis appears to be normal in Pgf 
knockout mice, suggesting that the role of Pgf in placental development may be 
redundant with other proangiogenic factors or there may be fundamental differences in 
the function of human and mouse Pgf in placental angiogenesis 31.  
PGF has been found to be an important marker for preeclampsia in pregnant 
women where reduced PGF serum levels are associated with disease progression 9,32. 
Serum concentrations of the soluble form of the VEGF receptor (sFLT-1) have also 
been shown to be increased in preeclampsia patients. Since sFLT-1 is capable of 
binding to free PGF and VEGF, one central hypothesis accounting for preeclampsia 
progression is an imbalance of angiogenic factors such as PGF cause by abnormal 
levels of sFLT-1 4,33-35. Despite considerable research effort in this area, the etiology 
and mechanism underlying preeclampsia are still not fully understood. Thus at present, 
the only effective treatment for preeclampsia is delivery of the placenta. Development 
of animal models that fully imitate this hypertensive disorder may broaden our 
understanding of this syndrome and contribute to our understanding of effective 
prevention and treatment 36. 
Three mouse models have been described that display characteristics of 
preeclampsia. A transgenic mouse model has been created with females expressing 
human angiotensinogen and males expressing renin. After mating these two separate 
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models, female mice develop hypertension, proteinuria, and glomerular enlargement 
during pregnancy which resembles aspects of human preeclampsia 37. The catechol-O-
methyltransferase (COMT) knockout mouse has also been described as a model for 
preeclampsia. COMT is an enzyme that inactivates catecholamines and metabolizes 
hydroxyestradiol to 2-methoxyestradiol (2-ME). Levels of COMT and 2-ME are 
significantly lower in women with severe preeclampsia 38. Pregnant mice deficient in 
COMT show a preeclampsia like phenotype such as placental insufficiency, 
hypertension and proteinuria 38. While both of the mouse models have generated 
considerable interest in preeclampsia research, neither are spontaneous nor display a 
more complete repertoire of symptoms linked to this human disease. 
The BPH/5 mouse is a subline derived from the spontaneous hypertensive strain 
BPH/2, but has a lower blood pressure than BPH/2 mouse 11. BPH/5 mice display 
elevated baseline blood pressure and perhaps most importantly, hypertensive clinical 
features of human preeclampsia during pregnancy 11. This finding is clearly consistent 
with the fact that women with elevated baseline blood pressure have an increased risk 
of preeclampsia 39. The blood pressure of pregnant BPH/5 mice is stable during the 
first two weeks of gestation, then increases at the beginning of the third week (third 
trimester), peaks before delivery and returns to prepregnancy level after delivery of 
pups 11. The BPH/5 mouse has late-gestational proteinuria and progressive 
glomerulosclerosis, which are also consistent with human preeclampsia 12. BPH/5 
mice show reduced expansion of the placenta toward the decidua starting as early as 
E12.5 in gestation, and decidual vessels of BPH/5 placentas have narrowed lumens 
and thickened walls 12. Although both BPH/5 mice and Dlx3-/- mice show placental 
defects such as reduced vascularization within the labyrinth, there is some difference 
between these two mouse placentas. The BPH/5 mouse placenta has reduced 
junctional zone 12 (a zone between decidua and labyrinth), while the Dlx3-/- mouse 
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placenta shows reduced labyrinth 1.    
Our present studies determined the relative gene expression of Dlx3 and Pgf in 
the placenta of BPH/5 mouse through gestation. We selected early, mid and late 
gestational ages in an attempt to examine possible changes in gene expression prior to 
the initiation of overt maternal disease symptoms. The direct comparison to the C57 
mouse strain as a control is based on the observation that one of the early lines that 
contributed to the selection of the BPH strains was C57. Our studies with these mice 
demonstrated that Dlx3 and Pgf mRNA expression levels were markedly lower in the 
BPH/5 mouse placenta compared to the control mouse in the early gestational stage. 
Interestingly, these changes clearly occur prior to maternal disease suggesting that 
early deficiencies in Dlx3 and Dlx3-dependent genes may underlie key genetic 
mechanisms leading to later onset of maternal disease. These early changes in Dlx3 
transcript levels are also correlated with reduced Pgf expression, consistent with what 
has been observed in pregnant women who later develop preeclampsia. Women that 
go on to develop preeclampsia have lower serum PGF levels early in gestation (13 to 
16 weeks) compared to women having normal pregnancies 8.   
In mice, at later gestational ages (E18.5), our results demonstrate that both Dlx3 
and Pgf mRNA expression were increased compared to the C57 control females. 
Initially, this shift from reduced Dlx3 and Pgf transcript levels to an overexpression 
scenario was difficult to reconcile. However, this shift may be explained by the 
apparent, progressive demise of BPH/5 embryos more severely affected by disease of 
the mother 11. One of the original observations made in the BPH/5 mouse model was 
reduced litter size. More recent analyses revealed that the BPH/5 phenotype was 
observed to have considerable variation with more severely affected embryos actually 
dying in utero. Thus, by late gestation (E18.5), the BPH/5 fetuses that remain are 
apparently the least affected.    
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Our goal with the analyses of the BPH/5 mouse model was to determine if 
expression of Dlx3 and Dlx3-dependent genes such as Pgf were altered during 
preeclampsia. Early gestational time points could be appropriately examined in this 
animal model as described above. However, our underlying interest was to determine 
if DLX3 and PGF expression were altered in women experiencing preeclampsia. 
Previous studies had shown that serum PGF level in some women with preeclampsia 
was reduced during late gestation compared to the controls 8. Based upon this link, we 
examined expression of DLX3 and PGF in term placentas from control and 
preeclampsia patients. In our preliminary studies, patients were paired by gestational 
age, labor status, maternal race, maternal age and parity (nullipara or multipara) to 
exclude these factors that may affect disease risk and progression. As predicted by 
earlier studies, PGF expression was significant lower in term placenta from 
preeclampsia patients compared with control (p=0.023). Consistent with these findings, 
DLX3 transcript abundance was also significantly reduced (p=0.041) suggesting the 
possibility of a correlation between reduced PGF expression and the putative regulator 
of PGF promoter activity, namely DLX3. In summary, these studies help to support 
the hypothesis that mis-expression of DLX3 and the DLX3 gene network may underlie 
an important genetic mechanism leading to maternal disease during pregnancy.  
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The placenta is a vital organ that provides a maternal-fetal interface. The placenta 
provides mechanisms of nutrient uptake, exchange of gases between the fetal and 
maternal blood supply and elimination of fetal waste products. Meanwhile, the 
placenta produces a host of hormones and growth factors which contribute to fetal 
growth and metabolism. Dlx3 is a homeobox-containing transcription factor, which is 
essential for normal placental development in the mouse. Dlx3 knock out mice die at 
E9.5-10 due to developmental defects of the labyrinth layer in the placenta 1. My 
hypothesis is that Dlx3 plays a critical role in placental development by regulating its 
related genes. This hypothesis is supported by the following lines of evidence: 
 
1. Dlx3 is a placental specific transcriptional regulator for some hormones such 
as the α subunit of hCG and progesterone.  
Previous studies from the Roberson lab have shown that Dlx3 is a cell-type 
specific transcriptional activator in placental trophoblasts. In human trophoblast cells, 
DLX3 plays a key role in regulating expression of the α subunit of hCG, a key 
hormone of early pregnancy in primate placenta 2. Trophoblast-derived hCG plays a 
critical role in the maintenance of progesterone secretion from the CL until the 
placenta can produce sufficient progesterone to maintain pregnancy 3. DLX3 binds to 
and transactivates the promoter of the α subunit of hCG gene via a cis acting element 
termed JRE. Mutations within the JRE markedly reduce basal expression of the α 
subunit of hCG because DLX3 cannot bind the mutant JRE 2. 
In addition to regulation of the α subunit of hCG, DLX3 has also been shown to 
be required for trophoblast-specific expression of the 3βHSD gene 4. 3βHSD is an 
enzyme essential for the biosynthesis of all active steroid hormones including 
progesterone. 3βHSD is expressed in the human placenta and is thought to be required 
for the biosynthesis of placental progesterone and thus the maintenance of pregnancy5. 
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In human placental cells, transfection studies have identified two novel trophoblast-
specific enhancer elements within the 3βHSD gene promoter. These two enhancers 
bind DLX3 and AP-2γ, a combination of cis elements and regulatory factors shared 
with regulation of the glycoprotein hormone α subunit promoter. Interestingly, the 
combined actions of DLX3 and AP-2γ appear to be necessary for the transcriptional 
regulation of both the glycoprotein hormone α subunit and 3βHSD genes in 
trophoblasts suggesting commonality in transcription factor regulatory combinations 
or codes directing cell-type specific gene expression 2,6. 
 
2. Dlx3 regulates trophoblast invasion and placental vascularization by 
regulating gene expression of Pgf and Mmp9. 
To develop a more comprehensive understanding of the gene profile regulated by 
Dlx3, microarray analysis was used to determine differences in gene expression within 
the placenta of Dlx3+/+ and Dlx3-/- mice. The array analysis revealed differential 
expression of 401 genes, of which 194 genes were reduced while 207 genes were 
increased. The loss of Dlx3 impacts the expression of a functionally diverse group of 
genes. The gene network analysis revealed two interrelated gene networks strongly 
impacted by the loss of Dlx3. One network was composed of a number of important 
signaling ligands/receptors (Pgf and EGF receptor), signaling molecules and 
extracellular matrix-related molecules (see Chapter 3 of this dissertation). This cell-to-
cell signaling and interaction gene network was linked to a second network composed 
of genes related to hematological disease. These two networks were linked via the 
putative regulation of hemoglobin genes though EGF receptor signaling. Regulation of 
embryonic/fetal forms of hemoglobin in fetal, nucleated erythrocytes may be 
consistent with the role of Dlx3 in supporting an emerging fetal vascular compartment 
associated with the placental labyrinth 1,7. Thus, changes in the Dlx3-modulated cell-
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to-cell signaling and interaction network affects another gene network related to 
hematological disease. These types of gene network relationships provide an important 
opportunity to examine the specific impact of related genes more broadly on the 
functional development and morphogenesis of the mouse placenta. 
Examination of the array data drew our attention to changes in expression of the 
Pgf gene. Few studies have been carried out to examine the gene regulation of Pgf. 
Hypoxia 8, high glucose 9 and some transcription factors such as FoxD110 and Gcm1 11 
have been shown to regulate Pgf gene expression. To expand this understanding of Pgf 
gene regulation, our results showed that loss of Dlx3 resulted in a marked reduction in 
mRNA expression and secretion of Pgf in the placenta of Dlx3-/- mice compared with 
the wild type mouse placenta. We investigated the molecular mechanisms involved in 
Dlx3-regulated expression of the Pgf gene promoter. We cloned 5.2 kb of the Pgf 5’ 
flanking sequence for use in reporter gene assays and determined that overexpression 
of Dlx3 markedly increased the Pgf promoter activity supporting the conclusion that 
Dlx3 may have a direct effect on activation of Pgf promoter in placental cells. Human 
PGF mRNA and protein secretion are also reduced by knocking down endogenous 
DLX3 using siRNA in choriocarcinoma cells. Thus, Dlx3 appears to be an important 
determinant for Pgf gene promoter activity and ultimately secretion in placental 
trophoblasts. 
To determine the functional importance of Dlx3 in the regulation of Pgf gene 
transcription, we mutated two putative Dlx3 binding sites in the context of 5.2 kb of 5’ 
flanking sequence of the mouse Pgf gene. Pgf promoter activity was markedly 
increased with Dlx3 overexpression and reduced by the combined mutation of both of 
the Dlx3 binding sites. DNA binding studies using electrophoretic mobility shift assay 
demonstrated that recombinant DLX3 or nuclear extracts from JEG3 cells could not 
bind to the mutant binding sites within the Pgf promoter suggesting that these putative 
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Dlx3 binding sites are required for regulation of Dlx3-induced Pgf gene promoter 
activity in placental trophoblast cells. Studies using chromatin immunoprecipitation to 
determine whether Dlx3 can bind to the binding site within the Pgf promoter will be 
essential to test whether Dlx3 has a direct effect on Pgf promoter. This study is now in 
progress and will provide important evidence that Dlx3 regulates Pgf gene expression 
through directly binding on Pgf promoter. 
In addition to Pgf, the gene transcript of Mmp9 was also reduced in the Dlx3-/- 
mouse placenta (in Chapter 3) and at early gestational stages in the BPH/5 mouse 
placenta compared to the control. MMP9 is an enzyme that belongs to a larger family 
of MMPs, which break down extracellular matrix. MMP9 is involved in normal 
physiological processes, such as embryonic development and tissue remodeling, as 
well as in disease processes, such as arthritis and cancer metastasis 12. Expression of 
MMPs by extravillous cytotrophoblasts plays an important role in placental invasion 
into the uterine endometrium during early pregnancy. In particular, MMP9 is strongly 
expressed by extravillous cytotrophoblasts during trophoblast invasion in the first 
trimester of gestation 13. Aberrant expression of MMP9 by extravillous 
cytotrophoblasts has been linked to preeclampsia 14,15. Studies from our lab showed 
that Dlx3 can regulate Mmp9 gene expression in the placenta. Dlx3 increased mouse 
Mmp9 gene promoter activity in a dose dependent manner. Furthermore, EMSA and 
ChIP assay demonstrated that Dlx3 could bind to the mouse and human MMP9 gene 
promoter respectively (PA Clark and MS Roberson, unpublished data).  
 
3. Dlx3 is involved in placental angiogenesis by regulating anti-angiogenesis 
factor thrombospondin 2 (Thbs2).   
Thbs2 is a matricellular glycoprotein that is involved in regulation of collagen 
matrix formation and blockade of angiogenesis 16. The gene expression of Thbs2 is 
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upregulated in Dlx3-/- mouse placenta using microarray analysis (see Chapter 3 of this 
dissertation). This finding was confirmed by q-PCR. The level of secreted protein of 
Thbs2 in the mouse placenta was Dlx3-/- > Dlx3+/- > Dlx3+/+ (PA Clark and MS 
Roberson, unpublished data). Thus, Dlx3 may regulate placental angiogenesis by 
inhibiting anti-angiogenesis factor Thbs2.  
In summary, Dlx3 is a very important factor in the regulation of placenta function 
by regulating placental hormones, trophoblast invasion, placental angiogenesis and 
vascularization. The function of Dlx3 in the placenta can be further studied by the 
following experiments: 
 
a) Tetraploid aggregation assay  
Embryonic stem (ES) cells give rise to all the structures of the fetus and to the 
extraembryonic mesoderm including the yolk sac, the allantois and the fetal blood 
vessels of the placenta, but not to the trophoblast of the placenta 17. However, 
tetraploid blastomeres, which are generated by fusing two-cell embryos, form 
trophoblast but not the fetus 18. Tetraploid aggregation assay is an assay that a 
tetraploid embryo is aggregated with diploid ES cells. The resulting placenta has 
trophoblast lineages of tetraploid genotype and fetal mesoderm and vasculature of the 
ES genotype 18. Dlx3 null mouse embryos die between E9.5-10 1. To determine the 
site of action of the Dlx3 gene, on the trophoblast or fetal component, tetraploid 
aggregation assay can be used. If the embryo is normal till birth when Dlx3-/- ES cells 
are combined with wild type tetraploid, tetraploid aggregation rescue the placental 
phenotype. This indicates that the primary defect lies in the trophoblast lineage. 
However, if no rescue of the embryonic defects, then the Dlx3 mutation must cause 
defects in the development of the fetal component of the placenta. 
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b) Conditional deletion of Dlx3 in epiblast 
Our traditional Dlx3 knockout mouse can not distinguish the role of Dlx3 
between extraembryonic tissue and embryonic tissue. The Meox2-Cre mouse is useful 
for determining the contribution of the placenta to the Dlx3-/- mouse embryo. Meox2-
Cre is the mouse line that expresses the Cre recombinase under the control of the 
endogenous Meox2 promoter. This promoter drives expression of Cre throughout the 
epiblast following implantation 19. It can be used to delete floxed gene alleles only in 
the embryo 20. This study is now in progress and our preliminary data showed that 
embryos with conditional inactivation of Dlx3 gene in the embryo survive until birth 
and weaning, but shows defects in hair, skin and teeth. The mice showed alopecia all 
over the body later in adult life (PA Clark and MS Roberson, unpublished data). 
Studies in Maria Morasso’s lab showed that conditional deletion of Dlx3 in the mouse 
epidermis results in complete alopecia, which was thought to be caused by failure of 
the hair shaft to form 21. However, there was no change in the hair follicles and cell 
layers of the skin in our mice. One explanation exists on the caveat of the Meox2-Cre 
mouse that the Cre expression in the epiblast is mosaic, which means that not all cells 
in the epiblast express Cre. Further more studies need to be done to address the 
mechanisms of the skin defects in our mice.  
 
c) Embryo transfer study 
To test the effect of the heterozygous mother on the placental defects in Dlx3-/- 
mouse, the embryo transfer studies can be used. All the blastocysts at E3.5, generated 
by the mating of Dlx3 heterozygous mouse, are transferred to pseudo-pregnant Dlx3 
wild type mother. At E9.5, the mouse embryo and placenta are collected. The placenta 
of Dlx3-/- mouse embryo is compared to the placenta of Dlx3+/+, Dlx3+/- mouse 
embryo to investigate if there is still placental defect in the Dlx3-/- mouse embryo. 
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How is Dlx3 regulated in the placenta? 
MicroRNA (miRNA) 
Recent studies have focused on miRNAs, short RNA molecules, on average 
22~23 nucleotides. MiRNAs are post-transcriptional regulators that bind to 
complementary sequences in the 3’ untranslated regions of target mRNA 22,23. MiRNA 
are highly conserved in eukaryotic organisms and are thought to be a vital and 
evolutionarily component of genetic regulation 24. In the serum of pregnant women, 
miRNAs are significantly elevated and their levels are correlated with pregnancy stage, 
which implies that serum miRNAs can be used as promising biomarkers 25. MiRNAs 
are differentially expressed in human placentas from preeclamptic pregnancies versus 
normal pregnancies 26. Future studies should investigate whether the miRNAs specific 
for Dlx3 are changed in preeclampsia. To examine this idea, we selected 5 miRNAs 
which potentially target on Dlx3 including hsa-miR-19a, hsa-miR-365, hsa-miR-9, 
hsa-miR-506 and mmu-miR-124a. Q-PCR will be used to detect the level of these 
miRNAs in the placenta of both control and preeclampsia patients. These studies are 
currently underway in the Roberson lab. 
 
Smad6 
In Chapter 2, we examined the binding partners of Dlx3 to verify the hypothesis 
that Dlx3 activity may be organized through association with other nuclear regulators 
of transcription. We demonstrated that DLX3 interacted with the inhibitory SMAD, 
SMAD6, a transcriptional regulator downstream of the BMP and TGFβ signaling 
pathways. DLX3 and SMAD6 are colocalized in the nucleus of choriocarcinoma cells 
and trophoblast cells from human placenta. Our study demonstrated that Dlx3 is a 
transcriptional activator of gene Esx1 by binding to Esx1 gene promoter. SMAD6 
effectively inhibited the binding of DLX3 to Esx1 gene promoter, resulting in SMAD6 
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attenuating DLX3-dependent promoter activation of the Esx1 promoter. Further, 
knockdown of endogenous SMAD6 by small interference RNA increased DLX3-
dependent expression of the Esx1 gene promoter. Collectively, these studies provide 
important evidence that DLX3 does not function alone in the context of trophoblast 
cell biology and is indeed influenced by interacting partners. 
We then investigated the mechanism of SMAD6 regulating the transcriptional 
effect(s) of DLX3 on its target genes. SMAD6-DLX3 interaction clearly resulted in a 
reduction of DLX3-DNA binding activity, probably via steric interference. Our results 
also demonstrated that the DLX3 domain interacting with SMAD6 included the first 
two α helices of the homeodomain. Because these two α helices are central to DNA 
binding, SMAD6 interaction would potentially interfere with DLX3 and DNA binding. 
This mechanism potentially alleviates a need for recruitment of transcriptional co-
repressors, since the DLX3-SMAD6 complex may preclude association of DLX3 with 
specific target gene promoter elements. Thus, SMAD6 repressed DLX3 transcriptional 
activity through inhibition of DLX3 and DNA binding. However, the binding domain 
of SMAD6 associating with DLX3 protein is unknown. Structure-function analysis of 
the SMAD6 protein will provide us with better insight into the binding region of 
SMAD6 with DLX3.    
A number of growth factors have been shown to regulate Smad6, such as EGF, 
TGFβ and BMPs 27. In many cases, the effects of these growth factors are mediated 
through R-Smads (Smad 1, 2, 3, 5 and 8) and C-Smad (Smad4) dependent 
transcriptional mechanisms. This has led to a hypothesis implicating an intracellular 
negative feedback loop, whereby positive TGFβ/BMP signals are modulated by 
accumulation of induced I-Smads 27. Interestingly, Dlx3 expression patterns during 
Xenopus development depend in part upon BMP/TGFβ signaling gradients 28,29. 
Inhibition of these gradients using the BMP receptor antagonist results in a dose-
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sensitive inhibition of Dlx3 mRNA expression. Dlx3 expression in mouse 
keratinocytes is also regulated by BMP/TGFβ in a manner potentially coordinate with 
I-Smad expression 30. This supports speculation that not only might BMP/TGFβ-
regulated Smad6 expression serve as a negative feedback mechanism controlling the 
duration of Smad signaling but increased BMP/TGFβ-dependent Smad6 expression 
may lead to important modulation of Dlx3-dependent gene expression.  
 
How is DLX3 gene expression changed in human preeclampsia?  
The observation that drew our attention to studying Pgf gene regulation was that 
PGF has been shown to be an important marker for preeclampsia in pregnant women. 
Women with preeclampsia have reduced PGF serum levels suggesting that the 
potential angiogenic properties of PGF may play a fundamental role in the progression 
of this disease 31,32. Despite considerable research on preeclampsia, the etiology and 
mechanism underlying preeclampsia are still not fully understood. Thus at present, the 
only effective treatment for preeclampsia is delivery of the placenta, thus removing 
any causal factors from maternal circulation. These conclusions are based in part on 
studies examining molar pregnancies. Hydatidiform mole has been shown to be 
associated with very early-onset preeclampsia. Although there are no fetal tissues, the 
mother has symptoms of preeclampsia 33.  
Development of animal models that fully imitate this hypertensive disorder may 
broaden our understanding of this syndrome 34. The BPH/5 mouse is the inbred mouse 
strain that serves as an important model for preeclampsia 35. The BPH/5 mouse 
displays late-gestational hypertension, proteinuria and progressive glomerulosclerosis, 
which are characteristics of human preeclampsia 36. We examined whether Dlx3 and 
Pgf were mis-regulated in BPH/5 mice. Gene transcript levels of Dlx3 and Pgf were 
determined at different gestational ages on both control C57 and BPH/5 mice. At early 
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gestational stages, Dlx3 and Pgf transcripts were reduced in the BPH/5 mouse placenta 
compared to controls; while at later gestational ages, both transcripts were 
overexpressed in the placentas of BPH/5 mouse. Similar preliminary studies were 
carried out after collecting placentas from both normal and preeclamptic human 
patients. We found that DLX3 and PGF transcript levels were significantly reduced in 
the term placenta from preeclampsia patients. These combined studies lead us to 
conclude that Dlx3 is an important transcriptional activator of the Pgf gene promoter. 
Moreover, mis-regulation of DLX3 was correlated with altered PGF gene during 
preeclampsia suggesting that DLX3 may be a new and important early genetic 
determinant regulating the etiology of this disease.  
    
A proposed model for the role of DLX3 in the pathogenesis of preeclampsia. 
The pathogenesis of preeclampsia is illustrated in the following figures (Figure 
5.1A and B). Genetic factors, immune abnormalities and oxidative stress may cause 
placental insufficiency, which in turn leads to decreased DLX3 expression maybe 
through elevated expression of miRNAs for Dlx3 or activation of TGFβ/Smad6 
pathway. Loss of DLX3 expression would likely lead to reduced PGF. The reduction 
in circulating PGF causes generalized endothelial dysfunction, resulting in 
preeclampsia characterized by hypertension, proteinuria and coagulation abnormalities. 
It remains unknown whether oxidative stress is the trigger (Figure5.1A) or the 
outcome (Figure 5.1B) of the reduced expression of DLX3 in the placenta of 
preeclamptic women. The mechanism in Figure 5.1 A is supported by the following 
evidence. Research has shown that markers of high oxidative stress are detectable 
through higher levels of lipid peroxidation and increased superoxide generation in the 
placenta of preeclamptic women 37. Studies reported in Chapter 4 of this dissertation 
demonstrate that Dlx3 transcript levels were reduced in the BPH/5 mouse placenta at 
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Figure 5.1. Summary of the pathogenesis of preeclampsia.  
Genetic factors, immune abnormalities and oxidative stress may cause placental 
insufficiency, which in turn leads to reduced circulating PGF to induce 
hypertension, proteinuria and other complications of preeclampsia. A. Oxidative 
stress is the trigger of the reduced expression of DLX3 in the placenta of 
preeclamptic women. B. Oxidative stress is the outcome of the reduced 
expression of DLX3 in preeclampsia.   
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Figure 5.1 (Continued) 
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early gestational stages and DLX3 transcript level was reduced in the term placenta 
from preeclampsia patients. The mechanism in Figure 5.1 B is supported by other 
evidence. There was an increase in oxidative stress such as protein carbonyls in the 
Dlx3+/- placentas. Dlx3+/- mothers that were fed with tempol in the water supply 
during pregnancy showed reduced oxidative stress in the placenta (PA Clark and MS 
Roberson, unpublished data). Tempol is a membrane-permeable radical scavenger that 
can reduce oxidant stress-mediated placental injuries 38. Further studies need to be 
done to investigate the mechanism that reduced Dlx3 expression results in an 
increased oxidative stress. 
In summary, this dissertation examines the binding partners of Dlx3 and 
transcript profile regulated by Dlx3 in trophoblast cells. The longer term goal of these 
studies is to form the foundation for how Dlx3 and targets of Dlx3 regulate the 
morphogenesis of the placenta and maintenance of a competent maternal-fetal 
interface. By unraveling Dx3 dependent mechanisms related to placental development 
in the mouse, we may have a better insight of human placenta and diseases such as 
preeclampsia in women. 
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APPENDIX I 
 
Microarray analysis data with 401 differentially expressed genes in Dlx3-/- mouse 
placenta compared to wild type  
 
ID 
Mean  
Log2(mut/wt)
 
Gene symbol 
 
Gene name 
1415684_at -0.16667 Apg5l autophagy 5-like (S. cerevisiae) 
1415793_at -0.3 Pnpo pyridoxine 5'-phosphate oxidase 
1415865_s_at -0.86667 Bpgm 2,3-bisphosphoglycerate mutase 
1415897_a_at 0.233333 Mgst1 
microsomal glutathione S-
transferase 1 
1415928_a_at 0.166667 Map1lc3b 
microtubule-associated protein 1 
light chain 3 beta 
1415949_at 0.333333 Cpe carboxypeptidase E 
1416022_at 0.333333 Fabp5 
fatty acid binding protein 5, 
epidermal 
1416063_x_at -1.4 Ceacam11 
CEA-related cell adhesion 
molecule 11 
1416192_at -0.16667 Napa 
N-ethylmaleimide sensitive 
fusion protein attachment protein 
alpha 
1416205_at 0.233333 Glb1 galactosidase, beta 1 
1416242_at -0.36667 Klhl13 kelch-like 13 (Drosophila) 
1416298_at -0.93333 Mmp9 matrix metalloproteinase 9 
1416346_at -0.16667 Timm8a 
translocase of inner 
mitochondrial membrane 8 
homolog a (yeast) 
1416446_at 0.233333 D9Wsu20e 
DNA segment, Chr 9, Wayne 
State University 20, expressed 
1416558_at -0.16667 Melk 
maternal embryonic leucine 
zipper kinase 
1416676_at 0.233333 Kng1 kininogen 1 
1416724_x_at 0.166667 Tcf4 transcription factor 4 
1416872_at -0.16667 Tm4sf6 
transmembrane 4 superfamily 
member 6 
1416915_at -0.16667 Msh6 mutS homolog 6 (E. coli) 
1416923_a_at 0.166667 Bnip3l 
BCL2/adenovirus E1B 19kDa-
interacting protein 3-like 
1416968_a_at 0.233333 Hsd3b7 
hydroxy-delta-5-steroid 
dehydrogenase, 3 beta- and 
steroid delta-isomerase 7 
1417017_at -0.73333 Cyp17a1 
cytochrome P450, family 17, 
subfamily a, polypeptide 1 
1417019_a_at -0.3 Cdc6 cell division cycle 6 homolog (S. 
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cerevisiae) 
1417024_at 0.166667 Hars histidyl-tRNA synthetase 
1417111_at 0.266667 Man1a mannosidase 1, alpha 
1417184_s_at -0.86667
Hbb-b1 /// Hbb-
b2 
hemoglobin, beta adult major 
chain /// hemoglobin, beta adult 
minor chain 
1417214_at 0.333333 Rab27b 
RAB27b, member RAS 
oncogene family 
1417346_at 0.3 Pycard 
PYD and CARD domain 
containing 
1417506_at -0.26667 Gmnn geminin 
1417553_at -0.33333 Plac1 placental specific protein 1 
1417693_a_at -0.33333 Gab1 
growth factor receptor bound 
protein 2-associated protein 1 
1417714_x_at -1.33333 Hba-a1 hemoglobin alpha, adult chain 1 
1417750_a_at -1.03333 MGI:1914962 
mitochondrial solute carrier 
protein 
1417829_a_at -0.4 Rab15 
RAB15, member RAS oncogene 
family 
1417831_at -0.23333 Smc1l1 
SMC (structural maintenance of 
chromosomes 1)-like 1 (S. 
cerevisiae) 
1417843_s_at -0.46667 Eps8l2 EPS8-like 2 
1417883_at 0.233333 Gstt2 glutathione S-transferase, theta 2 
1418021_at 0.333333 C4 
complement component 4 
(within H-2S) 
1418059_at 0.366667 Eltd1 
EGF, latrophilin seven 
transmembrane domain 
containing 1 
1418147_at -0.36667 Tcfap2c transcription factor AP-2, gamma
1418171_at 0.166667 Tceal8 
transcription elongation factor A 
(SII)-like 8 
1418191_at 0.266667 Usp18 ubiquitin specific protease 18 
1418206_at -0.23333 Sdf2l1 
stromal cell-derived factor 2-like 
1 
1418226_at -0.3 Orc2l 
origin recognition complex, 
subunit 2-like (S. cerevisiae) 
1418281_at -0.16667 Rad51 RAD51 homolog (S. cerevisiae) 
1418293_at 0.166667 Ifit2 
interferon-induced protein with 
tetratricopeptide repeats 2 
1418352_at -0.66667 Hsd17b2 
hydroxysteroid (17-beta) 
dehydrogenase 2 
1418432_at 0.233333 Cab39 calcium binding protein 39 
1418471_at -1.03333 Pgf placental growth factor 
1418475_at 0.266667 Scnn1b 
sodium channel, nonvoltage-
gated 1 beta 
1418492_at -0.33333 Grem2 gremlin 2 homolog, cysteine knot 
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superfamily (Xenopus laevis) 
1418493_a_at -3 Snca synuclein, alpha 
1418547_at 0.4 Tfpi2 tissue factor pathway inhibitor 2 
1418587_at 0.166667 Traf3 Tnf receptor-associated factor 3 
1418699_s_at -0.4 Fech ferrochelatase 
1418728_at -0.53333 Star 
steroidogenic acute regulatory 
protein 
1418826_at -0.16667 Ms4a6b 
membrane-spanning 4-domains, 
subfamily A, member 6B 
1418831_at -0.4 Pkp3 plakophilin 3 
1419018_at -0.6 Psx1 placenta specific homeobox 1 
1419136_at 0.233333 Akr1c18 
aldo-keto reductase family 1, 
member C18 
1419149_at -0.43333 Serpine1 
serine (or cysteine) proteinase 
inhibitor, clade E, member 1 
1419247_at 0.166667 Rgs2 
regulator of G-protein signaling 
2 
1419249_at -0.33333 Pftk1 PFTAIRE protein kinase 1 
1419325_at 0.466667 Nmu neuromedin U 
1419459_a_at -0.16667 2610529C04Rik RIKEN cDNA 2610529C04 gene
1419462_s_at -0.16667 Gtl3 gene trap locus 3 
1419494_a_at -0.16667 Tpd52 tumor protein D52 
1419595_a_at 0.3 Ggh gamma-glutamyl hydrolase 
1419640_at -0.16667 Purb 
purine rich element binding 
protein B 
1419657_a_at 0.166667 C330005L02Rik 
RIKEN cDNA C330005L02 
gene 
1419749_at 0.166667 Dnmt2 DNA methyltransferase 2 
1419873_s_at 0.166667 Csf1r 
colony stimulating factor 1 
receptor 
1419880_x_at -0.46667  Transcribed locus 
1420056_s_at -0.43333 Ptdsr phosphatidylserine receptor 
1420113_s_at -0.16667 2410022L05Rik RIKEN cDNA 2410022L05 gene
1420157_s_at -0.16667 Abcf1 
ATP-binding cassette, sub-family 
F (GCN20), member 1 
1420382_at -0.4 MGI:2176230 apolipoprotein B48 receptor 
1420476_a_at -0.36667 Nap1l1 
nucleosome assembly protein 1-
like 1 
1420479_a_at -0.3 Nap1l1 
nucleosome assembly protein 1-
like 1 
1420539_a_at -0.8 Chrdl2 chordin-like 2 
1420647_a_at -0.43333 Krt2-8 keratin complex 2, basic, gene 8 
1420973_at -0.33333 Arid5b 
AT rich interactive domain 5B 
(Mrf1 like) 
1421034_a_at 0.4 Il4ra interleukin 4 receptor, alpha 
1421268_at 0.166667 Ugcg 
UDP-glucose ceramide 
glucosyltransferase 
 177 
1421945_a_at -0.3 Bxdc1 brix domain containing 1 
1422411_s_at 0.166667
Ear1 /// Ear2 /// 
Ear3 
eosinophil-associated, 
ribonuclease A family, member 1 
/// eosinophil-associated, 
ribonuclease A family, member 2 
/// eosinophil-associated, 
ribonuclease A family, member 3
1422415_at 0.7 Ang2 
angiogenin, ribonuclease A 
family, member 2 
1422470_at 0.366667 Bnip3 
BCL2/adenovirus E1B 19kDa-
interacting protein 1, NIP3 
1422486_a_at 0.3 Smad4 MAD homolog 4 (Drosophila) 
1422513_at -0.36667 Ccnf cyclin F 
1422571_at 0.666667 Thbs2 thrombospondin 2 
1422636_at 0.166667 Dmtf1 
cyclin D binding myb-like 
transcription factor 1 
1422771_at -0.26667   
1422865_at 0.166667 Runx1 runt related transcription factor 1
1422943_a_at -0.23333 Hspb1 heat shock protein 1 
1423097_s_at 0.166667 Capn7 calpain 7 
1423369_at 0.233333 Fmr1 
fragile X mental retardation 
syndrome 1 homolog 
1423429_at -0.5 Pem 
placentae and embryos oncofetal 
gene 
1423450_a_at -0.26667 Hs3st1 
heparan sulfate (glucosamine) 3-
O-sulfotransferase 1 
1423484_at 0.366667 Bicc1 
bicaudal C homolog 1 
(Drosophila) 
1423518_at -0.26667 Csk c-src tyrosine kinase 
1423607_at 0.833333 Lum lumican 
1423623_at 0.166667 2810021B07Rik RIKEN cDNA 2810021B07 gene
1423662_at 0.166667 Atp6ap2 
ATPase, H+ transporting, 
lysosomal accessory protein 2 
1423691_x_at -0.53333 Krt2-8 keratin complex 2, basic, gene 8 
1423714_at -0.3 Asf1b 
ASF1 anti-silencing function 1 
homolog B (S. cerevisiae) 
1423859_a_at 0.833333 Ptgds 
prostaglandin D2 synthase 
(brain) 
1423922_s_at -0.33333 C77668 expressed sequence C77668 
1423946_at -0.26667 Pdlim2 PDZ and LIM domain 2 
1424092_at -0.53333 Epb4.1 erythrocyte protein band 4.1 
1424113_at -0.33333 Lamb1-1 laminin B1 subunit 1 
1424114_s_at -0.16667 Lamb1-1 laminin B1 subunit 1 
1424131_at 0.166667 Col6a3 procollagen, type VI, alpha 3 
1424202_at -0.16667 Seh1l SEH1-like (S. cerevisiae 
1424254_at 0.166667 Ifitm1 
interferon induced 
transmembrane protein 1 
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1424354_at 0.366667 1110007F12Rik RIKEN cDNA 1110007F12 gene
1424465_at -0.16667 AI413631 expressed sequence AI413631 
1424512_a_at -0.16667 Txndc9 thioredoxin domain containing 9 
1424533_a_at -0.3 3110023B02Rik RIKEN cDNA 3110023B02 gene
1424666_at 0.233333 5430405G24Rik 
RIKEN cDNA 5430405G24 
gene 
1424770_at -0.26667 Cald1 caldesmon 1 
1424852_at 0.3 Mef2c myocyte enhancer factor 2C 
1425028_a_at -0.43333 Tpm2 tropomyosin 2, beta 
1425163_at -0.46667
AI661453 /// 
LOC224833 
expressed sequence AI661453 /// 
hypothetical protein BC006605 
1425295_at 0.466667 Ear11 
eosinophil-associated, 
ribonuclease A family, member 
11 
1425391_a_at 0.233333 Osbpl5 oxysterol binding protein-like 5 
1425476_at 0.366667 Col4a5 procollagen, type IV, alpha 5 
1425814_a_at 0.433333 Calcrl calcitonin receptor-like 
1426001_at -0.26667 Eomes 
eomesodermin homolog 
(Xenopus laevis) 
1426351_at -0.23333 Hspd1 heat shock protein 1 (chaperonin)
1426361_at -0.3 5730454B08Rik RIKEN cDNA 5730454B08 gene
1426614_at 0.266667 Prkcbp1 
protein kinase C binding protein 
1 
1426622_a_at 0.7 Qpct 
glutaminyl-peptide 
cyclotransferase (glutaminyl 
cyclase) 
1426666_a_at -0.3 Unc84a unc-84 homolog A (C. elegans) 
1426734_at 0.166667 BC022623 cDNA sequence BC022623 
1426751_s_at -0.16667 Nup107 nucleoporin 107 
1426838_at -0.23333 Pold3 
polymerase (DNA-directed), 
delta 3, accessory subunit 
1426969_at 0.3 Trim23 tripartite motif protein 23 
1427040_at 0.166667 Mdfid 
MyoD family inhibitor domain 
containing 
1427095_at -0.63333 E030027H19Rik
RIKEN cDNA E030027H19 
gene 
1427123_s_at 0.233333 Copg2as2 
coatomer protein complex, 
subunit gamma 2, antisense 2 
1427199_at -0.16667 2510002A14Rik 
RIKEN cDNA 2510002A14 
gene 
1427236_a_at 0.166667 Mll5 
myeloid/lymphoid or mixed-
lineage leukemia 5 
1427990_at 0.233333 Usp45 ubiquitin specific protease 45 
1428187_at 0.166667 Cd47 
CD47 antigen (Rh-related 
antigen, integrin-associated 
signal transducer) 
1428326_s_at 0.166667 Hrsp12 heat-responsive protein 12 
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1428361_x_at -0.86667   
1428367_at 0.166667 Ndst1 
N-deacetylase/N-sulfotransferase 
(heparan glucosaminyl) 1 
1428657_at 0.166667 1110037N09Rik 
RIKEN cDNA 1110037N09 
gene 
1428675_at -0.53333   
1428760_at 0.166667 Snapc3 
small nuclear RNA activating 
complex, polypeptide 3 
1429227_x_at -0.43333 Nap1l1 
nucleosome assembly protein 1-
like 1 
1429294_at -0.4 Trip13 
thyroid hormone receptor 
interactor 13 
1429787_x_at -0.23333 Zwint ZW10 interactor 
1431059_x_at -0.26667 Htatsf1 HIV TAT specific factor 1 
1431099_at 0.3 Hoxd8 homeo box D8 
1431284_a_at -0.16667 2210013K02Rik 
RIKEN cDNA 2210013K02 
gene 
1431302_a_at -0.23333 Nudt7 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 7 
1432417_a_at 0.166667 6330415F13Rik RIKEN cDNA 6330415F13 gene
1433568_at 0.166667 Papd4 
PAP associated domain 
containing 4 
1433575_at 0.233333 Sox4 SRY-box containing gene 4 
1433588_at 0.166667 D6Wsu116e 
DNA segment, Chr 6, Wayne 
State University 116, expressed 
1433655_at 0.166667 Rnf141 Ring finger protein 141 
1433906_at 0.4 4933402J24Rik RIKEN cDNA 4933402J24 gene 
1434016_at 0.233333 D6Ertd365e 
DNA segment, Chr 6, ERATO 
Doi 365, expressed 
1434109_at -0.5 Sh3bgrl2 
SH3 domain binding glutamic 
acid-rich protein like 2 
1434148_at 0.366667 Tcf4 transcription factor 4 
1434195_at 0.633333 Prss35 protease, serine, 35 
1434419_s_at -0.23333 Tardbp TAR DNA binding protein 
1434472_at 0.166667 5031436O03Rik 
RIKEN cDNA 5031436O03 
gene 
1434646_s_at -0.16667 Sap18 Sin3-associated polypeptide 18 
1434674_at 0.166667   
1434739_at -0.43333 Fmr1nb 
fragile X mental retardation 1 
neighbor 
1434856_at 0.233333   
1434930_at -0.16667 Tpcn1 two pore channel 1 
1434931_at 0.333333   
1434999_at 0.166667 Suv420h1 
suppressor of variegation 4-20 
homolog 1 (Drosophila) 
1435091_at -0.23333 LOC243905 hypothetical LOC243905 
1435137_s_at 0.266667 1200015M12Rik RIKEN cDNA 1200015M12 
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gene 
1435290_x_at -0.16667 H2-Aa 
histocompatibility 2, class II 
antigen A, alpha 
1435416_x_at -0.23333 Pigq 
phosphatidylinositol glycan, 
class Q 
1435494_s_at -0.53333 5730453H04Rik 
RIKEN cDNA 5730453H04 
gene 
1435882_at -0.16667   
1435967_s_at 0.233333 Hibadh 
3-hydroxyisobutyrate 
dehydrogenase 
1435989_x_at -0.4 Krt2-8 keratin complex 2, basic, gene 8 
1436058_at -0.33333 Rsad2 
radical S-adenosyl methionine 
domain containing 2 
1436506_a_at 0.266667 1110008H02Rik 
RIKEN cDNA 1110008H02 
gene 
1436853_a_at -1.8 Snca synuclein, alpha 
1436979_x_at -0.16667 Rbm14 RNA binding motif protein 14 
1437103_at -0.3 C330012H03Rik
RIKEN cDNA C330012H03 
gene 
1437497_a_at -0.23333 Hspca heat shock protein 1, alpha 
1437502_x_at -0.5 Cd24a CD24a antigen 
1437515_at -0.33333   
1437810_a_at -1.06667 Hbb-bh1 
hemoglobin Z, beta-like 
embryonic chain 
1437902_s_at 0.266667 Rarres2 
retinoic acid receptor responder 
(tazarotene induced) 2 
1438164_x_at 0.166667 Flot2 flotillin 2 
1438167_x_at 0.166667 Flcn folliculin 
1438602_s_at 0.233333 Masp1 
mannan-binding lectin serine 
protease 1 
1439022_at -0.56667 Phactr1 phosphatase and actin regulator 1
1439045_x_at 0.366667 Mtac2d1 
membrane targeting (tandem) C2 
domain containing 1 
1439443_x_at -0.23333 Tkt transketolase 
1439444_x_at 0.166667 1110014C03Rik RIKEN cDNA 1110014C03 gene
1439450_x_at 0.166667 A230046K03Rik
RIKEN cDNA A230046K03 
gene 
1448021_at -1.06667  Transcribed locus 
1448029_at 0.166667 Tbx3 T-box 3 
1448123_s_at 0.366667   
1448160_at -0.26667 Lcp1 lymphocyte cytosolic protein 1 
1448182_a_at -0.46667 Cd24a CD24a antigen 
1448194_a_at -0.26667   
1448251_at 0.366667 9030425E11Rik RIKEN cDNA 9030425E11 gene
1448306_at 0.166667 Nfkbia 
nuclear factor of kappa light 
chain gene enhancer in B-cells 
inhibitor, alpha 
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1448339_at 0.166667 D9Wsu20e 
DNA segment, Chr 9, Wayne 
State University 20, expressed 
1448419_at 0.3 Pop4 
processing of precursor 4, 
ribonuclease P/MRP family, (S. 
cerevisiae) 
1448427_at 0.166667 Ndufa6 
NADH dehydrogenase 
(ubiquinone) 1 alpha 
subcomplex, 6 (B14) 
1448545_at 0.233333 Sdc2 syndecan 2 
1448590_at 0.166667 Col6a1 procollagen, type VI, alpha 1 
1448687_at -0.23333 1110035L05Rik RIKEN cDNA 1110035L05 gene
1448690_at -0.33333 Kcnk1 
potassium channel, subfamily K, 
member 1 
1448716_at -1.36667 Hba-x 
hemoglobin X, alpha-like 
embryonic chain in Hba complex
1448765_at 0.233333   
1448890_at 0.166667 Klf2 Kruppel-like factor 2 (lung) 
1449108_at -0.33333 Fdx1 ferredoxin 1 
1449119_at -0.16667 Arih2 ariadne homolog 2 (Drosophila) 
1449125_at -0.53333 2600017J23Rik RIKEN cDNA 2600017J23 gene 
1449327_at -1.26667 1600015I10Rik RIKEN cDNA 1600015I10 gene 
1449368_at 0.3 Dcn decorin 
1449451_at 0.333333 Serpinb11 
serine (or cysteine) proteinase 
inhibitor, clade B (ovalbumin), 
member 11 
1449556_at 0.166667
H2-T23 /// 
C920025E04Rik 
histocompatibility 2, T region 
locus 23 /// RIKEN cDNA 
C920025E04 gene 
1449591_at 0.3 Casp11 
caspase 11, apoptosis-related 
cysteine protease 
1449731_s_at 0.166667   
1450048_a_at -0.23333 Idh2 
isocitrate dehydrogenase 2 
(NADP+), mitochondrial 
1450344_a_at 0.566667 Ptger3 
prostaglandin E receptor 3 
(subtype EP3) 
1450569_a_at -0.3 Rbm14 RNA binding motif protein 14 
1450621_a_at -1.43333 Hbb-y 
hemoglobin Y, beta-like 
embryonic chain 
1450644_at 0.3 Zfp36l1 
zinc finger protein 36, C3H type-
like 1 
1450647_at 0.166667 Hps3 
Hermansky-Pudlak syndrome 3 
homolog (human) 
1450668_s_at -0.16667 Hspe1 
heat shock protein 1 (chaperonin 
10) 
1450697_at -0.16667 Slc30a7 
solute carrier family 30 (zinc 
transporter), member 7 
1450736_a_at -1.2 Hbb-bh1 hemoglobin Z, beta-like 
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embryonic chain 
1450783_at 0.233333 Ifit1 
interferon-induced protein with 
tetratricopeptide repeats 1 
1450826_a_at -0.43333 Saa3 serum amyloid A 3 
1450872_s_at 0.233333 Lip1 lysosomal acid lipase 1 
1451077_at 0.366667 Rpl5 ribosomal protein L5 
1451092_a_at -0.16667 Rangap1 
RAN GTPase activating protein 
1 
1451133_s_at 0.266667 8430437G11Rik 
RIKEN cDNA 8430437G11 
gene 
1451210_at -0.26667 Ppap2c 
phosphatidic acid phosphatase 
type 2c 
1451300_a_at -0.23333 6330407G04Rik 
RIKEN cDNA 6330407G04 
gene 
1451416_a_at -0.73333 Tgm1 
transglutaminase 1, K 
polypeptide 
1451431_a_at -0.16667 D2Bwg0891e 
DNA segment, Chr 2, Brigham 
& Women's Genetics 0891 
expressed 
1451564_at 0.366667 Parp14 
poly (ADP-ribose) polymerase 
family, member 14 
1452012_a_at -0.16667 Exosc1 exosome component 1 
1452061_s_at -0.16667 Strbp 
spermatid perinuclear RNA 
binding protein 
1452084_at -0.16667 2810055E05Rik RIKEN cDNA 2810055E05 gene
1452114_s_at 0.433333 Igfbp5 
insulin-like growth factor 
binding protein 5 
1452225_at 0.266667 2010106G01Rik 
RIKEN cDNA 2010106G01 
gene 
1452252_at -0.16667 3830408P06Rik RIKEN cDNA 3830408P06 gene
1452303_at 0.166667 Arhgef10 
Rho guanine nucleotide 
exchange factor (GEF) 10 
1452307_at -0.23333 Cables2 
Cdk5 and Abl enzyme substrate 
2 
1452318_a_at -0.4 Hspa1b heat shock protein 1B 
1452367_at -0.23333   
1452428_a_at 0.233333 B2m beta-2 microglobulin 
1452543_a_at 0.433333 Scgb1a1 
secretoglobin, family 1A, 
member 1 (uteroglobin) 
1452622_a_at 0.166667 Tradd 
TNFRSF1A-associated via death 
domain 
1452714_at 0.166667 1200003E16Rik RIKEN cDNA 1200003E16 gene
1452757_s_at -0.8   
1452778_x_at -0.33333 Nap1l1 
nucleosome assembly protein 1-
like 1 
1452792_at -0.16667 2810422M04Rik
RIKEN cDNA 2810422M04 
gene 
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1452839_at -0.16667 2410012M04Rik
RIKEN cDNA 2410012M04 
gene 
1452917_at -0.16667 Rfc5 
replication factor C (activator 1) 
5 
1453064_at 0.266667 5730466H23Rik 
RIKEN cDNA 5730466H23 
gene 
1454044_a_at 0.233333 Pex3 peroxisomal biogenesis factor 3 
1454967_at 0.233333   
1455915_at 0.166667 Galnt4 
UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 
4 
1455957_x_at -1.46667 Ceacam11 
CEA-related cell adhesion 
molecule 11 
1455987_at -0.16667   
1456174_x_at 0.166667 Ndrg1 
N-myc downstream regulated 
gene 1 
1456195_x_at 0.166667 Itgb5 integrin beta 5 
1456292_a_at 0.3 Vim vimentin 
1456309_x_at -0.33333 Lasp1 LIM and SH3 protein 1 
1456377_x_at -0.3 0610025L06Rik RIKEN cDNA 0610025L06 gene
1456541_x_at -0.16667 Atad3a 
ATPase family, AAA domain 
containing 3A 
1460194_at 0.166667 Phyh phytanoyl-CoA hydroxylase 
1460221_at -0.16667 MGI:1929282 telomerase binding protein, p23 
1460226_at -0.26667 Trap1a tumor rejection antigen P1A 
1460592_at -0.16667 Epb4.1l1 
erythrocyte protein band 4.1-like 
1 
1460679_at 0.166667 Exosc4 exosome component 4 
1428124_at -0.16667 Gtf2e1 
general transcription factor II E, 
polypeptide 1 (alpha subunit) 
1428261_at -0.16667 2310042L06Rik RIKEN cDNA 2310042L06 gene
1428386_at 0.233333 Acsl3 
UTP14, U3 small nucleolar 
ribonucleoprotein, homolog B 
(yeast) 
1428411_at 0.166667 1700020I14Rik RIKEN cDNA 1700020I14 gene 
1428497_at -0.16667 Secisbp2 SECIS binding protein 2 
1429012_at -0.53333 Arhgef6 
Rac/Cdc42 guanine nucleotide 
exchange factor (GEF) 6 
1429106_at -0.23333 6330544N02Rik 
RIKEN cDNA 6330544N02 
gene 
1429351_at 0.3 4930429H24Rik 
RIKEN cDNA 4930429H24 
gene 
1429503_at 0.333333 2900024C23Rik RIKEN cDNA 2900024C23 gene
1429633_at -0.3 MGI:2443930 Mblk1-related protein-2 
1430051_at 0.366667 4930486L24Rik RIKEN cDNA 4930486L24 gene
1430927_at 0.3 2010110O04Rik RIKEN cDNA 2010110O04 
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gene 
1432750_at 0.333333 2810409C01Rik RIKEN cDNA 2810409C01 gene
1433465_a_at -0.16667 AI467606 expressed sequence AI467606 
1433501_at 0.166667 Ctso cathepsin O 
1433664_at -0.16667 3010021M21Rik
RIKEN cDNA 3010021M21 
gene 
1433696_at -0.26667 D17Ertd441e 
DNA segment, Chr 17, ERATO 
Doi 441, expressed 
1433740_at 0.233333 2610301K12Rik 
RIKEN cDNA 2610301K12 
gene 
1433817_at 0.366667 Agpat3 
1-acylglycerol-3-phosphate O-
acyltransferase 3 
1433922_at -0.16667 Rab35 
RAB35, member RAS oncogene 
family 
1433976_at 0.166667 AI265725 Expressed sequence AI265725 
1434225_at 0.166667 Swap70 SWAP complex protein 
1434268_at 0.166667 Adar 
adenosine deaminase, RNA-
specific 
1434441_at 0.333333  
Mus musculus, clone 
IMAGE:4015738, mRNA 
1434548_at 0.266667 Tde1 tumor differentially expressed 1 
1434664_at 0.166667 2410129H14Rik 
RIKEN cDNA 2410129H14 
gene 
1434671_at 0.166667 B230337E12Rik 
RIKEN cDNA B230337E12 
gene 
1434716_at 0.166667   
1434957_at 0.3 Cdon 
Cell adhesion molecule-
related/down-regulated by 
oncogenes 
1435092_at 0.233333 Arl4 ADP-ribosylation factor-like 4 
1435238_x_at -0.26667 2310009A05Rik 
RIKEN cDNA 2310009A05 
gene 
1435283_s_at 0.233333 Gm967 gene model 967, (NCBI) 
1435361_at 0.5 AK129018 cDNA sequence AK129018 
1435423_x_at -0.16667 4933433P14Rik RIKEN cDNA 4933433P14 gene
1435445_at 0.366667 Ccnt2 cyclin T2 
1435796_at -0.23333 4933413A10Rik 
RIKEN cDNA 4933413A10 
gene 
1435829_at -0.3 B930008K04Rik
RIKEN cDNA B930008K04 
gene 
1435867_at 0.233333  Transcribed locus 
1435890_at 0.166667 5730596K20Rik 
RIKEN cDNA 5730596K20 
gene 
1436025_at 0.233333 A430106J12Rik RIKEN cDNA A430106J12 gene
1436029_at 0.166667 4930533K18Rik 
RIKEN cDNA 4930533K18 
gene 
1436122_at -0.43333   
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1436210_at 0.166667  
Transcribed locus, moderately 
similar to XP_359179.2 similar 
to hypothetical protein [Mus 
musculus] 
1436306_at -0.23333 B430201G11Rik
RIKEN cDNA B430201G11 
gene 
1436367_at 0.3  Transcribed locus 
1436389_at 0.166667 5730596K20Rik 
RIKEN cDNA 5730596K20 
gene 
1436424_at 0.266667 1600020E01Rik RIKEN cDNA 1600020E01 gene
1436568_at 0.333333 Jam2 junction adhesion molecule 2 
1436920_at 0.3 C030033F14Rik 
RIKEN cDNA C030033F14 
gene 
1437187_at -0.46667 E2f7 E2F transcription factor 7 
1437296_at -0.3 Pkn2 protein kinase N2 
1437393_at -0.16667 AI875142 expressed sequence AI875142 
1437451_at 0.233333 1110006O17Rik 
RIKEN cDNA 1110006O17 
gene 
1437748_at 0.166667 Fut11 fucosyltransferase 11 
1437869_at -0.16667 3222402P14Rik RIKEN cDNA 3222402P14 gene
1438030_at 0.266667 Rasgrp3 RAS, guanyl releasing protein 3 
1438294_at 0.433333 Sca1 
spinocerebellar ataxia 1 homolog 
(human) 
1438420_at 0.333333 Rnpc2 
RNA-binding region (RNP1, 
RRM) containing 2 
1438454_at 0.3 B430203M17Rik
RIKEN cDNA B430203M17 
gene 
1438730_at 0.4 BC028801 cDNA sequence BC028801 
1438884_at 0.233333 D830007B15Rik
RIKEN cDNA D830007B15 
gene 
1439107_a_at 0.233333 Mll5 
myeloid/lymphoid or mixed-
lineage leukemia 5 
1439687_at 0.166667 Rab14 
RAB14, member RAS oncogene 
family 
1439699_at 0.166667 Pgr Progesterone receptor 
1439811_at -0.46667 Mtr 
5-methyltetrahydrofolate-
homocysteine methyltransferase 
1439933_at 0.266667 B430316J06Rik RIKEN cDNA B430316J06 gene
1439972_at 0.266667 Etnk1 Ethanolamine kinase 1 
1440163_at 0.333333 6030490B17Rik RIKEN cDNA 6030490B17 gene
1441320_a_at -0.16667 AI413194 expressed sequence AI413194 
1441556_at 0.466667  Transcribed locus 
1441814_s_at 0.366667 2400006N03Rik 
RIKEN cDNA 2400006N03 
gene 
1442067_at 0.366667 Ror1 
Receptor tyrosine kinase-like 
orphan receptor 1 
1442332_at 0.166667 Tgfbr3 Transforming growth factor, beta 
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receptor III 
1442549_at -0.33333 Mbnl3 muscleblind-like 3 (Drosophila) 
1442827_at 0.333333 Tlr4 toll-like receptor 4 
1443088_at 0.5 9930031P18Rik RIKEN cDNA 9930031P18 gene
1444018_at 0.3 B930098A02Rik
RIKEN cDNA B930098A02 
gene 
1445862_at 0.166667 BC031575 cDNA sequence BC031575 
1447070_at -0.16667 Wbscr1 
Williams-Beuren syndrome 
chromosome region 1 homolog 
(human) 
1447704_s_at 0.166667 D530033C11Rik
RIKEN cDNA D530033C11 
gene 
1447807_s_at -0.53333 Plekhh1 
pleckstrin homology domain 
containing, family H (with 
MyTH4 domain) member 1 
1447852_x_at 0.233333 2900002H16Rik 
RIKEN cDNA 2900002H16 
gene 
1447897_x_at 0.4   
1447923_at 0.233333 1810026B05Rik RIKEN cDNA 1810026B05 gene
1452788_at -0.16667 Ppp2r5e 
protein phosphatase 2, regulatory 
subunit B (B56), epsilon isoform 
1452810_at -0.16667 4921521J11Rik RIKEN cDNA 4921521J11 gene 
1452984_at 0.166667 5730405I09Rik RIKEN cDNA 5730405I09 gene 
1453055_at 0.4 Sema6d 
sema domain, transmembrane 
domain (TM), and cytoplasmic 
domain, (semaphorin) 6D 
1453108_at 0.333333 2810429K17Rik 
RIKEN cDNA 2810429K17 
gene 
1453149_at -0.16667 MGI:1917156 
mitochondrial folate 
transporter/carrier 
1453269_at -0.3 Unc5b unc-5 homolog B (C. elegans) 
1453743_x_at -0.3 Phf14 PHD finger protein 14 
1454646_at 0.166667 E430026E19Rik 
RIKEN cDNA E430026E19 
gene 
1454680_at -0.23333 D5Ertd579e 
DNA segment, Chr 5, ERATO 
Doi 579, expressed 
1454740_at 0.233333 Mib1 
mindbomb homolog 1 
(Drosophila) 
1454764_s_at 0.166667 Slc38a1 
Solute carrier family 38, member 
1 
1455185_s_at -0.33333 Phf16 PHD finger protein 16 
1455223_at -0.66667 Igf2bp1 
insulin-like growth factor 2, 
binding protein 1 
1455649_at -0.63333   
1456156_at 0.266667 Lepr leptin receptor 
1456295_at 0.266667 B230114P17Rik 
RIKEN cDNA B230114P17 
gene 
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1456873_at 0.366667 Clic5 Chloride intracellular channel 5 
1457465_at -0.4 D430043L16Rik
RIKEN cDNA D430043L16 
gene 
1457491_at 0.233333 AA960558 expressed sequence AA960558 
1457555_at -0.23333   
1457635_s_at 0.5   
1457682_at 0.233333 9030420J04Rik RIKEN cDNA 9030420J04 gene 
1458353_at -0.4 A230063L24Rik
RIKEN cDNA A230063L24 
gene 
1458440_at -0.16667 LOC432572 
similar to sperm antigen 
HCMOGT-1 
1459476_s_at -0.16667 Csrp2bp 
cysteine and glycine-rich protein 
2 binding protein 
1459751_s_at -0.16667 Ppp1r16a 
protein phosphatase 1, regulatory 
(inhibitor) subunit 16A 
1459793_s_at 0.466667   
1459981_s_at 0.366667 Rsbn1 
rosbin, round spermatid basic 
protein 1 
1460462_at 0.366667 Med18 
mediator of RNA polymerase II 
transcription, subunit 18 
homolog (yeast) 
1460617_s_at -0.6 Rab6b 
RAB6B, member RAS oncogene 
family 
 
 
 
 
